The Impact of Weight Fluctuation on Atrial Substrate and the Prevention of Atrial Remodelling With the Use of Anti-Fibrotics by Twomey, Darragh Joseph
THE	  IMPACT	  OF	  WEIGHT	  FLUCTUATION	  ON	  ATRIAL	  SUBSTRATE	  




Darragh	  Twomey	  MBBS	  
	  
Centre	  for	  Heart	  Rhythm	  Disorders	  
Department	  of	  Cardiology	  
Royal	  Adelaide	  Hospital	  
and	  
School	  of	  Medicine	  
University	  of	  Adelaide	  
	  
	  
A	  thesis	  submitted	  to	  the	  University	  of	  Adelaide	  in	  fulfilment	  of	  
the	  requirements	  for	  the	  degree	  of	  Doctor	  of	  Philosophy	  
May	  2016	  
	   2	  
Table	  of	  contents	  
	  
Abstract	  ...........................................................................................................................	  5	  
Declaration	  ......................................................................................................................	  7	  
Acknowledgements	  ..........................................................................................................	  8	  
Presentations	  at	  Scientific	  Sessions	  ..................................................................................	  9	  
Prizes,	  scholarships	  and	  awards	  .......................................................................................	  9	  
Chapter	  1	  -­‐	  Introduction	  .................................................................................................	  10	  
1.1	  Atrial	  fibrillation	  and	  obesity	  –	  epidemiology	  ...........................................................	  10	  
1.2	  Atrial	  Fibrillation	  -­‐	  pathophysiology	  .........................................................................	  11	  
1.2.1	  Electrophysiological	  mechanisms	  of	  AF	  ..................................................................	  12	  
Initiation	  of	  AF	  ...........................................................................................................................	  12	  
Maintenance	  of	  AF	  .....................................................................................................................	  13	  
1.2.2	  Atrial	  remodelling	  ....................................................................................................	  14	  
Anatomical	  remodelling	  .............................................................................................................	  15	  
Electrical	  remodelling	  ................................................................................................................	  15	  
Structural	  remodelling	  ...............................................................................................................	  16	  
Atrial	  ectopy	  ..........................................................................................................................	  17	  
Molecular	  remodelling	  ...............................................................................................................	  18	  
Fibrosis	  ..................................................................................................................................	  18	  
Profibrotic	  molecules	  ............................................................................................................	  19	  
Inflammatory	  molecules	  .......................................................................................................	  26	  
Gap	  junction	  proteins	  ............................................................................................................	  27	  
Ion	  channels	  ..........................................................................................................................	  29	  
Reverse	  remodelling	  ..................................................................................................................	  30	  
1.3	  Obesity	  –	  pathophysiology	  in	  relation	  to	  AF	  .............................................................	  31	  
1.3.1	  Associated	  conditions	  ..............................................................................................	  31	  
Hypertension	  .............................................................................................................................	  31	  
Diabetes	  mellitus	  .......................................................................................................................	  32	  
Obstructive	  sleep	  apnoea	  ..........................................................................................................	  32	  
1.3.2	  Anatomical	  ..............................................................................................................	  33	  
Pericardial	  fat	  .............................................................................................................................	  34	  
1.3.3	  Electrophysiological	  .................................................................................................	  35	  
1.3.4	  Molecular	  ................................................................................................................	  35	  
1.3.5	  Weight	  loss	  ..............................................................................................................	  37	  
1.3.6	  Weight	  fluctuation	  ..................................................................................................	  38	  
1.4	  Upstream	  therapy	  for	  AF	  prevention	  .......................................................................	  38	  
1.4.1	  Renin-­‐angiotensin-­‐aldosterone	  system	  blockade	  ...................................................	  39	  
1.4.2	  Endothelin-­‐receptor	  blockade	  .................................................................................	  40	  
1.4.3	  Transforming	  growth	  factor	  receptor	  blockade	  ......................................................	  41	  
1.5	  Thesis	  aims	  ..............................................................................................................	  42	  
Chapter	  2	  –	  Weight	  cycling	  is	  associated	  with	  progressive	  atrial	  remodelling	  .................	  44	  
2.1	  Introduction	  ............................................................................................................	  44	  
2.2	  Methods	  ..................................................................................................................	  45	  
2.2.1	  Study	  Protocol	  .........................................................................................................	  45	  
2.2.2	  Weight	  control	  .........................................................................................................	  45	  
Weight	  fluctuation	  .....................................................................................................................	  46	  
2.2.3	  Animal	  anaesthesia	  .................................................................................................	  46	  
2.2.4	  Endocardial	  electrophysiological	  study	  ...................................................................	  46	  
	   3	  
Electroanatomical	  mapping	  .......................................................................................................	  47	  
Effective	  refractory	  periods	  .......................................................................................................	  48	  
AF	  induction	  ...............................................................................................................................	  48	  
Haemodynamic	  recordings	  ........................................................................................................	  49	  
2.2.5	  Terminal	  epicardial	  electrophysiological	  study	  .......................................................	  49	  
2.2.6	  Statistical	  Analysis	  ...................................................................................................	  50	  
2.3	  Results	  .....................................................................................................................	  50	  
2.3.1	  Weight,	  structural	  and	  haemodynamic	  parameters	  ...............................................	  50	  
2.3.2	  Electrophysiological	  parameters	  .............................................................................	  51	  
Conduction	  velocity	  -­‐	  endocardial	  .............................................................................................	  51	  
Conduction	  velocity	  –	  epicardial	  ................................................................................................	  52	  
Effective	  refractory	  periods	  .......................................................................................................	  52	  
AF	  inducibility	  .............................................................................................................................	  53	  
2.4	  Discussion	  ................................................................................................................	  54	  
2.5	  Conclusion	  ...............................................................................................................	  57	  
Chapter	  3	  -­‐	  The	  role	  of	  endothelin-­‐receptor	  blockade	  in	  the	  prevention	  of	  the	  substrate	  
for	  atrial	  fibrillation	  –	  an	  interventional	  study	  in	  an	  obese	  ovine	  model	  ..................	  65	  
3.1	  Introduction	  ............................................................................................................	  65	  
3.2	  Methods	  ..................................................................................................................	  66	  
3.2.1	  Study	  Protocol	  .........................................................................................................	  66	  
3.2.2	  Obese	  ovine	  model	  ..................................................................................................	  67	  
3.2.3	  Treatment	  (Endothelin	  Receptor	  Antagonist)	  group	  ...............................................	  67	  
3.2.4	  Animal	  anaesthesia	  .................................................................................................	  68	  
3.2.5	  Sequential	  endocardial	  electrophysiological	  study	  .................................................	  68	  
Electroanatomical	  mapping	  .......................................................................................................	  68	  
Effective	  refractory	  periods	  .......................................................................................................	  69	  
AF	  induction	  ...............................................................................................................................	  70	  
Haemodynamic	  recordings	  ........................................................................................................	  70	  
3.2.6	  Terminal	  epicardial	  electrophysiological	  study	  .......................................................	  70	  
3.2.7	  Cardiac	  MRI	  .............................................................................................................	  71	  
3.2.8	  Dual-­‐Energy	  X-­‐ray	  Absorptiometry	  (DEXA)	  .............................................................	  71	  
3.2.9	  Tissue	  analysis	  .........................................................................................................	  71	  
3.2.10	  Statistical	  Analysis	  .................................................................................................	  72	  
3.3	  Results	  .....................................................................................................................	  73	  
3.3.1	  Weight,	  structural	  and	  haemodynamic	  parameters	  ...............................................	  73	  
3.3.2	  Electrophysiological	  parameters	  .............................................................................	  73	  
Conduction	  velocity	  and	  conduction	  heterogeneity	  ..................................................................	  73	  
Effective	  refractory	  periods	  .......................................................................................................	  74	  
Signal	  fractionation	  ....................................................................................................................	  74	  
Atrial	  bipolar	  voltage	  .................................................................................................................	  74	  
AF	  inducibility	  .............................................................................................................................	  75	  
3.3.3	  Histological	  parameters	  ...........................................................................................	  75	  
Tissue	  fibrosis	  .............................................................................................................................	  75	  
Pro-­‐fibrotic	  proteins	  ...................................................................................................................	  75	  
Inflammation	  .............................................................................................................................	  76	  
Gap	  junctions	  .............................................................................................................................	  76	  
3.4	  Discussion	  ................................................................................................................	  76	  
3.5	  Conclusion	  ...............................................................................................................	  82	  
Chapter	  4	  –	  Treatment	  with	  tranilast	  prevents	  atrial	  remodelling	  and	  AF	  in	  an	  obese	  
ovine	  model	  ............................................................................................................	  93	  
4.1	  Introduction	  ............................................................................................................	  93	  
4.2	  Methods	  ..................................................................................................................	  94	  
	   4	  
4.2.1	  Study	  Protocol	  .........................................................................................................	  94	  
4.2.2	  Obesity	  induction	  ....................................................................................................	  94	  
4.2.3	  Treatment	  (tranilast)	  group	  .....................................................................................	  95	  
4.2.4	  Animal	  anaesthesia	  .................................................................................................	  95	  
4.2.5	  Endocardial	  electrophysiological	  study	  ...................................................................	  95	  
Electroanatomical	  mapping	  .......................................................................................................	  96	  
Effective	  refractory	  periods	  .......................................................................................................	  97	  
AF	  induction	  ...............................................................................................................................	  97	  
Haemodynamic	  recordings	  ........................................................................................................	  98	  
4.2.6	  Terminal	  epicardial	  electrophysiological	  study	  .......................................................	  98	  
4.2.7	  Cardiac	  MRI	  .............................................................................................................	  99	  
4.2.8	  Statistical	  Analysis	  ...................................................................................................	  99	  
4.3	  Results	  ...................................................................................................................	  100	  
4.3.1	  Weight,	  structural	  and	  haemodynamic	  parameters	  .............................................	  100	  
4.3.2	  Electrophysiological	  parameters	  ...........................................................................	  100	  
Atrial	  conduction	  .....................................................................................................................	  100	  
Effective	  refractory	  periods	  .....................................................................................................	  101	  
Signal	  fractionation	  ..................................................................................................................	  101	  
Atrial	  bipolar	  voltage	  ...............................................................................................................	  101	  
AF	  inducibility	  ...........................................................................................................................	  101	  
4.4	  Discussion	  ..............................................................................................................	  102	  
4.5	  Conclusion	  .............................................................................................................	  106	  
Chapter	  5	  –	  Conclusions	  and	  future	  directions	  ..............................................................	  114	  
Chapter	  6	  -­‐	  References	  .................................................................................................	  118	  
	   	  
	   5	  
Abstract	  
Atrial	  fibrillation	  (AF)	  is	  the	  commonest	  sustained	  arrhythmia	  in	  humans	  and	  is	  
responsible	  for	  a	  significant	  socioeconomic	  burden.	  Affected	  individuals	  can	  suffer	  
significant	  symptoms	  and	  are	  at	  risk	  of	  potentially	  life-­‐threatening	  complications.	  
Obesity	  is	  increasingly	  recognised	  as	  risk	  factor	  for	  the	  development	  of	  this	  
arrhythmia.	  
Weight	  fluctuation	  is	  common	  during	  attempted	  weight	  loss	  and	  has	  detrimental	  
cardiovascular	  effects	  in	  human	  cohort	  studies,	  including	  patients	  with	  AF.	  However,	  
the	  pathophysiological	  mechanisms	  by	  which	  this	  occurs	  are	  unclear.	  The	  first	  aim	  of	  
this	  thesis	  is	  to	  characterise	  the	  electrophysiological	  effects	  of	  weight	  fluctuation	  
using	  an	  obese	  ovine	  model.	  
Previous	  studies	  have	  demonstrated	  that	  obesity	  promotes	  the	  development	  of	  atrial	  
fibrosis	  as	  well	  as	  the	  upregulation	  of	  profibrotic	  factors	  in	  atrial	  tissue.	  The	  second	  
major	  aim	  of	  this	  thesis	  is	  to	  investigate	  the	  effect	  of	  blockade	  of	  these	  profibrotic	  
receptors	  on	  obesity-­‐related	  atrial	  remodelling.	  	  
Chapter	  2	  describes	  the	  use	  a	  fluctuating	  weight	  model	  in	  order	  to	  study	  the	  
electrophysiological	  changes	  over	  time.	  Weight	  fluctuation	  was	  associated	  with	  
progressive	  changes	  in	  atrial	  electrophysiology.	  This	  group	  demonstrated	  reduction	  in	  
conduction	  velocity	  when	  compared	  to	  a	  lean	  control	  group,	  particularly	  following	  a	  
second	  cycle	  of	  weight	  gain	  followed	  by	  weight	  loss.	  These	  changes	  were	  less	  severe	  
when	  compared	  to	  an	  obese	  group.	  Additionally,	  the	  changes	  in	  conduction	  were	  
more	  heterogeneous	  than	  in	  animals	  with	  persistent	  obesity.	  This	  resulted	  in	  an	  
increased	  propensity	  to	  AF	  when	  compared	  with	  lean	  controls.	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Chapter	  3	  investigates	  the	  role	  of	  endothelin	  receptor	  blockade	  in	  the	  prevention	  of	  
atrial	  substrate	  in	  obesity.	  Obesity	  was	  again	  induced	  in	  ovine	  subjects	  and	  two	  
groups	  were	  compared.	  One	  was	  treated	  with	  the	  endothelin	  receptor	  antagonist	  
(ERA)	  bosentan	  whilst	  the	  other	  acted	  as	  a	  control	  group.	  Animals	  treated	  with	  
bosentan	  had	  attenuation	  of	  obesity-­‐related	  conduction	  slowing.	  This	  was	  seen	  on	  
both	  endocardial	  and	  epicardial	  surfaces.	  Importantly,	  there	  was	  no	  effect	  on	  either	  
haemodynamics	  or	  refractory	  periods.	  AF	  inducibility	  was	  also	  reduced	  by	  ERA	  
treatment.	  Examination	  of	  atrial	  demonstrated	  reduced	  fibrosis	  and	  downregulation	  
of	  pro-­‐fibrotic	  factors	  with	  ERA	  treatment.	  Importantly,	  this	  effect	  was	  independent	  
of	  the	  TGF-­‐β	  pathway.	  
Chapter	  4	  examines	  the	  effect	  of	  the	  TGF-­‐β	  receptor	  antagonist	  tranilast	  on	  the	  obese	  
ovine	  atrium.	  A	  similar	  model	  of	  induced	  obesity	  was	  used	  to	  compare	  tranilast	  
treatment	  with	  a	  control	  group.	  Animals	  receiving	  tranilast	  demonstrated	  attenuation	  
of	  conduction	  slowing.	  Endo	  and	  epicardial	  mapping	  showed	  this	  slowing	  was	  
heterogeneous	  across	  atrial	  sites,	  perhaps	  suggesting	  a	  predominantly	  local	  
mechanism	  in	  the	  development	  of	  these	  electrophysiological	  changes.	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Chapter	  1	  -­‐	  Introduction	  
1.1	  Atrial	  fibrillation	  and	  obesity	  –	  epidemiology	  
Atrial	  fibrillation	  (AF)	  is	  the	  commonest	  arrhythmia	  in	  humans.	  The	  lifetime	  risk	  of	  
developing	  AF	  at	  aged	  55	  is	  23.8%	  in	  males	  and	  22.2%	  in	  females.1	  It	  is	  characterised	  
by	  irregular,	  chaotic	  atrial	  activity	  and	  subsequent	  irregular	  ventricular	  contraction.	  It	  
can	  cause	  significant	  symptoms	  such	  as	  breathlessness,	  palpitation	  and	  is	  associated	  
with	  potentially	  life-­‐threatening	  complications,	  in	  particular,	  stroke2,	  dementia3,	  4	  and	  
heart	  failure.5	  Individuals	  with	  AF	  have	  1.5	  to	  1.9	  times	  greater	  risk	  of	  risk	  of	  death.6	  
The	  incidence	  of	  AF	  is	  increasing	  and	  this	  rise	  is	  predicted	  to	  continue.7	  This	  is	  
associated	  with	  a	  dramatic	  increase	  the	  in	  use	  of	  health	  resources,	  surpassing	  both	  
heart	  failure	  and	  coronary	  artery	  disease.8	  One	  contributory	  factor	  is	  the	  aging	  
population,	  as	  the	  prevalence	  of	  AF	  is	  higher	  with	  increasing	  age.	  Less	  than	  1%	  of	  55	  
to	  59	  year	  olds	  have	  AF,	  whereas	  it	  affects	  over	  15%	  of	  those	  aged	  85	  and	  above.1	  In	  
addition,	  a	  number	  of	  other	  conditions	  are	  considered	  risk	  factors	  for	  AF.	  It	  has	  long	  
been	  recognised	  that	  hypertension,	  diabetes,	  coronary	  artery	  disease,	  cardiac	  failure	  
and	  valvular	  heart	  disease	  contribute	  to	  an	  individual’s	  risk	  of	  developing	  AF.9	  
Additionally,	  the	  presence	  of	  these	  risk	  factors	  increases	  the	  risk	  of	  thromboembolic	  
events.10	  However,	  it	  has	  also	  been	  noted	  that	  even	  after	  correcting	  for	  these	  known	  
factors,	  the	  increase	  in	  the	  prevalence	  of	  AF	  exceeds	  expectations.7	  This	  has	  given	  rise	  
to	  the	  concept	  of	  ‘novel’	  risk	  factors	  for	  AF.	  Obesity	  is	  a	  common,	  but	  frequently	  
underestimated	  example	  of	  one	  of	  these	  factors.	  
The	  incidence	  of	  obesity	  across	  the	  world	  is	  reaching	  epidemic	  levels,	  with	  60%	  of	  
Australian	  adults	  being	  overweight	  or	  obese.11	  It	  has	  doubled	  between	  1980	  and	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2000,	  and	  is	  projected	  to	  increase	  to	  over	  70%	  by	  2025.12	  Obesity	  is	  associated	  with	  
several	  of	  the	  known	  risk	  factors	  for	  AF,	  particularly	  hypertension,	  diabetes	  and	  sleep	  
apnoea.	  However,	  a	  number	  of	  large	  studies	  have	  shown	  that	  it	  also	  independently	  
increases	  the	  risk	  of	  AF,13,	  14	  with	  17.9%	  of	  cases	  attributable	  to	  obesity,	  second	  only	  
to	  hypertension.15	  Wanahita	  et	  al.	  performed	  a	  meta-­‐analysis	  of	  over	  78000	  patients	  
across	  5	  population-­‐based	  cohort	  studies	  and	  concluded	  that	  obesity	  increased	  the	  
risk	  of	  AF	  by	  49%.16	  A	  recent	  Danish	  study	  recently	  confirmed	  these	  findings	  with	  a	  
very	  large	  cohort	  of	  271,000	  young	  women.	  Over	  a	  median	  follow-­‐up	  period	  of	  4.6	  
years,	  the	  risk	  of	  AF	  was	  doubled	  in	  those	  with	  a	  BMI	  of	  30	  to	  35	  and	  tripled	  in	  those	  
with	  a	  BMI	  of	  over	  35.17	  Each	  unit	  increase	  in	  BMI	  increases	  the	  risk	  of	  AF	  by	  3	  to	  
5%.18	  Obesity	  is	  also	  associated	  with	  more	  severe	  forms	  of	  the	  disease;	  progression	  
from	  paroxysmal	  to	  persistent	  AF	  is	  more	  likely	  in	  obese	  patients.19	  	  
Interestingly,	  there	  are	  emerging	  reports	  of	  an	  obesity	  paradox	  for	  patients	  with	  
established	  AF.	  That	  is,	  that	  overweight	  and	  obese	  patients	  appear	  to	  have	  a	  lower	  all	  
cause	  and	  cardiovascular	  mortality.20	  Consistent	  in	  these	  reports	  however	  is	  
differential	  patient	  populations,	  frequently	  with	  obese	  patients	  presenting	  at	  a	  
younger	  age	  and	  with	  fewer	  comorbidities.21	  Whether	  this	  observation	  is	  proven	  in	  
more	  robust	  analysis	  is	  yet	  to	  be	  seen.	  
1.2	  Atrial	  Fibrillation	  -­‐	  pathophysiology	  
The	  pathophysiology	  of	  AF	  is	  a	  complex	  interplay	  between	  the	  fundamental	  
electrophysiological	  principles	  of	  triggered	  activity	  in	  the	  form	  of	  initiating	  focal	  
ectopic	  beats,	  and	  reentrant	  activity	  allowing	  maintenance	  of	  the	  arrhythmia.	  Atrial	  
‘remodelling’	  is	  a	  persistent	  change	  in	  atrial	  structure	  or	  function	  that	  can	  both	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increase	  ectopic	  burden	  and	  induce	  a	  substrate	  in	  atrial	  tissue,	  promoting	  reentry.22	  
Remodelling	  can	  be	  anatomical,	  electrophysiological	  or	  molecular.	  There	  are	  
numerous	  contributory	  factors	  and	  underlying	  conditions,	  many	  demonstrating	  
significant	  overlap	  in	  abnormalities	  within	  these	  categories.	  
Several	  animal	  models	  have	  been	  developed	  to	  allow	  study	  of	  the	  properties	  of	  the	  
fibrillating	  or	  fibrosed	  atrium.	  Atrial	  tachycardia,	  induced	  by	  rapid	  atrial	  pacing	  has	  
demonstrated	  predominantly	  electrical	  remodelling,	  whereas	  heart	  failure	  models	  
have	  also	  induced	  structural	  remodelling.	  Both	  models	  are	  associated	  with	  increased	  
inducibility	  of	  AF.	  More	  recently,	  an	  obese	  animal	  model	  has	  allowed	  more	  focussed	  
investigation	  of	  the	  effect	  on	  obesity	  on	  the	  structural	  and	  electrical	  properties	  of	  the	  
atria.23,	  24	  This	  model	  demonstrated	  both	  electrical	  and	  structural	  abnormalities	  and	  
increased	  propensity	  to	  AF.	  Importantly	  the	  animals	  in	  this	  model	  did	  not	  develop	  
obstructive	  sleep	  apnoea,	  a	  significant	  confounding	  condition	  in	  human	  studies.	  
1.2.1	  Electrophysiological	  mechanisms	  of	  AF	  
Ectopic	  foci	  act	  as	  triggers	  or	  initiators	  of	  fibrillatory	  episodes,	  whereas	  reentrant,	  
wavelet	  or	  rotor	  mechanisms	  contribute	  to	  the	  maintenance	  of	  these	  episodes.	  The	  
degree	  of	  maintenance	  depends	  on	  the	  underlying	  electrophysiological	  substrate.	  
Initiation	  of	  AF	  
Seminal	  observations	  by	  Haissaguerre	  et	  al.	  demonstrated	  that	  AF	  episodes	  were	  
frequently	  initiated	  by	  ectopic	  beats	  originating	  in	  the	  pulmonary	  veins	  and	  were	  
abolished	  by	  the	  application	  of	  RF	  energy.25	  Subsequent	  studies	  determined	  multiple	  
veins	  were	  often	  involved.26	  Based	  on	  this,	  electrical	  isolation	  of	  the	  pulmonary	  veins	  
has	  become	  a	  cornerstone	  of	  ablation	  procedures	  for	  AF.	  A	  small	  percentage	  of	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patients	  have	  a	  second	  initiating	  arrhythmia	  that	  may	  be	  amenable	  to	  ablation.27,28	  
Atrial	  ectopy	  in	  paroxysmal	  AF	  is	  more	  frequent	  and	  more	  premature	  prior	  to	  
episodes29	  and	  excessive	  atrial	  ectopy	  has	  recently	  been	  associated	  with	  stroke,	  even	  
in	  the	  absence	  of	  AF.30	  The	  electrophysiology	  of	  the	  pulmonary	  veins	  is	  different	  to	  
the	  adjacent	  atrial	  tissue	  and	  varies	  between	  proximal	  and	  distal	  portions	  of	  the	  
veins31,	  with	  more	  marked	  differences	  in	  patients	  with	  AF.32	  The	  relationship	  of	  the	  
veins	  to	  the	  atrial	  tissue	  is	  complex,	  with	  muscular	  extensions	  extending	  into	  each	  
structure33	  and	  the	  presence	  of	  pacemaker-­‐type	  cells	  within	  venous	  tissue.34	  
Conduction	  between	  atrium	  and	  vein	  is	  relatively	  slow,	  particularly	  after	  extrastimuli,	  
and	  histological	  examination	  of	  the	  junction	  often	  shows	  abrupt	  changes	  in	  fibre	  
orientation.35	  Clinically,	  this	  is	  demonstrated	  by	  distinct	  electrical	  activation	  by	  
venous	  tissue.32	  
Sources	  of	  ectopy	  also	  exist	  outside	  the	  pulmonary	  veins.36	  These	  are	  less	  common,	  
but	  may	  play	  a	  greater	  role	  in	  patients	  with	  persistent	  AF,	  given	  the	  reduced	  
effectiveness	  of	  pulmonary	  vein	  isolation.	  It	  is	  unclear,	  however,	  if	  ablation	  outside	  
the	  pulmonary	  veins	  has	  an	  impact	  on	  outcomes.37	  
Maintenance	  of	  AF	  
The	  mechanisms	  involved	  in	  the	  maintenance	  of	  fibrillation	  in	  cardiac	  tissue	  have	  
been	  examined	  for	  over	  a	  century.	  Demonstration	  of	  circus	  motion	  seen	  in	  animal	  
models	  developed	  into	  the	  concept	  of	  reentry.38	  It	  was	  postulated	  that	  atrial	  flutter	  
and	  fibrillation	  both	  involved	  a	  single	  reentrant	  circuit,	  with	  AF	  having	  a	  smaller	  and	  
only	  partially	  recovered	  ‘excitable	  gap’.	  Early	  computer	  models	  of	  AF	  suggested	  that	  
in	  fact	  multiple	  wavelets	  existed,	  progressing	  randomly	  across	  the	  atria.39	  This	  was	  
later	  confirmed	  in	  animal	  models	  40	  and	  it	  was	  theorised	  that	  maintenance	  of	  AF,	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through	  ‘daughter	  wavelets’,	  relied	  upon	  a	  critical	  mass	  of	  tissue,	  shortened	  
refractory	  periods	  and	  slowed,	  heterogeneous	  conduction	  though	  the	  tissue.	  
The	  existence	  of	  transient	  rotatory	  electrical	  activity	  or	  ‘rotors’	  was	  theorised	  by	  
independent	  groups	  as	  a	  potential	  arrhythmia	  mechanism.41,	  42	  A	  transient,	  single	  
point	  acts	  as	  a	  pivot	  to	  a	  spiral	  wave	  which	  can	  be	  static	  or	  meandering.	  This	  
propagates	  across	  cardiac	  tissue,	  interacting	  with	  anatomical	  structures	  and	  areas	  of	  
functional	  conduction	  block,	  resulting	  in	  wave	  fragmentation.	  Technological	  
advancements	  in	  high-­‐density	  optical	  mapping	  allowed	  visualisation	  of	  rotors,	  initially	  
in	  fibrillating	  ventricular	  tissue,43	  then	  in	  AF.44	  Using	  multipolar	  basket	  catheters	  and	  
advanced	  phase	  mapping	  techniques,	  rotors	  have	  been	  seen	  in	  human	  subjects	  in	  
both	  right	  and	  left	  atria.45	  Subsequent	  studies	  have	  suggested	  that	  ablation	  of	  these	  
sites	  may	  be	  an	  effective	  strategy	  for	  invasive	  management	  of	  AF.46	  
1.2.2	  Atrial	  remodelling	  
Atrial	  remodelling	  is	  a	  multifactorial	  process	  promoting	  both	  the	  occurrence	  and	  
maintenance	  of	  AF.	  Macroscopic	  structural	  abnormalities,	  in	  particular	  atrial	  
dilatation,	  are	  present	  in	  many	  clinical	  conditions	  associated	  with	  the	  development	  of	  
AF	  and	  are	  thought	  to	  provide	  a	  larger	  surface	  area	  for	  reentrant	  circuits.	  
Electrophysiological	  changes	  were	  first	  demonstrated	  with	  a	  rapid	  atrial-­‐pacing	  
model,	  with	  shortening	  of	  atrial	  refractory	  periods.	  Subsequent	  models	  of	  induced	  
heart	  failure	  and	  obesity	  have	  demonstrated	  abnormalities	  in	  atrial	  conduction	  in	  
conjunction	  with	  molecular	  changes	  such	  as	  interstitial	  fibrosis,	  ion	  channel	  
abnormalities,	  upregulation	  of	  profibrotic	  factors	  and	  disruption	  of	  cell-­‐to-­‐cell	  
communication.	  Recent	  invasive	  human	  studies	  have	  confirmed	  many	  of	  these	  
abnormalities	  in	  patients	  with	  risk	  factors	  for	  AF.	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Anatomical	  remodelling	  
Several	  large	  population	  based	  studies	  have	  shown	  an	  association	  between	  atrial	  
diameter	  and	  incidence	  of	  AF.47	  In	  the	  Framingham	  cohort,	  a	  5mm	  increase	  in	  LA	  
diameter	  was	  associated	  with	  a	  40%	  increase	  in	  incident	  AF.48	  LA	  dilatation	  can	  be	  
caused	  by,	  and	  has	  adverse	  prognostic	  implications	  in,	  several	  conditions	  associated	  
with	  AF,	  in	  particular	  hypertension49,	  systolic50	  and	  diastolic51	  heart	  failure,	  as	  well	  as	  
being	  prognostic	  in	  the	  general	  population.52	  
Obesity	  had	  the	  strongest	  association	  with	  left	  atrial	  dilatation	  in	  a	  cohort	  study	  of	  
1000	  randomly	  selected	  German	  residents,	  with	  an	  odds	  ratio	  of	  2.4.	  This	  was	  
independent	  from	  the	  presence	  of	  hypertension,	  which	  conferred	  an	  odds	  ratio	  of	  2.2	  
(p<0.001).53	  In	  patients	  with	  established	  hypertension,	  obesity	  doubles	  the	  likelihood	  
of	  having	  LA	  dilatation.54	  The	  Framingham	  group	  examined	  factors	  influencing	  
incident	  AF	  in	  5000	  patients	  and	  found	  increased	  BMI	  was	  associated	  with	  an	  
increased	  risk	  of	  developing	  AF.	  After	  adjustment	  for	  clinical	  confounders	  using	  
multivariate	  analysis,	  increased	  LA	  diameter	  was	  the	  only	  remaining	  association.14	  
Obesity	  and	  LA	  size	  have	  also	  been	  shown	  to	  be	  independently	  predictive	  of	  
progression	  from	  paroxysmal	  to	  persistent	  AF.19	  
Electrical	  remodelling	  
Seminal	  work	  by	  Wijffel	  at	  al	  involved	  rapid	  atrial	  pacing	  to	  induce	  and	  maintain	  AF	  in	  
goats,	  the	  so-­‐called	  ‘atrial	  tachycardia’	  model.55	  After	  only	  24	  hours	  of	  rapid	  atrial	  
pacing,	  the	  duration	  and	  rate	  of	  AF	  episodes	  increased	  significantly	  and	  at	  1-­‐3	  weeks,	  
AF	  became	  sustained.	  This	  study	  coined	  the	  phrase	  ‘AF	  begets	  AF’	  and	  also	  offered	  
early	  insight	  into	  the	  electrical	  remodelling	  process.	  The	  main	  electrophysiological	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abnormality	  was	  a	  reduction	  in	  atrial	  refractory	  periods,	  occurring	  as	  early	  as	  6	  hours,	  
with	  further	  reduction	  at	  24	  hours.	  Notably,	  no	  change	  in	  conduction	  velocity	  was	  
noted	  at	  any	  time	  point.	  A	  later	  study	  rapidly	  paced	  the	  atria	  of	  dogs	  for	  6	  weeks.	  In	  
addition	  to	  ERP	  reduction,	  there	  was	  also	  a	  reduction	  in	  conduction	  velocity,	  which	  
was	  slower	  to	  develop	  than	  the	  changes	  in	  ERP.56	  A	  subsequent	  study	  using	  a	  similar	  
model	  demonstrated	  similar	  changes	  in	  refractory	  periods	  within	  30	  minutes	  of	  
commencement	  of	  high	  rate	  atrial	  pacing.	  Treatment	  with	  atropine	  and	  propranolol	  
excluded	  autonomic	  tone	  as	  a	  contributory	  factor	  and	  in	  a	  subset	  of	  animals,	  calcium	  
channel	  blockade	  prevented	  electrical	  remodelling,	  suggesting	  the	  involvement	  of	  
specific	  ion	  channels	  in	  this	  pathophysiological	  state.57	  
Structural	  remodelling	  
To	  avoid	  the	  potentially	  confounding	  effect	  of	  atrial	  pacing	  and	  associated	  electrical	  
remodelling,	  Li	  et	  al.	  developed	  a	  model	  of	  congestive	  heart	  failure	  to	  investigate	  the	  
indirect	  effect	  on	  atrial	  electrophysiology.58	  Rapid	  ventricular	  pacing	  for	  5	  weeks	  in	  a	  
canine	  model	  induced	  LV	  impairment.	  The	  atrial	  electrophysiology	  of	  this	  CHF	  group	  
was	  compared	  with	  a	  rapid	  atrial	  pacing	  (RAP)	  group	  and	  a	  control	  group.	  The	  RAP	  
group	  demonstrated	  reduction	  in	  ERP	  and	  increased	  ERP	  heterogeneity,	  without	  
change	  in	  conduction	  velocity.	  In	  contrast,	  the	  CHF	  group	  showed	  no	  change	  in	  tissue	  
refractoriness,	  but	  did	  demonstrate	  marked	  localised	  reduction	  in	  conduction	  
velocity.	  Importantly,	  these	  electrical	  differences	  were	  associated	  with	  a	  dramatic	  
increase	  in	  the	  degree	  of	  fibrosis,	  with	  no	  significant	  differences	  between	  control	  and	  
RAP	  groups.	  The	  conduction	  slowing	  and	  ultrastructural	  changes	  demonstrated	  by	  
this	  study	  were	  termed	  ‘structural	  remodelling’.	  Similar	  findings	  are	  associated	  with	  
animal	  models	  of	  hypertension59,	  60,	  drug-­‐induced	  cardiomyopathy61,	  62,	  coronary	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artery	  disease62	  and,	  importantly,	  obesity.23	  The	  obese	  model	  developed	  by	  Abed	  et	  
al.	  induced	  obesity	  over	  an	  eight-­‐month	  period.	  Progressive	  atrial	  structural	  and	  
electrical	  abnormalities	  were	  demonstrated	  with	  increasing	  weight.	  Conduction	  
slowing	  and	  heterogeneity,	  without	  changes	  in	  refractory	  periods,	  led	  to	  increased	  AF	  
inducibility.	  On	  analysis	  of	  atrial	  tissue,	  obesity	  was	  associated	  with	  increased	  atrial	  
fibrosis	  and	  upregulation	  of	  a	  number	  of	  profibrotic	  factors.23	  
Human	  endocardial	  mapping	  studies	  have	  consistently	  found	  abnormalities	  in	  the	  
atria	  of	  patients	  with	  cardiovascular	  disease.	  A	  cohort	  of	  individuals	  with	  heart	  failure	  
but	  no	  history	  of	  AF	  had	  detailed	  right	  atrial	  electrophysiological	  studies.	  When	  
compared	  with	  controls,	  they	  had	  heterogeneous	  reduction	  in	  conduction	  velocities,	  
higher	  refractory	  periods,	  lower	  bipolar	  voltage	  and	  more	  signal	  fractionation.63	  
These	  findings	  were	  strongly	  suggestive	  of	  underlying	  structural	  remodelling	  and	  
similar	  abnormalities	  were	  found	  in	  the	  atria	  of	  patients	  with	  hypertension,64	  sleep	  
apnoea65,	  mitral	  valve	  disease66,	  atrial	  septal	  defects67	  and	  even	  in	  patients	  with	  lone	  
AF.68	  	  
Atrial	  ectopy	  
Structural	  remodelling	  may	  increase	  atrial	  ectopic	  burden,	  which	  could	  contribute	  to	  
the	  initiation	  of	  AF	  episodes.	  Ectopic	  beats	  can	  be	  caused	  by	  enhanced	  automaticity	  
and	  both	  early	  (EAD)	  and	  delayed	  (DAD)	  afterdepolarisations.	  Increased	  automaticity	  
has	  not	  been	  clearly	  demonstrated	  to	  occur	  in	  conditions	  predisposing	  to	  atrial	  
substrate,	  but	  upregulation	  of	  the	  ‘funny	  current’,	  an	  important	  contributor	  to	  
automatic	  depolarisation,	  has	  been	  demonstrated	  in	  AF	  substrate	  models.69,	  70	  Late	  
depolarisations	  are	  associated	  with	  calcium	  channel	  abnormalities,	  and	  have	  been	  
found	  in	  both	  atrial	  pacing	  and	  CHF	  models	  of	  AF,	  with	  enhancement	  of	  calcium	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loading.71,	  72	  Although	  early	  afterdepolarisations	  have	  been	  shown	  to	  play	  a	  potential	  
role	  in	  the	  pathogenesis	  of	  AF,	  the	  relationship	  is	  not	  clear.	  
Molecular	  remodelling	  
A	  multitude	  of	  molecular	  abnormalities	  are	  associated	  with	  atrial	  remodelling.	  
Fibrosis,	  a	  common	  finding	  in	  diseased	  organs,	  underpins	  many	  of	  the	  
electrophysiological	  abnormalities	  associated	  with	  AF.	  Numerous	  pro-­‐fibrotic	  and	  
inflammatory	  molecules	  are	  involved	  to	  varying	  degrees.	  There	  is	  considerable	  
overlap	  between	  these	  pathways,	  with	  multiple	  complex	  interactions	  and	  feedback	  
loops	  (figure	  1)	  but	  the	  exact	  mechanisms	  remain	  incompletely	  understood.	  	  
Fibrosis	  
Tissue	  fibrosis	  is	  characterised	  by	  fibroblast	  proliferation,	  accumulation	  of	  
extracellular	  matrix	  proteins	  and	  collagen	  deposition.	  It	  is	  a	  feature	  of	  most	  cardiac	  
conditions,	  particularly	  post	  myocardial	  infarction	  and	  cardiomyopathy.	  Several	  
mechanistic	  studies	  have	  demonstrated	  that	  fibrotic	  tissue	  also	  acts	  as	  a	  substrate	  for	  
AF,	  with	  strong	  associations	  between	  atrial	  fibrosis	  and	  conduction	  abnormalities	  
such	  as	  conduction	  heterogeneity	  or	  reduction	  in	  conduction	  velocity,	  along	  with	  
increased	  susceptibility	  to	  AF.	  Induced	  atrial	  fibrosis	  was	  first	  demonstrated	  in	  the	  
canine	  heart	  failure	  model	  developed	  by	  Li	  et	  al.	  as	  discussed	  in	  the	  previous	  
section.58	  Subsequent	  animal	  studies	  have	  demonstrated	  similar	  fibrotic	  processes	  
with	  associated	  electrophysiological	  abnormalities	  in	  response	  to	  aging,73	  
hypertension59,	  60,	  drug-­‐induced	  cardiomyopathy61,	  coronary	  artery	  disease62	  and	  
obesity.23	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Patients	  with	  AF	  have	  atrial	  fibrosis	  on	  analysis	  of	  surgically	  excised	  tissue	  when	  
compared	  with	  patients	  without	  AF.74	  This	  was	  also	  found	  on	  tissue	  biopsy	  samples	  of	  
patients	  with	  lone	  AF.75	  Recent	  advances	  in	  MRI	  technology	  have	  allowed	  for	  the	  
direct	  visualisation	  of	  fibrotic	  areas	  in	  atrial	  tissue	  and	  have	  shown	  a	  strong	  
correlation	  between	  the	  degree	  of	  fibrosis	  and	  success	  following	  AF	  ablation.76	  
Profibrotic	  molecules	  
Endothelin	  
Endothelin-­‐1	  (ET-­‐1)	  was	  discovered	  in	  1988	  by	  Yanagisawa	  et	  al.77	  The	  21-­‐amino	  acid	  
peptide	  was	  shown	  to	  be	  one	  of	  the	  most	  potent	  vasoconstrictors	  in	  existence.	  	  Three	  
other	  active	  isoforms	  (ET-­‐2,	  3	  and	  4)	  have	  subsequently	  been	  discovered	  and	  are	  less	  
relevant	  to	  the	  cardiovascular	  system.	  All	  isoforms	  are	  converted	  from	  ‘big-­‐ET’	  
molecules	  by	  ET	  converting	  enzymes.	  ET-­‐1	  is	  predominantly	  produced	  by	  endothelial	  
cells,	  with	  a	  study	  of	  endothelial	  cell-­‐specific	  ET-­‐1	  knock-­‐out	  mice	  demonstrating	  a	  65-­‐
80%	  reduction	  in	  plasma	  and	  tissue	  ET-­‐178	  but	  is	  also	  produced	  by	  vascular	  smooth	  
muscle	  and	  cardiomyocytes.	  Two	  distinct	  endothelin	  receptors	  were	  found	  soon	  after	  
the	  existence	  of	  the	  protein.	  These	  are	  both	  transmembrane	  G	  protein-­‐coupled	  
receptors,	  ET-­‐A	  and	  ET-­‐B.79	  Activation	  of	  these	  receptors	  may	  have	  synergistic	  or	  
opposing	  effects,	  depending	  on	  the	  site	  of	  the	  receptors	  and	  the	  physiological	  state.	  
The	  predominant	  effect	  of	  endothelin	  is	  vasoconstriction,	  which	  occurs	  across	  
multiple	  organs,	  with	  significant	  involvement	  in	  both	  systemic	  and	  pulmonary	  
hypertension.77,	  80,	  81	  Additional	  effects	  include	  vascular	  smooth	  muscle	  
proliferation82,	  cardiomyocyte	  hypertrophy	  and	  ET-­‐B	  mediated	  vasodilatation	  through	  
nitric	  oxide	  and	  prostacyclin	  release.83	  	  
	   20	  
ET-­‐1	  is	  released	  from	  infarcted	  areas	  of	  cardiac	  tissue84	  and	  elevation	  of	  serum	  ET-­‐1	  
correlates	  with	  a	  worse	  prognosis	  following	  MI.85	  Plasma	  ET-­‐1	  also	  correlates	  with	  the	  
severity	  of	  stable	  coronary	  artery	  disease	  even	  in	  the	  absence	  of	  left	  ventricular	  
dysfunction.86	  An	  ET-­‐1	  over-­‐expression	  mouse	  model	  induced	  dilated	  
cardiomyopathy.87	  Plasma	  ET-­‐1	  is	  also	  elevated	  in	  patients	  with	  heart	  failure	  and	  
correlates	  with	  severity.88	  Zolk	  et	  al.	  examined	  ventricular	  tissue	  from	  patients	  
undergoing	  heart	  transplantation	  for	  end	  stage	  dilated	  cardiomyopathy	  and	  found	  
elevation	  of	  tissue	  ET-­‐1	  and	  ET-­‐A,	  but	  a	  reduction	  in	  ET-­‐B.89	  Interestingly,	  blockade	  of	  
human	  ET-­‐A	  receptors	  was	  negatively	  inotropic	  in	  normal	  hearts,	  but	  had	  no	  effect	  in	  
a	  cohort	  with	  dilated	  cardiomyopathy.90	  	  
Human	  atrial	  tissue	  demonstrates	  positive	  inotropy	  in	  response	  to	  endothelin	  
incubation.91	  One	  study	  demonstrated	  arrhythmic	  contractions	  of	  human	  atrial	  tissue	  
in	  response	  to	  ET-­‐1,	  which	  were	  unchanged	  by	  blockade	  of	  the	  ET-­‐A	  receptor.92	  
Several	  studies	  of	  its	  chronotropic	  effect	  have	  reported	  conflicting	  results.93,	  94	  
Analysis	  of	  atrial	  tissue	  at	  the	  time	  of	  cardiothoracic	  surgery	  have	  also	  had	  discrepant	  
results.	  One	  study	  showed	  endothelin	  receptor	  downregulation	  in	  those	  who	  were	  
known	  to	  have	  AF,	  however	  this	  was	  using	  right	  atrial	  tissue.95	  In	  another	  study,	  
increased	  endothelin-­‐1	  expression	  in	  left	  atrial	  tissue	  was	  associated	  with	  increased	  
AF	  burden,	  hypertension	  and	  atrial	  dilatation,	  which	  persisted	  after	  multivariate	  
analysis.96	  Elevated	  serum	  endothelin-­‐1	  levels	  are	  predictive	  of	  failure	  after	  AF	  
ablation.97	  
Evidence	  that	  endothelin	  was	  directly	  involved	  in	  fibrosis	  was	  first	  discovered	  in	  
patients	  with	  systemic	  sclerosis.	  ET-­‐1	  plasma	  levels	  were	  elevated;	  more	  diffuse	  
disease	  was	  associated	  with	  higher	  concentrations.	  Additionally,	  fibrotic	  skin	  and	  lung	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tissue	  demonstrated	  elevated	  ET	  expression.	  Subsequent	  studies	  determined	  ET	  
mediates	  fibrosis	  in	  cardiac,	  lung,	  renal	  and	  hepatic	  tissue.98	  Guarda	  et	  al.	  first	  
demonstrated	  endothelin-­‐1	  to	  be	  directly	  responsible	  for	  cardiac	  fibrosis.	  Cardiac	  
fibroblasts	  maintained	  in	  ET-­‐1	  had	  a	  dose	  dependant	  increase	  in	  collagen	  deposition	  
compared	  with	  controls.99	  Endothelin	  exposure	  is	  associated	  with	  fibrosis,	  decreased	  
gap	  junction	  expression	  and	  conduction	  slowing	  in	  ventricular	  myocytes.100	  Animal	  
models	  of	  ischaemic	  and	  diabetic	  cardiomyopathy	  and	  obesity-­‐related	  atrial	  fibrosis	  
are	  associated	  with	  upregulation	  of	  endothelin-­‐A	  and	  -­‐B	  receptors.101,	  102,	  23	  
Several	  cytokines	  and	  profibrotic	  factors	  associated	  with	  AF	  have	  been	  shown	  to	  
promote	  transcription	  of	  endothelin.	  TGF-­‐β	  is	  a	  powerful	  inducer	  of	  ET	  upregulation	  
and	  release	  in	  endothelial,	  vascular	  smooth	  muscle	  and	  cardiac	  cells,	  acting	  via	  the	  
ALK-­‐5	  cytoplasmic	  signalling	  pathway	  and	  the	  Smad	  transcription	  factor	  pathway.98,	  
103	  Notably,	  blockade	  of	  endothelin	  receptors	  prevents	  the	  pro-­‐fibrotic	  actions	  of	  TGF-­‐
β	  in	  the	  kidneys	  of	  hypertensive	  and	  diabetic	  rats.98	  Angiotensin	  II	  also	  induces	  
endothelin	  production	  and	  acts	  via	  cytoplasmic	  protein	  kinase	  C,104,	  105	  and	  blockade	  
of	  angiotensin	  converting	  enzyme	  directly	  inhibits	  endothelin	  production.106	  
Angiotensin	  increases	  tissue	  endothelin	  and	  induces	  vascular	  hypertrophy,	  an	  effect	  
blocked	  by	  blockade	  of	  ET-­‐A	  receptors.	  Leptin,	  a	  hormone	  well	  recognised	  to	  be	  
secreted	  by	  adipocytes,	  induces	  ET-­‐1	  in	  human	  endothelial	  cells.107	  Along	  with	  TGF-­‐β	  
and	  angiotensin,	  leptin	  also	  acts	  via	  the	  AP-­‐1	  (Fos/Jun)	  transcription	  factor.	  
Transforming	  growth	  factor	  beta	  
TGF-­‐β	  plays	  a	  central	  role	  in	  fibrosis.	  It	  exists	  in	  3	  isoforms	  and	  is	  produced	  by	  a	  wide	  
variety	  of	  cells	  (epithelial,	  endothelial,	  connective	  tissue	  and	  haemopoietic).	  
Overexpression	  in	  animal	  models	  results	  in	  fibrosis	  of	  the	  kidney,	  liver	  and	  lung	  and	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high	  levels	  of	  the	  molecule	  are	  found	  in	  fibrotic	  organs.	  It	  is	  a	  potent	  stimulator	  of	  
extracellular	  matrix	  production	  and	  deposition.108	  In	  cardiac	  tissue,	  it	  induces	  
myofibroblast	  differentiation	  and	  is	  stimulated	  by	  myocardial	  infarction,	  cardiac	  
failure	  and	  hypertrophy.109	  The	  Smad	  pathway	  plays	  a	  central	  role	  in	  the	  signalling	  of	  
TGF-­‐β.110	  Overexpression	  in	  mice	  is	  associated	  with	  cardiac	  hypertrophy,	  enhanced	  
contractility	  in	  response	  to	  beta	  adrenergic	  agonists,	  and	  interstitial	  fibrosis.111	  This	  
model	  also	  demonstrated	  increased	  susceptibility	  to	  AF,	  reduced	  right	  atrial	  
conduction	  velocity	  and	  increased	  left	  atrial	  conduction	  heterogeneity.112	  A	  study	  by	  
Nakajima	  et	  al.	  demonstrated	  a	  model	  with	  enhanced	  local	  TGF-­‐β	  activity	  was	  
associated	  with	  atrial	  but	  not	  ventricular	  fibrosis.	  This	  was	  associated	  with	  increased	  
susceptibility	  to	  AF.113	  Abed	  et	  al.	  demonstrated	  obesity-­‐related	  TGF-­‐β	  overexpression	  
was	  associated	  with	  atrial	  conduction	  abnormalities	  and	  increased	  AF	  burden.23	  A	  
number	  of	  clinical	  conditions	  are	  associated	  with	  increased	  expression	  of	  TGF-­‐β	  in	  
ventricular	  tissue,	  including	  dilated114,	  hypertrophic115	  and	  valvular116	  
cardiomyopathy.	  Patients	  with	  AF	  have	  increased	  TGF-­‐β	  expression	  in	  excised	  atrial	  
tissue,	  and	  increased	  chronicity	  is	  associated	  with	  higher	  TGF-­‐β	  protein	  and	  mRNA	  
levels.117	  Increased	  serum	  TGF-­‐β	  is	  predictive	  of	  recurrence	  following	  AF	  ablation,	  but	  
only	  in	  patients	  with	  non-­‐paroxysmal	  AF.118	  It	  is	  also	  associated	  with	  atrial	  fibrosis	  of	  
excised	  appendage	  tissue	  and	  persistence	  of	  AF	  one	  year	  following	  the	  surgical	  maze	  
procedure.119	  
Angiotensin	  II	  is	  well	  recognised	  as	  a	  mediator	  of	  TGF-­‐β	  activity	  in	  myocardial	  
infarction.120-­‐122	  Angiotensin	  II	  stimulation	  also	  induces	  increased	  expression	  of	  TGF-­‐β	  
in	  neonatal	  cardiac	  myocytes	  and	  fibroblasts.123	  Animals	  deficient	  in	  in	  TGF-­‐β	  do	  not	  
develop	  cardiac	  hypertrophy	  in	  the	  presence	  of	  angiotensin	  II.124	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Treatment	  with	  ET-­‐1	  upregulated	  cardiac	  TGF-­‐β	  expression	  in	  diabetic	  rats	  and	  ET-­‐1	  
gene	  silencing	  inhibited	  TGF-­‐β	  signalling	  activation.125	  PDGF-­‐A,	  C	  and	  D	  all	  induced	  
TGF-­‐β	  production	  in	  cardiomyocytes	  in	  a	  chronic	  rejection	  rat	  model.126	  	  
Angiotensin	  II	  
The	  renin-­‐angiotensin-­‐aldosterone	  system	  (RAAS)	  is	  well	  recognised	  as	  having	  an	  
important	  role	  in	  several	  cardiac	  conditions,	  including	  hypertension,	  cardiac	  failure	  
and	  atherosclerosis.	  Inhibition	  of	  angiotensin	  converting	  enzyme	  is	  a	  cornerstone	  of	  
clinical	  heart	  failure	  management.	  RAAS	  activation	  is	  also	  involved	  in	  the	  
pathophysiology	  of	  AF.	  Angiotensin	  II	  has	  the	  most	  pronounced	  pathophysiological	  
effect	  and	  activates	  several	  profibrotic	  pathways	  via	  the	  AngII	  receptor	  type	  1	  (AT1)	  
and	  though	  the	  activation	  of	  fibroblasts	  to	  become	  myofibroblasts.22	  Mice	  with	  
overexpression	  of	  angiotensin	  converting	  enzyme	  and	  hence	  higher	  AngII	  levels	  
develop	  atrial	  dilatation,	  fibrosis	  and	  AF.127	  In	  a	  model	  of	  AF-­‐induced	  atrial	  fibrosis,	  
AngII	  mediated	  the	  degree	  of	  fibrosis	  via	  the	  Smad	  signalling	  pathway.128	  Atrial	  
substrate	  development	  in	  a	  congestive	  cardiac	  failure	  model	  was	  associated	  with	  
upregulation	  of	  AngII	  receptors	  in	  atrial	  tissue,	  which	  preceded	  elevation	  of	  plasma	  
levels,	  suggesting	  atrial	  tissue	  may	  produce	  AngII	  in	  response	  to	  pro-­‐fibrotic	  stimuli.129	  
Similarly,	  an	  obese	  AF	  animal	  model	  demonstrated	  similar	  upregulation	  with	  
increasing	  atrial	  fibrosis.23	  
The	  action	  of	  angiotensin	  II	  is	  closely	  tied	  to	  TGF-­‐β.	  Activation	  of	  the	  AT1	  receptor	  
induces	  production	  of	  TGF-­‐β,	  and	  AngII-­‐related	  fibrosis	  is	  reliant	  on	  the	  presence	  of	  
TGF-­‐β.130	  This	  autocrine	  loop	  acts	  through	  ALK5,	  Smad2,	  3	  and	  4	  and	  JNK	  signalling	  
pathways.131	  Angiotensin	  has	  an	  influence	  on	  ET,	  CTGF	  and	  PDGF	  but	  the	  reverse	  has	  
not	  been	  demonstrated.	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Connective	  tissue	  growth	  factor	  
CTGF	  is	  a	  potent	  profibrotic	  protein,	  originally	  identified	  on	  the	  surface	  and	  
extracellular	  matrix	  of	  fibroblasts.132	  Initially	  found	  to	  be	  involved	  in	  fibrotic	  processes	  
in	  skin,	  neoplasia	  and	  renal	  disease,	  it	  was	  subsequently	  determined	  to	  be	  
upregulated	  in	  atherosclerotic	  lesions	  and	  in	  ischaemic	  and	  infarcted	  myocardium.133	  
Human	  arterial	  tissue	  had	  undetectable	  levels	  of	  CTGF	  mRNA	  and	  protein,	  whereas	  
atherosclerotic	  arteries	  showed	  high	  expression	  in	  vascular	  smooth	  muscle	  cells	  in	  
association	  with	  fibrosis.134	  Left	  atrial	  tissue	  of	  patients	  with	  AF	  shows	  significant	  
upregulation	  of	  CTGF	  when	  compared	  to	  those	  in	  sinus	  rhythm.	  Using	  a	  mouse	  model,	  
this	  was	  shown	  to	  be	  regulated	  by	  AngII	  though	  the	  Rac-­‐1	  signalling	  pathway.135	  	  
TGF-­‐β,	  AngII	  and	  ET-­‐1	  have	  all	  been	  shown	  to	  induce	  CTGF	  activity.	  CTGF	  alone	  is	  only	  
weakly	  pro-­‐fibrotic;	  however	  in	  combination	  with	  TGF-­‐β,	  it	  has	  significant	  profibrotic	  
effects	  and	  may	  be	  required	  for	  TGF-­‐β	  to	  maximally	  induce	  fibrosis.133	  Ruperez	  at	  al.	  
studied	  CTGF	  expression	  in	  rat	  aortic	  tissue.	  Normal	  animals	  demonstrated	  
undetectable	  CTGF.	  Following	  AngII	  infusion,	  CTGF	  production	  was	  induced	  after	  3	  
days	  without	  evidence	  of	  ECM	  overproduction.	  At	  7	  days,	  CTGF	  overexpression	  
continued,	  along	  with	  the	  accumulation	  of	  several	  proteins	  associated	  with	  the	  ECM.	  
This	  early	  induction	  of	  CTGF	  induction	  is	  suggestive	  a	  central	  role	  in	  AngII-­‐related	  
fibrosis.134	  Elevated	  CTGF	  mRNA	  was	  found	  in	  the	  ventricular	  tissue	  of	  rats	  with	  
experimentally	  induced	  myocardial	  infarction.	  This	  mRNA	  induction	  was	  prevented	  by	  
angiotensin	  receptor	  blockade.136	  ET-­‐1	  upregulates	  CTGF	  mRNA	  expression,	  promoter	  
activity,	  and	  protein	  production	  in	  rat	  vascular	  smooth	  muscle	  cells.137	  and	  ET-­‐1	  gene	  
silencing	  inhibits	  CTGF	  cardiac	  expression	  in	  diabetic	  rats.125	  ET-­‐1	  infusion	  induces	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CTGF	  expression	  in	  mouse	  atrial	  tissue	  and	  CTGF	  silencing	  reduces	  expression	  of	  some	  
ECM	  components,	  suggestive	  of	  a	  downstream	  action.138	  
Platelet	  derived	  growth	  factor	  
PDGF	  is	  a	  growth	  factor	  involved	  in	  cell	  proliferation,	  smooth	  muscle	  cell	  growth	  and	  
angiogenesis	  and	  exists	  in	  multiple	  forms,	  AA,	  BB,	  AB,	  CC	  and	  DD,	  and	  has	  2	  receptors,	  
α	  and	  β.133	  It	  is	  a	  required	  element	  for	  fibroblast	  division	  and	  has	  long	  been	  
demonstrated	  to	  play	  a	  central	  role	  in	  wound	  healing.139	  It	  is	  predominantly	  
synthesised,	  stored	  and	  released	  by	  activated	  platelets,	  but	  is	  also	  produced	  by	  a	  
wide	  variety	  of	  cells,	  including	  those	  of	  the	  endothelium.	  A	  transgenic	  mouse	  model	  
with	  overexpression	  of	  PDGF	  developed	  cardiac	  fibrosis,	  hypertrophy	  and	  
impairment.140	  There	  is	  also	  heightened	  expression	  of	  PDGF	  and	  its	  receptor	  in	  atrial	  
tissue,	  when	  compared	  to	  ventricular,	  and	  this	  difference	  is	  exaggerated	  in	  heart	  
failure.141	  Exposure	  of	  myocytes	  to	  myofibroblasts	  induces	  shortening	  of	  action	  
potentials	  and	  reduction	  in	  calcium	  currents	  and	  similar	  effects	  are	  seen	  with	  direct	  
exposure	  to	  PDGF-­‐AB.	  Pre-­‐treatment	  with	  a	  PDGF-­‐neutralising	  antibody	  blocked	  these	  
effects	  in	  both	  scenarios,	  strongly	  suggesting	  electromechanical	  remodelling	  of	  
myocytes	  can	  be	  caused	  by	  myofibroblast	  exposure,	  whose	  action	  may	  be	  due	  to	  
PDGF-­‐AB	  release.142	  Another	  study	  examined	  pressure	  overloaded	  mice	  and	  
demonstrated	  upregulation	  of	  PDGF-­‐A	  in	  cardiac	  mast	  cells,	  with	  associated	  atrial	  
fibrosis.	  Blockade	  of	  PDGF	  receptors	  attenuated	  the	  fibrotic	  response	  and	  reduced	  AF	  
inducibility.143	  	  
PDGF-­‐BB	  was	  potentiated	  by	  ET-­‐1	  in	  aortic	  smooth	  muscle	  cells.144	  This	  was	  further	  
demonstrated	  by	  Mayyas	  et	  al,	  using	  microarray	  analysis	  of	  human	  left	  atrial	  
appendage	  tissue	  to	  demonstrate	  that	  endothelin-­‐1	  regulates	  PDGF	  expression.96	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TGF-­‐β-­‐induced	  growth	  responses	  of	  smooth	  muscle	  cells	  are	  associated	  with	  
enhanced	  production	  of	  PDGF-­‐AA	  but	  are	  only	  partially	  inhibited	  by	  PDGF-­‐AA	  
neutralisation.145	  Angiotensin	  II	  stimulates	  PDGF-­‐B	  expression	  in	  vascular	  smooth	  
muscle	  through	  mechanisms	  involving	  Ras-­‐ERK	  and	  JNK	  signalling	  pathways.146	  
Inflammatory	  molecules	  
Inflammation	  is	  increasingly	  recognised	  as	  one	  of	  the	  pathological	  processes	  in	  the	  
pathogenesis	  of	  AF.	  The	  pro-­‐fibrotic	  factors	  discussed	  above	  are	  also	  pro-­‐
inflammatory,	  but	  other	  molecules	  are	  also	  involved.	  Inflammatory	  cardiac	  conditions	  
such	  as	  pericarditis	  and	  myocarditis	  and	  inflammatory	  states	  such	  as	  during	  the	  post-­‐
operative	  period,	  have	  an	  association	  with	  AF,	  with	  the	  incidence	  of	  arrhythmia	  
coinciding	  with	  peak	  C-­‐reactive	  protein	  levels.147	  Atrial	  septal	  biopsies	  taken	  from	  
patients	  with	  ‘lone’	  AF	  revealed	  two-­‐thirds	  actually	  had	  features	  of	  occult	  
myocarditis.75	  Inflammatory	  cells	  have	  been	  demonstrated	  in	  animals	  with	  atrial	  
fibrosis.148	  
C-­‐reactive	  protein	  
Elevation	  of	  C	  reactive	  protein	  in	  human	  subjects	  is	  associated	  with	  both	  the	  current	  
and	  future	  presence	  of	  AF,149	  persistence	  of	  AF150	  and	  is	  predictive	  of	  both	  
unsuccessful	  cardioversion151	  and	  failure	  of	  catheter	  ablation.152	  However,	  there	  is	  
little	  data	  suggestive	  that	  CRP	  is	  more	  than	  just	  a	  marker	  of	  inflammation	  rather	  than	  
an	  active	  participant.	  	  	  
Interleukins	  
IL-­‐6	  is	  thought	  to	  be	  member	  of	  the	  interleukin	  family	  most	  associated	  with	  AF	  and	  
has	  an	  active	  role	  in	  its	  pathogenesis.	  It	  is	  a	  pleiotropic	  cytokine	  produced	  by	  T-­‐cells,	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macrophages	  and	  endothelial	  cells.	  Patients	  with	  chronic	  AF	  have	  higher	  IL-­‐6	  serum	  
levels	  that	  controls	  in	  sinus	  rhythm,153	  as	  do	  those	  with	  longer	  duration	  of	  AF	  and	  
larger	  atrial	  diameter.154	  Raised	  IL-­‐6	  levels	  also	  predict	  a	  lower	  success	  rate	  following	  
AF	  ablation.155	  Elevation	  of	  IL-­‐6	  was	  also	  predictive	  of	  the	  development	  of	  AF	  in	  over	  
3000	  patients	  with	  chronic	  kidney	  disease.156	  It	  is	  not	  clear,	  however	  if	  these	  
associations	  are	  due	  to	  the	  pro-­‐inflammatory	  effects	  of	  the	  underlying	  risk	  factors	  
associated	  with	  AF	  rather	  than	  to	  the	  disease	  itself.157	  Several	  other	  interleukins	  are	  
potentially	  involved	  in	  the	  pathogenesis	  of	  AF.	  Elevated	  IL-­‐2,	  IL-­‐8	  and	  IL-­‐10	  (but	  not	  IL-­‐
6)	  following	  cardiac	  surgery	  were	  predictive	  of	  post-­‐operative	  AF.158,	  159	  
Oxidative	  stress	  
Oxidative	  stress,	  in	  the	  form	  of	  overproduction	  of	  reactive	  oxygen	  species	  (ROS),	  is	  a	  
likely	  to	  play	  a	  significant	  role	  in	  both	  cardiac	  fibrosis,	  thrombosis	  and	  inflammatory	  
pathways.160	  Nicotinamide	  adenine	  dinucleotide	  phosphate-­‐oxidase	  (NADPH	  oxidase)	  
is	  a	  potential	  enzymic	  source	  of	  ROS	  and	  can	  be	  induced	  by	  rapid	  atrial	  pacing	  and	  
atrial	  stretch.161	  Angiotensin	  II	  also	  increases	  NADPH	  oxidase	  activity,	  but	  importantly,	  
the	  hypertrophic	  and	  fibrotic	  effects	  of	  AngII	  were	  suppressed	  in	  NADPH-­‐knockout	  
animals.162	  ROS	  have	  been	  shown	  to	  damage	  cardiac	  myofibrils163	  and	  cause	  calcium	  
overload.	  Analysis	  of	  human	  atrial	  appendages	  removed	  during	  mitral	  valve	  surgery	  
demonstrated	  increased	  NADPH	  activity	  in	  patients	  with	  a	  history	  of	  AF	  than	  in	  
controls.164	  
Gap	  junction	  proteins	  
Gap	  junction	  proteins,	  also	  known	  as	  connexins,	  connect	  the	  cytoplasm	  of	  adjoining	  
cells	  using	  two	  hemichannels,	  each	  comprised	  of	  six	  connexin	  proteins.165	  They	  allow	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the	  passage	  of	  both	  small	  molecules,	  typically	  less	  than	  1KDa	  in	  size,	  and	  play	  a	  critical	  
role	  in	  regulation	  of	  electrical	  conduction.	  Several	  connexins	  have	  been	  found	  in	  
cardiac	  tissue.	  Cx43	  is	  the	  most	  widespread	  and	  abundant	  of	  these	  proteins,	  followed	  
by	  Cx40,	  which	  is	  generally	  localised	  to	  conduction	  tissue.	  Gap	  junctions	  permit	  the	  
transmission	  of	  action	  potentials	  from	  one	  cell	  to	  another	  and,	  in	  atrial	  tissue,	  are	  
typically	  found	  at	  the	  end	  of	  cardiomyocytes,	  alongside	  desmosomes	  and	  actin	  
filaments.	  The	  arrangement	  of	  these	  connections	  is	  unique	  to	  atrial	  tissue	  and	  may	  
partially	  explain	  the	  anisotropy	  commonly	  found	  in	  the	  atrium.	  Disruption	  of	  connexin	  
function	  is	  associated	  with	  reduced	  intercellular	  conduction	  and	  subsequently	  with	  
AF.165	  Prolonged	  AF	  induced	  by	  rapid	  atrial	  pacing	  is	  associated	  with	  reduction	  in	  
connexin	  expression,	  with	  complete	  reversal	  following	  four	  months	  of	  sinus	  
rhythm.166	  AF	  in	  surgical	  patients	  is	  also	  associated	  reduction	  of	  Cx43,	  as	  well	  as	  with	  
lateralisation	  of	  both	  Cx40	  and	  Cx43	  within	  cells,	  with	  tissue	  from	  patients	  in	  SR	  
confined	  to	  the	  intercalated	  discs.74	  
Several	  relevant	  molecules	  have	  been	  demonstrated	  to	  have	  a	  direct	  effect	  on	  cardiac	  
connexin	  expression.	  Notably,	  ventricular	  myocytes	  exposed	  to	  endothelin-­‐1	  were	  
found	  to	  have	  both	  conduction	  slowing	  and	  reduced	  Cx43	  expression	  on	  
immunofluorescence.100	  In	  contrast,	  angiotensin	  II	  exposure	  increased	  ventricular	  
Cx43	  expression.167	  Cx43	  has	  also	  recently	  been	  demonstrated	  to	  contribute	  to	  TGF-­‐β	  
induced	  differentiation	  of	  cardiac	  fibroblasts	  to	  myofibroblasts.168	  Therapeutic	  
interventions	  targeting	  connexins	  show	  promising	  results.	  Bikou	  et	  al.	  used	  gene	  
therapy	  to	  restore	  AF-­‐induced	  Cx43	  under-­‐expression	  and	  demonstrated	  reduced	  
progression	  to	  persistent	  AF.169	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Ion	  channels	  
Calcium	  channels	  play	  a	  major	  role	  in	  the	  pathophysiology	  of	  AF.	  Early	  studies	  of	  the	  
rapid	  atrial	  pacing	  model	  demonstrated	  calcium	  overload	  in	  response	  to	  the	  rapid	  
atrial	  rates;	  atrial	  remodelling	  was	  prevented	  by	  the	  calcium	  channel	  blocker	  
verapamil	  and	  worsened	  by	  hypercalcaemia.57	  Patch	  clamp	  studies	  have	  shown	  this	  is	  
associated	  with	  reduction	  in	  density	  of	  L-­‐type	  calcium	  currents.	  The	  expected	  
reduction	  in	  action	  potential	  duration	  was	  prevented	  by	  calcium	  channel	  blockade,	  
strongly	  implicating	  calcium	  in	  the	  electrical	  remodelling	  process.170	  This	  reduction	  in	  
L-­‐type	  calcium	  currents	  was	  later	  seen	  in	  the	  atrial	  cells	  of	  patients	  with	  AF.171	  
Transcriptional	  downregulation	  of	  the	  Cav1.2	  α-­‐subunit	  underlies	  this	  current	  
abnormality,172	  acting	  via	  the	  calmodulin–calcineurin–NFAT	  system.173	  
Potassium	  channels,	  particularly	  inward	  rectifiers	  are	  responsible	  for	  the	  negative	  
resting	  membrane	  potential	  of	  the	  cardiomyocyte.	  In	  AF,	  this	  becomes	  more	  
negative,	  mainly	  due	  to	  increased	  expression	  of	  the	  channel	  subunit	  Kir2.1	  causing	  
enlargement	  of	  the	  potassium	  channel.	  This	  results	  in	  action	  potential	  shortening	  and	  
may	  be	  involved	  in	  AF	  induction,	  particularly	  in	  the	  setting	  of	  vagally	  mediated	  or	  
ischaemia-­‐related	  AF.	  Voltage	  gated	  potassium	  channels	  have	  also	  been	  implicated	  
but	  study	  findings	  have	  been	  inconsistent.22	  The	  rapid	  atrial	  pacing	  model	  is	  also	  
associated	  with	  downregulation	  of	  the	  INa	  sodium	  channel.	  This	  may	  play	  a	  role	  in	  the	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Reverse	  remodelling	  	  
There	  is	  some	  evidence	  that	  reversal	  of	  atrial	  substrate	  can	  occur	  if	  the	  stimulus	  for	  
substrate	  formation	  is	  no	  longer	  present.	  Echocardiographic	  improvement	  of	  atrial	  
function	  and	  size	  was	  seen	  in	  a	  cohort	  of	  patients	  undergoing	  permanent	  pacemaker	  
implantation	  when	  asynchronous	  ventricular	  only	  pacing	  was	  reprogrammed	  to	  
synchronous	  dual	  chamber	  pacing.176	  Another	  study	  examined	  the	  right	  atrium	  of	  
patients	  before	  and	  after	  atrial	  septal	  defect	  closure.	  Post	  closure	  right	  atrial	  volumes	  
showed	  significant	  reduction.	  There	  was	  partial	  resolution	  of	  the	  refractory	  period	  
abnormalities	  but	  persistence	  of	  conduction	  delay	  in	  the	  form	  of	  widely	  split	  double	  
potentials	  at	  the	  crista	  terminalis.177	  John	  et	  al.	  studied	  patients	  with	  mitral	  stenosis,	  
before	  and	  after	  mitral	  commissurotomy.	  Immediately	  following	  the	  procedure,	  there	  
was	  a	  reduction	  in	  atrial	  volume,	  improvement	  in	  conduction	  velocity	  and	  atrial	  
voltage,	  without	  changes	  in	  refractoriness.	  A	  subset	  of	  patients	  were	  restudied	  after	  
at	  least	  6	  months	  and	  demonstrated	  further	  reductions	  in	  atrial	  volumes	  and	  
improvements	  in	  conduction	  and	  bipolar	  voltage.178	  An	  animal	  study	  using	  a	  
ventricular	  pacing	  heart	  failure	  model	  found	  that	  5	  weeks	  after	  termination	  of	  pacing	  
and	  recovery	  of	  ventricular	  function,	  atrial	  function	  improved	  and	  propensity	  to	  AF	  
was	  reduced,	  however	  atrial	  conduction	  remained	  abnormal	  and	  there	  was	  no	  
reduction	  in	  the	  degree	  of	  fibrosis	  on	  histological	  examination.179	  It	  is	  possible	  that	  
the	  degree	  of	  reversibility	  is	  dependant	  on	  the	  severity	  and	  duration	  of	  the	  stimulus.	  
Additionally,	  the	  length	  of	  time	  required	  for	  recovery	  is	  unknown.	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1.3	  Obesity	  –	  pathophysiology	  in	  relation	  to	  AF	  
It	  is	  well	  recognised	  that	  obesity	  causes	  conditions	  associated	  with	  the	  development	  
of	  AF,	  in	  particular,	  hypertension,	  diabetes	  and	  obstructive	  sleep	  apnoea.	  Several	  of	  
these	  conditions	  often	  co-­‐exist	  and	  elucidating	  the	  contribution	  of	  each	  individual	  
condition	  can	  be	  challenging.	  As	  well	  as	  these	  indirect	  associations,	  the	  role	  of	  fat	  
itself	  is	  becoming	  increasingly	  clear.	  Adipose	  tissue	  has	  been	  demonstrated	  to	  play	  
and	  active	  role	  in	  endocrine	  and	  inflammatory	  processes.	  In	  particular,	  epicardial	  and	  
pericardial	  fat	  may	  have	  directly	  deleterious	  effects	  on	  atrial	  structure	  and	  function.	  	  
1.3.1	  Associated	  conditions	  
Hypertension	  
Elevated	  blood	  pressure	  is	  one	  of	  the	  leading	  causes	  of	  AF.	  In	  the	  Framingham	  cohort,	  
it	  increased	  the	  risk	  of	  AF	  by	  40	  to	  50%.9	  The	  multitude	  of	  mechanisms	  by	  which	  
obesity	  causes	  hypertension	  remain	  incompletely	  understood.	  Contributing	  factors	  
include	  sympathetic	  nervous	  system	  activation,	  impairment	  of	  natriuresis,	  
upregulation	  of	  the	  renin-­‐angiotensin-­‐aldosterone	  axis,	  neurohormonal	  imbalance	  
and	  endothelial	  dysfunction.180	  	  
Animal	  models	  of	  hypertension	  have	  demonstrated	  atrial	  dilatation,	  conduction	  
slowing,	  predisposition	  to	  AF	  and	  increased	  atrial	  fibrosis	  in	  animals	  treated	  with	  
unilateral	  renal	  artery	  clipping.	  Notably,	  these	  abnormalities	  developed	  in	  the	  short-­‐
term,	  and	  continued	  to	  develop	  over	  a	  4-­‐month	  period.59,	  181	  Similar	  findings	  have	  
been	  demonstrated	  in	  alternative	  hypertensive	  animal	  models	  60	  and	  endocardially	  in	  
human	  subjects.64	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Diabetes	  mellitus	  
The	  risk	  of	  developing	  AF	  in	  diabetes	  is	  similar	  to	  that	  of	  hypertension.9	  Almost	  90%	  
of	  individuals	  with	  type	  2	  diabetes	  are	  obese.	  Insulin	  resistance	  is	  thought	  to	  be	  the	  
underlying	  pathophysiological	  mechanism	  of	  hyperglycaemia	  and	  the	  subsequent	  
sequelae,	  but	  there	  is	  also	  evidence	  that	  the	  major	  insulin-­‐producing	  cells,	  pancreatic	  
B	  cells,	  are	  also	  dysfunctional.	  The	  mechanisms	  by	  which	  obesity	  causes	  diabetes	  are	  
not	  fully	  understood,	  but	  an	  inflammatory	  mediated	  process	  in	  a	  genetically	  
susceptible	  individual	  is	  the	  likely	  cause.182	  There	  is	  limited	  data	  on	  the	  effect	  of	  
diabetes	  on	  cardiac	  electrophysiology,	  but	  one	  study	  used	  a	  rat	  model	  of	  induced	  
diabetes	  resulting	  in	  conduction	  slowing	  and	  increased	  ventricular	  fibrillation	  
inducibility.183	  This	  was	  not	  associated	  with	  tissue	  fibrosis	  or	  changes	  in	  sodium	  or	  
potassium	  currents.	  No	  published	  studies	  have	  examined	  the	  effect	  on	  atrial	  tissue.	  	  	  	  
Obstructive	  sleep	  apnoea	  
Obesity	  is	  a	  prominent	  cause	  of	  sleep	  apnoea,	  with	  up	  to	  45%	  of	  obese	  subjects	  being	  
affected	  by	  the	  condition.	  It	  is	  a	  clear	  cause	  of	  hypertension	  and	  has	  been	  heavily	  
implicated	  in	  the	  development	  of	  other	  cardiac	  diseases,	  its	  presence	  conferring	  a	  
two	  to	  four	  fold	  risk	  of	  incident	  AF.184	  185	  Fat	  deposition	  around	  the	  upper	  airway	  
results	  in	  a	  reduced	  luminal	  diameter	  with	  subsequent	  increased	  collapsibility	  and	  
increased	  thoracic	  fat	  deposition	  reduces	  residual	  capacity.186	  This	  causes	  
intermittent	  hypoxia,	  with	  saturations	  as	  low	  as	  60%	  in	  severe	  cases,	  which	  causes	  
accelerated	  atherosclerosis187	  and	  stimulates	  production	  of	  cytokines,	  in	  addition	  to	  
those	  already	  produced	  by	  adipocytes,	  with	  the	  degree	  of	  elevation	  correlating	  with	  
disease	  severity.188	  In	  addition	  to	  elevating	  system	  blood	  pressure,	  sleep	  apnoea	  also	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causes	  pulmonary	  hypertension,	  which	  is	  reversible	  through	  CPAP	  therapy.	  As	  in	  
patients	  with	  primary	  pulmonary	  hypertension,	  increased	  endothelin-­‐1	  levels	  have	  
been	  found	  in	  patients	  with	  OSA	  and	  this	  has	  been	  postulated	  as	  a	  direct	  cause	  of	  
systemic	  hypertension.189	  Animal	  studies	  have	  shown	  application	  of	  an	  endothelin	  
receptor	  antagonist	  negated	  the	  effect	  of	  simulated	  sleep	  apnoea	  on	  cerebral	  
vasculature	  and	  oxidative	  stress.190	  In	  one	  study,	  hypercapnia	  but	  not	  hypoxia,	  was	  
associated	  with	  adverse	  atrial	  electrophysiology	  and	  increased	  AF	  inducibility	  was	  
seen	  following	  normalization	  of	  CO2.191	  In	  another,	  recurrent	  apnoeic	  episodes	  in	  
normal	  weight	  rats	  increased	  inducibility	  of	  AF	  and	  caused	  atrial	  fibrosis	  and	  Cx43	  
downregulation.192	  Multiple	  studies	  have	  suggested	  severity	  of	  sleep	  apnoea	  
correlates	  strongly	  with	  poor	  outcomes	  in	  patients	  with	  AF;	  treatment	  of	  sleep	  
apnoea	  with	  CPAP	  is	  beneficial,	  for	  example	  in	  patients	  following	  AF	  ablation,	  but	  this	  
requires	  confirmation	  in	  a	  randomised	  controlled	  trial.193	  
1.3.2	  Anatomical	  
Obesity	  was	  found	  to	  be	  the	  strongest	  predictor	  of	  left	  atrial	  (LA)	  size	  in	  a	  large	  cohort	  
of	  hypertensive	  patients54	  as	  well	  as	  in	  a	  randomly	  selected	  cohort	  of	  over	  1000	  
subjects	  from	  the	  general	  population.53	  Detailed	  echocardiography	  examining	  LA	  
strain	  rates	  have	  also	  shown	  a	  reduction	  in	  LA	  function	  in	  obese	  children.194	  
Ventricular	  effects	  are	  also	  seen	  with	  obesity.	  Although	  overt	  systolic	  dysfunction	  is	  
uncommon	  in	  the	  absence	  of	  concomitant	  cardiac	  disease,	  abnormalities	  of	  diastolic	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Pericardial	  fat	  
There	  is	  increasing	  evidence	  that	  fat	  surrounding	  the	  heart	  has	  a	  direct	  effect	  on	  
cardiac	  tissue.	  The	  Framingham	  data	  set	  initially	  provided	  a	  link	  between	  pericardial	  
fat	  and	  AF.	  Computed	  tomography-­‐measured	  pericardial	  fat	  volume,	  but	  not	  
intrathoracic	  or	  abdominal	  fat,	  was	  associated	  with	  the	  prevalence	  of	  AF	  in	  a	  cohort	  
of	  3217	  patients,	  54	  of	  which	  had	  AF.	  This	  association	  persisted	  following	  adjustment	  
for	  BMI.197	  Batal	  and	  colleagues	  found	  that	  increasing	  thickness	  of	  fat	  between	  the	  
left	  atrium	  and	  oesophagus	  was	  associated	  with	  increasing	  severity	  of	  AF.	  The	  median	  
thickness	  of	  this	  fat	  depot	  was	  0.34cm,	  0.39cm	  and	  0.56cm	  in	  patients	  with	  no	  AF,	  
paroxysmal	  and	  persistent	  AF	  respectively.	  This	  difference	  persisted	  even	  after	  
multivariate	  adjustment	  for	  age,	  BMI	  and	  LA	  area.198	  Magnetic	  resonance	  imaging	  is	  
also	  useful	  in	  measuring	  pericardial	  fat	  to	  predict	  severity	  of	  AF,	  as	  demonstrated	  by	  
Wong	  et	  al.,	  who	  studied	  130	  patients,	  110	  of	  whom	  had	  known	  AF.	  Both	  periatrial	  
and	  periventricular	  fat	  were	  associated	  with	  AF	  severity	  and	  were	  also	  predictive	  of	  
outcome	  following	  AF	  ablation.	  The	  predictive	  nature	  of	  epicardial	  fat	  again	  persisted	  
following	  adjustment	  for	  other	  risk	  factors,	  importantly	  including	  BMI.199	  Venteclef	  et	  
al.	  elegantly	  demonstrated	  the	  direct	  secretory	  action	  of	  epicardial	  adipose	  tissue	  by	  
comparing	  the	  effect	  of	  human	  epicardial	  and	  subcutaneous	  on	  the	  development	  of	  
atrial	  fibrosis	  in	  a	  rat	  heart.	  Atrial	  fibrosis	  was	  increased	  two-­‐fold	  in	  tissue	  incubated	  
with	  epicardial	  fat	  when	  compared	  to	  subcutaneous.	  Additional	  analyses	  determined	  
epicardial	  fat	  secreted	  more	  MMP1,	  8	  and	  9,	  Activin	  A	  (a	  member	  of	  the	  TGF-­‐β	  
superfamily)	  and	  VEGF.	  TGF-­‐β1,	  however,	  was	  unchanged	  between	  fat	  types.200	  This	  
increased	  secretion	  of	  cytokines	  may	  be	  due	  to	  relative	  hypoxia	  of	  the	  tissue	  in	  the	  
obese	  state.201	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1.3.3	  Electrophysiological	  
A	  study	  by	  Abed	  et	  al.	  examined	  the	  atrial	  characteristics	  in	  an	  obese	  ovine	  model.	  
With	  increasing	  weight	  gain,	  atrial	  conduction	  slowed	  and	  became	  more	  
heterogeneous,	  with	  no	  effect	  on	  refractory	  periods.	  AF	  was	  more	  easily	  induced	  and	  
has	  a	  longer	  duration	  in	  obese	  animals	  when	  compared	  with	  control.23	  These	  findings	  
were	  extended	  in	  a	  more	  chronic	  ovine	  model	  of	  obesity.	  In	  this	  study,	  Mahajan	  et	  al.	  
demonstrated	  areas	  of	  low	  voltage	  endocardially,	  adjacent	  to	  regions	  rich	  in	  
pericardial	  fat.	  In	  addition,	  the	  authors	  observed	  the	  novel	  feature	  of	  pericardial	  fat	  
infiltration	  of	  the	  adjacent	  atrial	  myocardium,	  potentially	  a	  unique	  component	  of	  the	  
substrate	  for	  AF	  in	  obesity.24	  
In	  patients	  undergoing	  AF	  ablation,	  obesity	  was	  associated	  with	  shortening	  of	  ERP	  in	  
the	  atrium	  and	  pulmonary	  veins.	  Although	  LA	  conduction	  velocities	  were	  similar	  in	  
obese	  and	  non-­‐obese	  groups,	  those	  with	  obesity	  had	  slower	  longitudinal	  PV	  
conduction.202	  
1.3.4	  Molecular	  
Obesity	  is	  associated	  with	  an	  inflammatory	  response,	  albeit	  one	  that	  is	  10	  to	  100-­‐fold	  
lower	  than	  those	  observed	  in	  people	  with	  acute	  inflammatory	  or	  immune	  diseases,	  as	  
evidenced	  by	  elevation	  in	  a	  wide	  variety	  of	  inflammatory	  markers.	  Adipose	  tissue	  was	  
previously	  thought	  to	  be	  a	  bystander	  in	  obese	  individuals,	  but	  has	  more	  recently	  been	  
shown	  to	  be	  actively	  involved	  in	  the	  cardiovascular	  sequelae	  of	  obesity	  through	  the	  
secretion	  of	  numerous	  cytokines	  and	  hormone-­‐like	  factors,	  including	  leptin,	  TNF-­‐α,	  IL-­‐
6	  and	  resistin.203	  These	  pro-­‐inflammatory	  molecules	  have	  a	  direct	  effect	  on	  
endothelial	  function	  and	  are	  associated	  with	  systemic	  inflammation	  and	  oxidative	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stress,	  leading	  to	  arterial	  stiffness204,	  atherosclerosis205	  and	  hypertension.206	  
Increased	  levels	  of	  these	  substances	  are	  directly	  associated	  with	  an	  increase	  in	  
cardiovascular	  events.207,	  208	  
Obesity	  also	  has	  an	  effect	  on	  factors	  directly	  implicated	  in	  AF.	  The	  study	  by	  Abed	  et	  al.	  
mentioned	  in	  the	  previous	  section	  also	  revealed	  upregulation	  of	  TGF-­‐β,	  ET,	  PDGF	  and	  
CTGF	  in	  atrial	  tissue	  correlated	  with	  weight	  and	  the	  associated	  structural	  and	  
electrophysiological	  abnormalities.23	  
Analysis	  of	  fat	  in	  obese	  rats	  demonstrated	  in	  increased	  expression	  of	  TGF-­‐β209	  and	  
TGF-­‐β	  expression	  in	  human	  adipose	  tissue	  correlates	  strongly	  with	  BMI.210	  It	  is	  also	  
released	  directly	  from	  human	  adipose	  tissue	  and	  this	  is	  enhanced	  by	  insulin	  
exposure.211	  TGF-­‐β	  is	  also	  involved	  in	  regulation	  of	  insulin	  transcription.212	  
Analysis	  of	  plasma	  samples	  from	  obese	  and	  non-­‐obese	  subjects	  showed	  elevation	  of	  
ET-­‐1	  in	  obesity,	  with	  or	  without	  associated	  hypertension.	  Following	  a	  period	  of	  caloric	  
restriction,	  weight	  loss	  was	  associated	  with	  a	  reduction	  in	  ET-­‐1,	  even	  in	  patients	  
without	  hypertension	  at	  baseline.213	  Individuals	  with	  obesity	  have	  enhanced	  
vasoconstriction	  when	  exposed	  to	  endothelin.214	  Diabetes-­‐associated	  cardiac	  fibrosis	  
was	  suppressed	  in	  endothelin	  knock-­‐out	  mice.125	  	  
Serum	  AngII	  is	  associated	  with	  BMI	  and	  markers	  of	  insulin	  resistance,	  with	  significant	  
reduction	  with	  weight	  loss.215	  Obese	  rats	  had	  an	  enhanced	  hypertensive	  response	  to	  
angiotensin	  II,	  with	  aldosterone	  acting	  as	  an	  intermediary	  hormone.216	  Treatment	  of	  
well,	  obese	  individuals	  with	  an	  aldosterone	  antagonist	  improved	  echocardiographic	  
markers	  of	  subtle	  LV	  dysfunction	  and	  reduced	  serological	  markers	  of	  fibrosis.217	  
CTGF	  was	  upregulated	  in	  adipose	  tissue	  of	  obese	  mice218	  and	  a	  recent	  study	  by	  
Pellegrinelli	  et	  al.	  found	  upregulation	  of	  CTGF	  in	  adipocytes	  cultured	  with	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decellularised	  material	  of	  adipose	  tissue	  and,	  with	  correlation	  of	  CTGF	  and	  the	  degree	  
of	  peri-­‐adipocyte	  fibrosis.219	  Obese	  rats	  have	  higher	  PDGF	  plasma	  levels	  and	  mRNA	  
levels	  in	  adipose	  tissue,	  with	  macrophages	  being	  the	  dominant	  source	  of	  PDGF	  
expression.220	  
1.3.5	  Weight	  loss	  
Several	  animal	  studies	  have	  demonstrated	  beneficial	  cardiac	  changes	  in	  response	  to	  
weight	  loss,	  including	  reduction	  in	  oxidative	  stress	  and	  inflammation,221	  and	  
improvements	  in	  diastolic	  dysfunction.222	  Weight	  loss	  has	  been	  demonstrated	  to	  
impact	  the	  outcome	  of	  patients	  diagnosed	  with	  AF.	  Abed	  et	  al.	  randomised	  150	  
patients	  with	  AF	  to	  receive	  a	  weight	  management	  program	  or	  standard	  care.	  Over	  15	  
months,	  those	  receiving	  weight	  reduction	  advice	  were	  significantly	  less	  symptomatic,	  
and	  had	  a	  lower	  AF	  burden,	  with	  both	  fewer	  episodes	  and	  lower	  cumulative	  
duration.223	  Pathak	  et	  al.	  assessed	  the	  effect	  of	  aggressive	  risk	  factor	  management	  in	  
61	  patients	  undergoing	  AF	  ablation,	  compared	  with	  88	  control	  subjects	  over	  a	  follow	  
up	  period	  of	  over	  40	  months.224	  The	  intervention	  group	  lost	  a	  mean	  of	  13.2	  ±	  5.4kg,	  
and	  this	  was	  associated	  with	  significantly	  improved	  outcomes	  following	  AF	  ablation.	  
At	  the	  end	  of	  the	  follow	  up	  period	  32.9%	  and	  87%	  of	  patients	  in	  the	  intervention	  arm	  
were	  arrhythmia	  free	  following	  single	  and	  multiple	  procedures	  respectively.	  In	  
contrast,	  only	  9.7%	  and	  18%	  of	  those	  undergoing	  standard	  care	  were	  free	  from	  AF.	  A	  
larger	  cohort	  with	  5-­‐year	  follow	  up	  data	  confirmed	  that	  the	  improvements	  in	  both	  AF	  
symptomatology	  and	  objective	  measures	  of	  AF	  burden	  were	  sustained	  in	  the	  long	  
term.	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1.3.6	  Weight	  fluctuation	  
Fluctuating	  weight	  has	  long	  been	  thought	  to	  be	  detrimental	  to	  cardiac	  well-­‐being,	  
even	  when	  compared	  to	  more	  obese	  patients	  with	  stable	  weight.	  This	  has	  been	  
demonstrated	  in	  several	  retrospective	  population	  studies.	  Several	  studies	  have	  
showed	  very	  significant	  increases	  in	  cardiac	  mortality	  in	  patients	  with	  a	  fluctuating	  
weight,	  when	  compared	  with	  both	  lean	  and	  obese,	  stable	  weight	  patients,225,	  226	  
whereas	  others	  have	  not	  found	  a	  correlation.227	  Another	  study	  demonstrated	  
significantly	  lower	  HDL	  levels	  in	  patients	  who	  reported	  the	  greatest	  weight	  cycling.228	  
The	  LEGACY	  study	  analysed	  355	  patients	  with	  AF	  and	  obesity.	  Patients	  with	  weight	  
fluctuation	  had	  improved	  outcomes	  than	  those	  with	  stable	  or	  increasing	  weight,	  but	  
significantly	  worse	  outcomes	  than	  those	  with	  linear	  weight	  loss.	  Subgroup	  analysis	  of	  
the	  179	  patients	  with	  fluctuating	  weight	  showed	  wide	  fluctuation	  was	  associated	  with	  
adverse	  cardiac	  remodelling	  and	  increased	  risk	  of	  AF	  recurrence	  when	  compared	  with	  
those	  with	  minimal	  fluctuation.229	  The	  pathophysiology	  behind	  these	  findings	  has	  not	  
been	  determined	  and	  mechanistic	  links	  have	  been	  elusive,	  prominently	  due	  to	  the	  
inability	  to	  perform	  randomised	  controlled	  human	  trials	  and	  the	  heterogeneity	  of	  the	  
groups	  being	  studied.	  
1.4	  Upstream	  therapy	  for	  AF	  prevention	  
Management	  of	  AF	  historically	  used	  antiarrhythmic	  therapy	  to	  alter	  atrial	  
electrophysiology.	  In	  the	  event	  of	  failure	  of	  these	  agents,	  a	  more	  interventional	  
approach,	  for	  example	  RF	  ablation	  of	  AF,	  is	  subsequently	  considered.	  With	  the	  
discovery	  of	  atrial	  remodelling	  acting	  as	  a	  substrate	  for	  AF,	  recent	  focus	  has	  shifted	  to	  
reversal	  of	  this	  substrate	  to	  reduce	  AF	  burden,	  treating	  the	  arrhythmia	  ‘upstream’.	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1.4.1	  Renin-­‐angiotensin-­‐aldosterone	  system	  blockade	  
RAAS	  blockade	  is	  the	  most	  widely	  investigated	  upstream	  therapy,	  with	  a	  number	  of	  
positive	  human	  trials.	  Madrid	  et	  al.	  studied	  154	  patients	  undergoing	  electrical	  
cardioversion	  of	  persistent	  AF.	  All	  patients	  were	  treated	  with	  the	  antiarrhythmic	  
amiodarone	  and	  79	  were	  also	  given	  the	  Angiotensin	  II	  receptor	  blocker	  (ARB)	  
irbesartan.	  After	  two	  months,	  85%	  of	  patients	  given	  irbesartan	  maintained	  sinus	  
rhythm,	  compared	  with	  63%	  in	  patients	  who	  did	  not.	  After	  a	  median	  follow	  up	  period	  
of	  254	  days,	  this	  remained	  significantly	  higher	  (79%	  vs	  56%,	  p=0.007).230	  Similar	  
results	  were	  found	  in	  a	  trial	  using	  an	  angiotensin	  converting	  enzyme	  inhibitor	  
(ACEi).231	  Treatment	  with	  ACEi	  also	  reduces	  the	  incidence	  of	  new	  AF	  in	  several	  cardiac	  
conditions.	  Wachtell	  et	  al.	  examined	  over	  9000	  patients	  with	  hypertension	  and	  left	  
ventricular	  hypertrophy	  as	  part	  of	  the	  randomised	  controlled	  LIFE	  trial,	  comparing	  
antihypertensive	  treatment	  with	  the	  ARB	  losartan	  and	  the	  beta-­‐blocker	  atenolol.	  New	  
onset	  AF	  occurred	  in	  6.8	  per	  1,000	  years	  of	  follow	  up	  in	  patients	  treated	  with	  losartan	  
vs	  10.1	  per	  1,000	  in	  those	  taking	  atenolol	  (p<0.001).	  In	  patients	  already	  diagnosed	  
with	  AF,	  losartan	  was	  also	  protective	  when	  examining	  the	  composite	  end	  point	  of	  
cardiovascular	  events,	  stroke,	  and	  hospitalisation	  for	  heart	  failure.232	  ACEi	  also	  
prevents	  new	  onset	  AF	  following	  myocardial	  infarction233	  and	  in	  patients	  with	  heart	  
failure.234,	  235	  In	  a	  recent	  randomised	  controlled	  trial	  of	  120	  patients	  undergoing	  AF	  
ablation,	  treatment	  with	  an	  ARB	  improved	  outcomes	  in	  a	  dose	  dependant	  manner.236	  
However,	  several	  large	  trials	  comparing	  RAAS	  blockade	  with	  alternative	  anti-­‐
hypertensives	  have	  not	  revealed	  any	  significant	  benefit	  with	  ACEi	  or	  ARBs,	  either	  on	  
incident	  AF	  or	  other	  cardiovascular	  conditions.237	  The	  recent	  ANTIPAF	  study	  was	  the	  
first	  trial	  to	  prospectively	  examine	  AF	  control	  in	  patients	  with	  known	  paroxysmal	  AF	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without	  structural	  heart	  disease.	  After	  1	  year	  of	  follow-­‐up,	  ARB	  treatment	  failed	  to	  
demonstrate	  any	  benefit	  on	  AF	  burden	  when	  compared	  with	  placebo.238	  
An	  alternative	  target	  of	  the	  RAAS	  system,	  aldosterone	  receptor	  blockade,	  is	  used	  
commonly	  for	  patients	  with	  LV	  dysfunction,	  after	  a	  mortality	  benefit	  was	  noted	  in	  the	  
RALES	  trial.239	  Treatment	  with	  eplerenone	  improved	  maintenance	  of	  sinus	  rhythm	  
following	  cardioversion	  of	  long-­‐standing	  persistent	  AF.240	  Animal	  studies	  suggest	  
reduction	  of	  atrial	  remodelling	  and	  AF	  inducibility	  in	  a	  hypertensive	  rat	  model	  treated	  
with	  epleronone241	  and	  canine	  model	  treated	  with	  spironolactone.242	  
1.4.2	  Endothelin-­‐receptor	  blockade	  
Following	  the	  discovery	  of	  increased	  levels	  of	  ET-­‐1	  in	  the	  serum243	  and	  upregulation	  in	  
the	  lung	  tissue	  of	  patients	  with	  pulmonary	  hypertension244,	  blockade	  of	  these	  
receptors	  has	  been	  extensively	  studied,	  in	  particular	  bosentan,	  an	  orally	  active	  non-­‐
peptide	  antagonist	  of	  both	  endothelin	  receptor	  subtypes,	  with	  a	  predominance	  for	  
ET-­‐A.	  Early	  animal	  studies	  showed	  that	  endothelin-­‐receptor	  antagonism	  decreased	  
inflammation,	  reduced	  deterioration	  of	  pulmonary	  vessel	  permeability	  and	  prevented	  
the	  development	  of	  fibrosis	  in	  subjects	  with	  pulmonary	  inflammation.245,	  246	  It	  was	  
shown	  to	  reduce	  pulmonary	  arterial	  pressure	  and	  right	  ventricular	  hypertrophy	  with	  
no	  change	  in	  systemic	  vascular	  resistance,	  prior	  to	  human	  trials.247	  Endothelin	  
receptor	  blockade	  is	  now	  a	  widely	  accepted	  treatment	  for	  both	  mild	  and	  severe	  forms	  
of	  the	  disease,	  following	  human	  trials	  demonstrating	  clear	  clinical	  benefit,	  namely	  
improved	  exercise	  tolerance,	  haemodynamics	  and	  prognosis.248-­‐250	  Macitentan,	  a	  
newer	  dual	  receptor	  antagonist,	  has	  recently	  completed	  a	  phase	  3	  trial,	  where	  it	  
demonstrated	  a	  significant	  effect	  on	  mortality,	  without	  the	  hepatotoxicity	  and	  fluid	  
retention	  seen	  in	  previous	  trials	  of	  endothelin	  receptor	  antagonists.251	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Studies	  have	  also	  investigated	  the	  effect	  on	  endothelin-­‐receptor	  antagonism	  in	  left	  
ventricular	  dysfunction	  following	  the	  discovery	  that	  bosentan	  treatment	  significantly	  
reduced	  left	  ventricular	  collagen	  density,	  improved	  haemodynamics	  and	  offered	  a	  
survival	  benefit	  in	  a	  heart	  failure	  model	  in	  rats252,	  and	  reduced	  ventricular	  fibrosis	  due	  
to	  hypertension	  and	  diabetes.98,	  253	  Initial	  human	  studies	  showed	  an	  improvement	  in	  
haemodynamics,	  however	  longer	  term	  trials	  did	  not	  support	  their	  use,	  predominantly	  
due	  to	  the	  side	  effect	  of	  fluid	  retention.	  Recently,	  a	  human	  trial	  showed	  ERA	  
treatment	  slowed	  the	  progression	  of	  coronary	  atherosclerosis.254	  Seccia	  et	  al.	  
demonstrated	  that	  in	  a	  hypertensive	  rat	  model,	  blockade	  of	  both	  ET-­‐A	  and	  ET-­‐B	  
receptors	  resulted	  in	  reduced	  cardiac	  fibrosis,	  but	  pure	  ET-­‐A	  receptor	  antagonism	  did	  
not,255	  evidence	  that	  dual	  receptor	  blockade	  may	  be	  required	  for	  prevention	  of	  
cardiac	  remodelling.	  
1.4.3	  Transforming	  growth	  factor	  receptor	  blockade	  
TGF-­‐β	  blockade	  has	  been	  studied	  in	  several	  pre-­‐clinical	  cardiac	  models.	  Studies	  
investigating	  its	  role	  in	  myocardial	  infarction	  have	  demonstrated	  potentially	  
conflicting	  results.	  Early	  TGF-­‐β	  blockade	  following	  infarction	  exacerbated	  cardiac	  
failure,	  prevented	  myocardial	  remodelling	  and	  increased	  mortality.256,	  257	  This	  was	  
associated	  with	  enhanced	  neutrophil	  infiltration,	  increased	  expression	  of	  profibrotic	  
factors,	  in	  particular,	  TNF-­‐α,	  IL-­‐6,	  IL-­‐1h,	  MCP-­‐1	  and	  MMP.	  In	  contrast,	  inhibition	  late	  
after	  infarction	  had	  a	  beneficial	  effect	  on	  cardiac	  remodelling,	  with	  reduced	  collagen	  
deposition.258	  Pressure	  overloaded	  rats	  developed	  cardiac	  hypertrophy,	  fibrosis	  and	  
diastolic	  dysfunction,	  all	  of	  which	  were	  reduced	  by	  blockade	  of	  TGF-­‐β.259	  Investigation	  
of	  atrial	  effects	  was	  possible	  through	  the	  use	  of	  a	  rapid	  atrial	  pacing	  model	  in	  dogs.	  
Half	  of	  the	  group	  were	  treated	  with	  the	  TGF-­‐β	  antagonist	  tranilast.	  Animals	  who	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received	  treatment	  developed	  significantly	  less	  ERP	  reduction,	  conduction	  slowing,	  
atrial	  fibrosis,	  calcium	  channel	  reduction	  and	  inducibility	  of	  AF.260	  
Human	  studies	  of	  tranilast	  have	  unfortunately	  been	  less	  successful.	  Despite	  two	  initial	  
studies	  reporting	  a	  reduction	  in	  coronary	  artery	  restenosis,261,	  262	  a	  large	  multicentre	  
trial	  showed	  the	  treatment	  had	  no	  effect	  on	  any	  coronary	  artery	  disease	  
parameter.263	  Although	  it	  is	  used	  in	  Asia	  as	  a	  treatment	  for	  asthma	  and	  to	  promote	  
wound	  healing,	  minimal	  data	  exists	  to	  support	  this.	  
1.5	  Thesis	  aims	  
This	  thesis	  aims	  to	  examine	  the	  effect	  of	  weight	  fluctuation	  on	  atrial	  
electrophysiology,	  in	  comparison	  with	  obesity	  and	  normal	  weight.	  It	  then	  investigates	  
the	  effect	  of	  anti-­‐fibrotic	  treatment	  on	  the	  atrial	  substrate	  associated	  with	  obesity,	  
particularly	  in	  regards	  to	  the	  electrophysiological	  properties	  of	  the	  atrium.	  We	  hope	  
to	  also	  grant	  some	  insight	  into	  the	  molecular	  actions	  of	  these	  interventions.	  Chapter	  3	  
investigates	  the	  effect	  of	  endothelin	  receptor	  blockade	  and	  chapter	  4	  examines	  the	  
effect	  of	  blockade	  of	  transforming	  growth	  factor.	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Chapter	  2	  –	  Weight	  cycling	  is	  associated	  with	  progressive	  atrial	  
remodelling	  
2.1	  Introduction	  
Obesity	  has	  a	  clear	  relationship	  with	  the	  development	  of	  atrial	  fibrillation	  and	  is	  
associated	  with	  increased	  atrial	  fibrosis	  and	  a	  pro-­‐inflammatory	  state.14,23	  Several	  
prospective	  studies	  have	  identified	  that	  significant	  fluctuations	  in	  weight,	  or	  ‘weight	  
cycling’	  confers	  an	  increased	  risk	  of	  developing	  coronary	  heart	  disease	  and	  increases	  
all-­‐cause	  and	  cardiovascular	  mortality.226,	  264	  Even	  when	  weight	  fluctuation	  occurs	  in	  
early	  life,	  the	  effects	  can	  be	  seen	  over	  the	  following	  25	  years.265	  Fluctuation	  in	  weight	  
also	  causes	  activation	  of	  the	  sympathetic	  nervous	  system	  with	  resultant	  increased	  
heart	  rate	  and	  blood	  pressure	  variability,	  as	  well	  as	  fluctuation	  in	  renal	  and	  pancreatic	  
function.266	  Weight	  cycling	  has	  a	  high	  prevalence	  in	  the	  general	  population,	  occurring	  
in	  18%	  of	  men	  and	  27%	  of	  women.267	  This	  common	  clinical	  scenario	  has	  recently	  been	  
found	  to	  be	  associated	  with	  increased	  arrhythmia	  burden	  in	  patients	  with	  known	  AF,	  
in	  a	  ‘dose-­‐dependant’	  fashion.229	  The	  pathophysiology	  behind	  these	  findings	  is	  not	  
clear;	  data	  is	  inevitably	  retrospective	  and	  studies	  often	  consist	  of	  heterogeneous	  
populations	  and	  lack	  standard	  definitions	  for	  weight	  cycling.	  
Using	  an	  obese	  ovine	  model,	  we	  sought	  to	  examine	  the	  effect	  on	  atrial	  
electrophysiology	  in	  animals	  with	  induced	  weight	  fluctuation	  in	  comparison	  with	  both	  
obese	  and	  lean	  controls.	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2.2	  Methods	  
Twenty-­‐four	  ovine	  (Merino	  cross)	  subjects	  were	  studied	  according	  to	  National	  Health	  
and	  Medical	  Research	  Council	  of	  Australia	  guidelines	  on	  animal	  research.	  Animal	  
research	  committees	  of	  the	  University	  of	  Adelaide	  and	  South	  Australian	  Health	  and	  
Medical	  Research	  Institute	  granted	  approval	  for	  the	  study.	  
2.2.1	  Study	  Protocol	  
Animals	  were	  randomised	  into	  3	  groups:	  obese,	  weight	  fluctuation	  and	  lean	  control.	  
All	  animals	  underwent	  sequential	  electrophysiological	  studies	  as	  shown	  in	  figure	  1.	  
The	  weight	  fluctuation	  group	  had	  2	  ‘cycles’	  of	  weight	  gain	  followed	  by	  weight	  loss.	  
Investigations	  were	  performed	  when	  animals	  reached	  their	  baseline	  weight	  after	  the	  
first	  cycle	  (cycle	  1)	  at	  68	  weeks.	  Repeat	  investigations	  and	  terminal	  studies	  were	  
performed	  once	  the	  animals	  again	  reached	  their	  baseline	  weight	  (cycle	  2)	  after	  a	  
further	  74	  weeks.	  Eight	  animals	  were	  commenced	  on	  high	  fat	  diet	  at	  study	  
commencement	  and	  this	  was	  continued	  for	  the	  duration	  of	  the	  study.	  Seven	  lean	  
animals	  were	  used	  as	  controls	  and	  had	  their	  weight	  maintained	  at	  baseline.	  These	  
two	  groups	  were	  studied	  at	  the	  same	  time-­‐points	  as	  the	  weight	  fluctuation	  animals	  to	  
allow	  comparison.	  Percutaneous	  endocardial	  electrophysiological	  and	  
electroanatomical	  evaluation	  was	  performed	  on	  all	  animals.	  Additionally	  at	  terminal	  
study,	  high-­‐density	  mapping	  of	  the	  epicardial	  surface	  was	  performed	  using	  a	  90	  pole	  
plaque,	  to	  allow	  more	  detailed	  electrophysiological	  study.	  	  
2.2.2	  Weight	  control	  
Obesity	  was	  induced	  using	  a	  diet	  of	  high	  fat	  pellets	  consisting	  of	  wheat,	  barley	  and	  
canola	  seed.	  Excess	  voluntary	  intake	  was	  of	  grass	  alfalfa	  silage	  and	  hay.	  As	  previously	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described,	  the	  pellets	  were	  gradually	  introduced	  at	  8%	  excess	  basal	  energy	  
requirements	  and	  rationed	  to	  70%	  of	  the	  total	  dry	  matter	  intake.	  	  
Weight	  loss	  was	  induced	  by	  gradual	  removal	  of	  the	  high	  fat	  pellets	  and	  the	  
introduction	  of	  high	  quality	  cereal	  hay	  at	  75%	  of	  usual	  intake.	  
Weights	  were	  recorded	  weekly	  and	  reported	  weights	  were	  those	  taken	  prior	  to	  
electrophysiological	  procedures	  in	  a	  shorn	  and	  fasted	  state.	  Haematological	  and	  
biochemical	  indices	  were	  monitored	  using	  blood	  collected	  prior	  to	  each	  invasive	  
procedure.	  
Weight	  fluctuation	  
Animals	  in	  the	  weight	  fluctuation	  group	  were	  commenced	  on	  the	  high	  fat	  diet	  and	  
this	  was	  continued	  until	  their	  weights	  were	  20%	  higher	  than	  baseline.	  At	  this	  stage,	  
the	  weight	  loss	  diet	  was	  introduced	  to	  reduce	  the	  weight	  back	  to	  their	  baseline	  
weights.	  Once	  this	  was	  achieved,	  this	  constituted	  one	  cycle	  and	  electrophysiological	  
testing	  was	  performed.	  	  
2.2.3	  Animal	  anaesthesia	  
General	  anaesthesia	  was	  used	  for	  all	  procedures.	  Diazepam	  0.4mg/kg	  was	  given	  prior	  
to	  induction	  with	  ketamine	  5mg/kg.	  Isoflurane	  2.5%	  with	  4	  litres/minute	  of	  oxygen	  
was	  used	  for	  maintenance.	  Non-­‐invasive	  blood	  pressure,	  heart	  rate,	  pulse	  oximetry	  
and	  end-­‐tidal	  CO2	  were	  continuously	  monitored.	  
2.2.4	  Endocardial	  electrophysiological	  study	  
Percutaneous	  internal	  jugular	  and	  femoral	  venous	  access	  was	  obtained.	  Via	  the	  
internal	  jugular	  route,	  a	  10-­‐pole	  coronary	  sinus	  (CS)	  catheter	  (2–5–2	  mm	  inter-­‐
electrode	  spacing)	  was	  positioned	  with	  the	  proximal	  bipole	  at	  the	  CS	  ostium.	  To	  allow	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left	  atrial	  mapping,	  transseptal	  puncture	  was	  performed	  using	  an	  SL0	  sheath	  and	  BRK	  
needle.	  Surface	  ECG	  and	  bipolar	  endocardial	  electrograms	  were	  monitored	  
continuously	  and	  stored	  on	  a	  digital	  amplifier/recorder	  system	  (LabSystem	  Pro,	  Bard	  
Electrophysiology,	  Lowell,	  MA).	  Electrogram	  filters	  were	  applied	  from	  30	  to	  500	  Hz.	  
Electroanatomical	  mapping	  
Electroanatomical	  maps	  were	  created	  in	  sinus	  rhythm	  using	  the	  Carto	  XP	  system	  
(Biosense	  Webster,	  Diamond	  Bar,	  CA)	  as	  previously	  described.	  Right	  and	  left	  atrial	  
maps	  were	  recorded	  using	  a	  3.5-­‐mm	  tip	  catheter	  ablation	  catheter	  (Navistar,	  
Biosense	  Webster,	  Diamond	  Bar,	  CA)	  with	  a	  minimum	  of	  80	  points	  in	  each	  chamber.	  
Endocardial	  contact	  was	  confirmed	  with	  a	  combination	  of	  electrogram	  stability,	  
fluoroscopy	  and	  the	  Carto	  point	  stability	  criteria	  (≤6mm	  stability	  in	  space,	  ≤5ms	  in	  
local	  activation	  time).	  Location,	  voltage	  and	  activation	  timing	  were	  recorded	  at	  each	  
point.	  For	  analysis	  the	  atria	  was	  divided	  as	  follows:	  Septal	  right	  atrium	  (RA);	  High	  
lateral	  RA;	  Low	  lateral	  RA;	  Posterior	  left	  atrium	  (LA);	  Lateral	  LA;	  and	  Inferior	  LA.	  The	  
following	  parameters	  were	  determined:	  
1. Regional	  Conduction	  velocity	  
• The	  direction	  of	  conduction	  was	  determined	  from	  examination	  of	  
isochronal	  maps.	  3-­‐5	  pairs	  of	  points	  were	  taken	  in	  the	  direction	  of	  
conduction,	  with	  velocity	  being	  calculated	  using	  the	  distance	  and	  
timing	  as	  reported	  by	  the	  mapping	  system.	  
2. Signal	  fractionation	  
• This	  was	  defined	  as	  a	  signal	  greater	  than	  50ms	  duration	  with	  four	  or	  
more	  deflections.	  
3. Bipolar	  voltage	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• Low	  voltage	  was	  defined	  as	  an	  area	  with	  three	  contiguous	  points	  with	  
a	  bipolar	  voltage	  of	  <0.5mV.	  
• Scar	  was	  an	  area	  with	  three	  contiguous	  points	  <0.05mV.	  
4. Atrial	  volume	  
Effective	  refractory	  periods	  
Effective	  refractory	  period	  (ERP)	  was	  measured	  at	  three	  times	  the	  tissue	  capture	  
threshold	  at	  a	  pulse	  width	  of	  2ms,	  using	  a	  Micropace	  EPS	  320	  stimulator	  (Micropace,	  
Canterbury,	  Australia).	  This	  was	  performed	  from	  the	  following	  8	  sites:	  Septal	  RA;	  High	  
lateral	  RA;	  Low	  lateral	  RA;	  Posterior	  LA;	  Lateral	  LA;	  Inferior	  LA;	  Proximal	  coronary	  
sinus	  (CS);	  and	  Distal	  CS.	  Eight	  S1	  stimuli	  were	  delivered	  with	  S1	  cycle	  lengths	  of	  400	  
and	  200ms,	  with	  incremental	  S2	  impulses	  (10ms	  increments),	  commencing	  at	  a	  
coupling	  interval	  of	  100ms.	  The	  ERP	  was	  the	  longest	  S1-­‐S2	  interval	  without	  atrial	  
capture.	  The	  mean	  of	  two	  attempts	  was	  recorded.	  An	  additional	  attempt	  was	  made	  if	  
the	  difference	  between	  attempts	  was	  greater	  than	  10ms.	  	  	  
AF	  induction	  
Inducibility	  of	  AF	  was	  determined	  using	  a	  burst	  pacing	  protocol	  from	  the	  left	  atrial	  
appendage,	  performed	  at	  the	  terminal	  study.	  Twenty	  impulses	  were	  delivered	  at	  the	  
lowest	  cycle	  length	  with	  1:1	  atrial	  capture.	  An	  episode	  was	  defined	  as	  irregular	  atrial	  
activity	  lasting	  greater	  than	  or	  equal	  to	  2	  seconds.	  This	  protocol	  was	  repeated	  five	  
times	  and	  the	  number	  of	  episodes	  and	  total	  duration	  were	  recorded.	  Sustained	  AF	  
was	  defined	  as	  an	  episode	  lasting	  >10	  minutes.	  In	  the	  event	  of	  sustained	  AF,	  no	  
further	  testing	  was	  performed.	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Haemodynamic	  recordings	  
Non-­‐invasive	  systolic	  blood	  pressure	  and	  invasive	  mean	  right	  atrial	  and	  systolic	  right	  
ventricular	  pressures	  via	  the	  SR0	  sheath	  were	  recorded	  at	  the	  start	  of	  each	  
procedure.	  Mean	  left	  atrial	  pressure	  was	  recorded	  immediately	  following	  transseptal	  
puncture.	  
2.2.5	  Terminal	  epicardial	  electrophysiological	  study	  
Left	  lateral	  thoracotomy	  was	  performed	  to	  access	  the	  left	  atrium.	  A	  custom	  made	  90-­‐
pole	  plaque	  was	  placed	  on	  the	  left	  atrial	  appendage	  and	  connected	  to	  the	  computer-­‐
based	  digital	  amplifier/recorder	  system	  (LabSystem	  Pro,	  Bard	  Electrophysiology,	  
Lowell,	  MA).	  Pacing	  was	  performed	  from	  each	  of	  the	  four	  corners	  of	  the	  plaque	  at	  
400ms.	  Epicardial	  electrograms	  were	  recorded	  and	  the	  following	  determined:	  
1. Effective	  refractory	  periods	  were	  measured	  using	  the	  same	  protocol	  as	  the	  
endocardial	  study.	  	  
2. Conduction	  velocity	  was	  determined	  using	  activation	  maps	  analysed	  by	  
custom	  software,	  as	  previously	  described.59	  The	  peak	  of	  the	  largest	  amplitude	  
deflection	  on	  each	  bipolar	  electrogram	  was	  automatically	  annotated	  and	  
manually	  verified.	  Local	  conduction	  velocity	  was	  calculated	  for	  each	  point	  
from	  triangulated	  local	  vectors,	  allowing	  subsequent	  calculation	  of	  mean	  
velocity	  for	  each	  map.	  
3. Conduction	  heterogeneity	  was	  calculated	  using	  established	  phase	  mapping	  
techniques	  integrated	  into	  the	  software,	  as	  previously	  described.59	  Absolute	  
conduction	  phase	  delay	  was	  calculated	  by	  subtracting	  the	  5th	  from	  the	  95th	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percentile	  of	  the	  phase	  difference	  distribution	  (P5-­‐95).	  Conduction	  
heterogeneity	  index	  was	  derived	  from	  dividing	  P5-­‐95	  by	  the	  median	  (P50).	  
2.2.6	  Statistical	  Analysis	  
Normally	  distributed	  data	  was	  expressed	  as	  mean	  ±	  standard	  deviation	  and	  compared	  
using	  unpaired	  t-­‐test.	  Analysis	  of	  variance	  was	  used	  to	  detect	  differences	  between	  
groups	  over	  time.	  Due	  to	  the	  dependence	  in	  observations	  from	  the	  same	  animal,	  
conduction	  velocity	  and	  ERP	  across	  regions	  were	  analysed	  using	  a	  mixed	  effects	  
model	  ANOVA.	  Sheep	  ID	  was	  used	  as	  a	  random	  effect	  and	  combinations	  of	  group,	  
timepoint	  and	  region	  were	  used	  as	  fixed	  effects.	  A	  maximum	  of	  two	  fixed	  effects	  
were	  entered	  into	  the	  statistical	  model	  at	  one	  time,	  with	  testing	  of	  both	  main	  effects	  
and	  their	  interaction.	  If	  a	  significant	  interaction	  was	  present,	  post-­‐hoc	  testing	  was	  
performed.	  AF	  duration	  was	  non-­‐parametric;	  therefore	  log-­‐transformation	  was	  
performed	  prior	  to	  t-­‐test	  comparison,	  with	  values	  expressed	  as	  median	  and	  
interquartile	  range.	  P-­‐values	  of	  less	  than	  0.05	  were	  considered	  statistically	  significant.	  
Analyses	  were	  performed	  using	  SPSS	  version	  23	  (SPSS	  Inc.	  Chicago,	  IL).	  
2.3	  Results	  
2.3.1	  Weight,	  structural	  and	  haemodynamic	  parameters	  	  
The	  changes	  in	  weight,	  body	  fat,	  haemodynamics	  and	  cardiac	  structure	  are	  shown	  in	  
table	  1a	  and	  1b,	  following	  the	  first	  (cycle	  1)	  and	  second	  (cycle	  2)	  cycles	  of	  weight	  
change.	  The	  fluctuating	  weight	  group	  returned	  to	  baseline	  weight	  prior	  to	  each	  study.	  
During	  cycle	  1,	  the	  mean	  maximum	  weight	  of	  this	  group	  was	  89±4kg,	  and	  during	  cycle	  
2,	  the	  mean	  weight	  peaked	  at	  99±6kg.	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After	  cycle	  1,	  the	  obese	  group	  was	  a	  significantly	  higher	  weight	  than	  both	  lean	  and	  
fluctuating	  weight	  groups.	  Right	  and	  left	  atrial	  pressures	  were	  significantly	  higher	  in	  
this	  group,	  and	  there	  was	  a	  trend	  towards	  larger	  atrial	  volumes.	  The	  fluctuating	  
weight	  group	  had	  numerically	  higher	  left	  atrial	  pressure	  and	  volume	  than	  the	  lean	  
group,	  but	  this	  did	  not	  reach	  statistical	  significance.	  	  
After	  cycle	  2,	  the	  obese	  group	  again	  had	  significantly	  higher	  weights	  than	  fluctuating	  
and	  lean	  animals.	  When	  compared	  with	  lean	  controls,	  obese	  animals	  had	  significantly	  
elevated	  atrial	  and	  right	  ventricular	  pressures,	  larger	  left	  atrial	  volume	  and	  a	  strong	  
trend	  towards	  increased	  systolic	  blood	  pressure.	  At	  this	  timepoint,	  the	  fluctuating	  
weight	  group	  had	  developed	  significantly	  increased	  left	  atrial	  pressure	  and	  volume	  
when	  compared	  to	  the	  lean	  control	  group.	  When	  compared	  with	  the	  obese	  group,	  
the	  fluctuating	  weight	  group	  had	  a	  similar	  left	  atrial	  volume,	  whereas	  the	  LA	  pressure	  
was	  significantly	  lower.	  	  
2.3.2	  Electrophysiological	  parameters	  
Conduction	  velocity	  -­‐	  endocardial	  
Conduction	  slowing	  was	  seen	  in	  the	  obese	  group	  and	  was	  relatively	  preserved	  over	  
time	  in	  lean	  animals,	  with	  a	  significant	  difference	  at	  mid	  point	  (1.01±0.06	  vs	  
1.26±0.05m/s,	  p<0.001)	  and	  end	  point	  study	  (0.96±0.06	  vs	  1.25±0.05m/s,	  p<0.001).	  
Following	  the	  first	  cycle,	  the	  weight	  fluctuation	  group	  demonstrated	  no	  significant	  
difference	  in	  overall	  conduction	  when	  compared	  with	  lean	  controls	  (1.21±0.06	  vs	  
1.26±0.05m/s,	  p=NS)	  as	  shown	  in	  figure	  2.	  On	  examination	  of	  individual	  regions,	  
however,	  there	  was	  significant	  reduction	  in	  conduction	  velocity	  at	  the	  inferior	  left	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atrial	  region	  of	  the	  fluctuating	  group	  when	  compared	  with	  lean	  animals	  (0.99±0.14	  vs	  
1.25±0.13,	  p=0.001).	  
At	  the	  end	  of	  cycle	  2,	  the	  weight	  fluctuation	  group	  developed	  significant	  overall	  
conduction	  slowing	  (1.21±0.06	  vs	  1.07±0.06m/s,	  p<0.001),	  whereas	  the	  lean	  control	  
group	  was	  unchanged	  (figure	  2).	  However,	  the	  conduction	  slowing	  seen	  in	  the	  
fluctuating	  weight	  group	  was	  not	  as	  severe	  as	  the	  obese	  group	  (1.07±0.06m/s	  vs	  
0.96±0.07m/s,	  p<0.001).	  Again,	  regional	  heterogeneity	  was	  present	  and	  was	  more	  
widespread	  than	  after	  cycle	  1.	  Conduction	  was	  significantly	  slower	  in	  the	  fluctuating	  
weight	  group	  at	  the	  inferior	  LA	  (1.02±0.13	  vs	  1.21±0.13,	  p=0.001),	  posterior	  LA	  
(0.96±0.13	  vs	  1.29±0.12,	  p<0.001)	  and	  lower	  lateral	  RA	  (0.95±0.15	  vs	  1.18±0.14,	  
p<0.001)	  in	  comparison	  with	  lean	  controls.	  All	  of	  these	  areas	  of	  reduced	  conduction	  
showed	  similar	  velocities	  to	  the	  obese	  group	  (p=NS	  for	  all	  3	  regions).	  
Conduction	  velocity	  –	  epicardial	  
At	  endpoint	  study,	  mean	  conduction	  velocity	  on	  the	  epicardial	  surface	  was	  significant	  
lower	  in	  the	  obese	  group	  (0.92±0.05m/s)	  and	  in	  the	  weight	  fluctuation	  group	  
(0.98±0.04m/s)	  when	  compared	  with	  the	  control	  group	  (1.06±0.05m/s,	  p<0.01).	  
There	  were	  no	  significant	  differences	  between	  epicardial	  plaque	  sites.	  	  
Conduction	  heterogeneity	  was	  similar	  in	  the	  obese	  (1.67±0.33)	  and	  control	  groups	  
(1.72±0.33),	  but	  significantly	  higher	  in	  the	  fluctuating	  weight	  group	  (2.26±0.30	  
p<0.01).	  
Effective	  refractory	  periods	  
Endocardial	  ERPs	  were	  not	  significantly	  different	  in	  any	  of	  the	  3	  groups	  following	  the	  
first	  cycle	  (figure	  4).	  However,	  following	  the	  cycle	  2,	  there	  was	  a	  significant	  reduction	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in	  ERP	  at	  a	  drivetrain	  of	  400ms	  in	  the	  group	  with	  continuous	  weight	  gain,	  when	  
compared	  with	  controls	  (153±18	  vs	  178±20ms,	  p=0.045),	  with	  a	  trend	  with	  a	  200ms	  
drivetrain	  (p=0.09).	  There	  were	  no	  significant	  regional	  differences	  between	  any	  
groups	  at	  either	  drivetrain	  cycle	  length	  (region*group	  interaction=NS).	  
The	  weight	  fluctuation	  group	  showed	  no	  change	  in	  ERP	  over	  time	  and	  was	  
comparable	  to	  the	  lean	  control	  group	  after	  cycle	  1	  and	  cycle	  2.	  
Epicardial	  ERPs	  demonstrated	  similar	  ERPs	  between	  obese	  and	  lean	  groups	  as	  shown	  
in	  figure	  5.	  The	  weight	  fluctuation	  group	  had	  significantly	  higher	  ERPs	  than	  both	  
obese	  and	  lean	  groups	  with	  a	  drivetrain	  of	  200ms,	  with	  a	  trend	  towards	  higher	  ERPs	  
at	  400ms.	  There	  were	  no	  significant	  regional	  differences	  between	  any	  groups	  at	  
either	  drivetrain	  (region*group	  interaction=NS).	  
AF	  inducibility	  
AF	  duration	  at	  the	  end	  of	  the	  study	  is	  shown	  in	  figure	  6.	  The	  obese	  group	  had	  a	  
significantly	  longer	  overall	  AF	  duration	  than	  the	  lean	  group	  (59s	  [IQR	  66.7]	  vs	  4s	  [IQR	  
7.0],	  p<0.001)	  and	  significantly	  more	  episodes	  (100%	  [IQR	  30]	  vs	  20%	  [IQR	  40],	  
p<0.001).	  The	  weight	  fluctuation	  group	  also	  had	  significantly	  longer	  AF	  duration	  than	  
the	  lean	  controls	  (29s	  [IQR	  77.5]	  vs	  4s	  [IQR	  7],	  p=0.04).	  There	  was	  also	  a	  trend	  to	  
more	  episodes	  in	  the	  weight	  fluctuation	  group	  (60%	  [IQR	  70]	  vs	  20%	  [IQR	  40],	  
p=0.08).	  The	  obese	  group	  had	  a	  longer	  duration	  of	  AF	  than	  the	  weight	  fluctuation	  
group,	  but	  this	  did	  not	  reach	  statistical	  significance.	  There	  was	  a	  trend	  towards	  the	  
obese	  group	  having	  more	  AF	  episodes	  induced	  than	  the	  weight	  fluctuation	  group	  
(100%	  [IQR	  30]	  vs	  60%	  [IQR	  70],	  p=0.06).	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2.4	  Discussion	  
This	  study	  presents	  new	  information	  on	  the	  impact	  of	  weight	  fluctuation	  on	  the	  atrial	  
substrate	  and	  propensity	  to	  AF.	  It	  provides	  important	  insights	  into	  the	  
haemodynamic,	  structural	  and	  electrophysiological	  remodelling	  of	  the	  atria	  with	  
fluctuations	  in	  weight.	  We	  have	  previously	  demonstrated	  progressive	  elevation	  of	  
cardiac	  pressures,	  chamber	  dilatation,	  conduction	  slowing	  and	  increased	  AF	  
inducibility	  with	  increasing	  obesity.	  This	  study	  confirms	  these	  findings	  and	  
additionally	  demonstrates	  that	  weight	  cycling,	  when	  compared	  to	  lean	  controls,	  is	  
associated	  with:	  
1) Reduction	  in	  endocardial	  atrial	  conduction	  velocity	  following	  the	  second	  cycle	  
of	  weight	  gain	  followed	  by	  weight	  loss,	  despite	  return	  to	  normal	  weight.	  This	  
was	  not	  seen	  following	  the	  first	  cycle	  of	  weight	  change.	  
2) Reduction	  in	  epicardial	  conduction	  velocity	  at	  the	  end	  of	  the	  study.	  
3) Increased	  left	  atrial	  pressure	  and	  volume.	  These	  values	  were	  numerically	  
higher	  following	  the	  first	  cycle,	  but	  did	  not	  reach	  statistical	  significance	  until	  
after	  the	  second	  cycle.	  
4) Increased	  AF	  duration.	  
5) No	  change	  in	  endocardial	  atrial	  refractory	  periods	  and	  higher	  epicardial	  
refractory	  periods	  
Heterogeneity	  of	  conduction	  slowing	  
When	  compared	  with	  obese	  animals,	  the	  reduction	  in	  conduction	  velocity	  was	  
significantly	  less	  in	  animals	  subjected	  to	  weight	  fluctuation.	  Notably,	  the	  reduction	  in	  
conduction	  velocity	  seen	  in	  the	  weight	  fluctuation	  group	  was	  heterogeneous	  across	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different	  atrial	  sites.	  This	  is	  in	  contrast	  to	  the	  homogeneous	  reduction	  seen	  with	  
sustained	  weight	  gain.	  This	  may	  be	  due	  to	  the	  studies	  being	  performed	  at	  an	  earlier	  
stage	  of	  the	  disease;	  however,	  it	  may	  be	  related	  to	  the	  distribution	  of	  epicardial	  fat.	  It	  
is	  well	  recognised	  that	  fat	  contains	  an	  array	  of	  cytokines,	  with	  increased	  levels	  in	  
epicardial	  fat	  when	  compared	  to	  fat	  from	  the	  abdomen.268	  Recent	  studies	  have	  found	  
fat	  also	  directly	  secretes	  pro-­‐inflammatory	  and	  pro-­‐fibrotic	  molecules,	  which	  act	  on	  
local	  structures.	  In	  particular,	  epicardial	  fat	  has	  been	  shown	  to	  directly	  induce	  atrial	  
fibrosis.200	  With	  the	  fluctuations	  in	  weight	  seen	  in	  our	  study,	  fat	  turnover	  and	  hence	  
secretory	  action	  may	  be	  increased,	  inducing	  more	  pronounced	  local	  effects.	  Following	  
the	  first	  cycle,	  although	  conduction	  was	  unaffected	  overall,	  a	  pronounced	  reduction	  
in	  conduction	  was	  seen	  in	  the	  inferior	  region	  of	  the	  left	  atrium.	  This	  is	  in	  close	  
proximity	  to	  the	  atrio-­‐ventricular	  groove	  and	  its	  large	  associated	  fat	  depot.	  Following	  
the	  second	  cycle,	  the	  posterior	  left	  atrium	  and	  lower	  lateral	  right	  atrium	  were	  
similarly	  affected.	  The	  posterior	  LA	  also	  has	  an	  epicardial	  fat	  depot	  and	  previous	  
studies	  have	  even	  demonstrated	  that,	  on	  histological	  examination,	  this	  fat	  infiltrates	  
the	  atrial	  tissue,	  which	  may	  be	  one	  of	  the	  mechanisms	  by	  which	  abnormalities	  in	  
conduction	  and	  signal	  voltage	  occur.24	  The	  lower	  lateral	  RA	  region	  is	  in	  close	  
proximity	  to	  the	  right	  atrio-­‐ventricular	  groove	  and	  its	  associated	  fat	  depot.	  The	  
association	  between	  volume	  of	  epicardial	  fat	  in	  each	  area	  and	  its	  secretory	  action	  
requires	  further	  investigation.	  
Atrial	  dilatation	  and	  pressure	  elevation	  
Animals	  with	  weight	  fluctuation	  developed	  progressive	  left	  atrial	  dilatation	  and	  
increased	  left	  atrial	  pressure	  when	  compared	  with	  lean	  animals,	  however	  this	  was	  not	  
as	  severe	  as	  seen	  in	  the	  obese	  animals.	  It	  is	  unclear	  whether	  these	  abnormalities	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persist	  with	  prolonged	  weight	  normalisation.	  Previous	  studies	  have	  demonstrated	  
partial	  reversibility	  of	  these	  structural	  changes	  with	  weight	  loss,	  but	  to	  date,	  full	  
reversibility	  has	  not	  been	  shown.229	  
Effective	  refractory	  period	  reduction	  
Another	  finding	  that	  has	  not	  previously	  been	  demonstrated	  in	  this	  model	  is	  the	  
significant	  reduction	  in	  endocardial	  atrial	  ERP	  in	  the	  sustained	  obesity	  group.	  Previous	  
obese	  ovine	  studies	  found	  no	  change	  in	  ERP	  in	  the	  intermediate	  or	  longer	  term.23,	  24	  
Mahajan	  et	  al	  studied	  animals	  that	  became	  obese	  over	  a	  period	  of	  72	  weeks;	  our	  
study	  was	  more	  than	  double	  in	  duration.	  This	  may	  explain	  the	  difference	  in	  these	  
findings,	  and	  would	  suggest	  that	  changes	  in	  conduction	  occur	  at	  an	  earlier	  stage,	  
whereas	  refractory	  period	  changes	  occur	  later	  in	  the	  disease	  process.	  Reduction	  in	  
ERP	  has	  been	  demonstrated	  in	  human	  subjects	  by	  Munger	  et	  al.	  Obese	  individuals	  
had	  a	  reduced	  ERP	  across	  several	  right	  and	  left	  atrial	  sites,	  particularly	  in	  the	  
pulmonary	  veins.202	  However,	  this	  study	  was	  performed	  in	  patients	  undergoing	  
ablation	  for	  highly	  symptomatic,	  drug	  refractory	  AF,	  which	  may	  contribute	  to	  these	  
changes	  in	  atrial	  electrophysiology	  and	  may	  limit	  extrapolation	  to	  the	  general	  obese	  
population.	  	  
Atrial	  fibrillation	  inducibility	  
The	  duration	  of	  atrial	  fibrillation	  during	  the	  induction	  protocol	  was	  significantly	  longer	  
in	  the	  weight	  fluctuation	  group	  when	  compared	  with	  lean	  controls.	  This	  is	  in	  keeping	  
with	  investigation	  by	  Pathak	  and	  colleagues,	  who	  examined	  the	  outcome	  of	  179	  
patients	  with	  AF	  and	  weight	  fluctuation	  as	  part	  of	  the	  LEGACY	  study.229	  Fluctuation	  in	  
weight	  had	  a	  negative	  impact	  on	  outcome	  over	  a	  follow	  up	  period	  of	  5	  years.	  Patients	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with	  less	  than	  2%	  fluctuation	  had	  a	  dramatically	  improved	  prognosis	  when	  compared	  
with	  those	  with	  greater	  than	  5%,	  with	  AF	  free	  survival	  of	  85%	  and	  44%	  respectively.	  
Clinical	  implications	  
From	  a	  clinical	  perspective,	  this	  study	  may	  help	  in	  the	  counselling	  and	  management	  of	  
patients	  embarking	  on	  a	  weight	  loss	  programme.	  Although	  some	  data	  suggests	  
poorer	  outcomes	  following	  weight	  cycling,	  our	  study	  shows	  that,	  while	  weight	  cycling	  
is	  not	  optimal	  with	  regards	  to	  atrial	  structure	  and	  function,	  persistent	  obesity	  is	  
associated	  with	  even	  more	  pronounced	  abnormalities.	  
Limitations	  
The	  pathophysiology	  demonstrated	  in	  this	  ovine	  study,	  as	  with	  all	  animal	  models,	  may	  
differ	  with	  human	  subjects.	  The	  distribution	  of	  epicardial	  fat	  may	  vary	  and	  different	  
fibrotic	  pathways	  may	  predominate.	  The	  degree	  of	  weight	  fluctuation	  was	  higher	  in	  
the	  second	  cycle,	  which	  may	  have	  accentuated	  the	  differences	  between	  time-­‐points.	  
Although	  the	  weight	  fluctuation	  group	  returned	  to	  normal	  weight	  after	  both	  cycles,	  
the	  abnormal	  atrial	  electrophysiology	  seen	  after	  the	  second	  cycle	  may	  have	  
normalised	  after	  a	  more	  prolonged	  period	  of	  weight	  normalisation.	  Further	  studies	  
are	  warranted	  to	  determine	  the	  permanence	  of	  these	  abnormalities.	  
2.5	  Conclusion	  	  
Weight	  fluctuation	  is	  associated	  with	  the	  development	  of	  abnormal	  atrial	  
electrophysiology	  and	  propensity	  to	  AF,	  despite	  return	  to	  normal	  weight.	  However,	  
these	  changes	  are	  not	  as	  severe	  as	  with	  progressive	  weight	  gain.	  These	  findings	  may	  
assist	  in	  the	  management	  of	  patients	  undergoing	  weight	  loss.	   	  
	   58	  
Table	  1a	  and	  b.	  Structural	  and	  haemodynamic	  characteristics	  of	  obese,	  fluctuating	  and	  
lean	  groups	  at	  cycle	  1	  (top)	  and	  cycle	  2	  (bottom).	  







(obese	  vs	  lean)	  
Weight	  (kg)	  
	   90±3	   74±6	   72±5	   <0.001	   NS	   <0.001	  
Systolic	  BP	  
(mmHg)	   81±10	   77±9	   83±7	   NS	   NS	   NS	  
RV	  systolic	  
pressure	  (mmHg)	   16±2	   14±4	   13±3	   NS	   NS	   NS	  
RA	  pressure	  
(mmHg)	   6.5±2.6	   2.9±1.1	   2.4±1.2	   0.002	   NS	   0.001	  
LA	  pressure	  
(mmHg)	   7.5±2.1	   5.5±1.2	   4.0±1.5	   0.1	   NS	   0.005	  
LA	  volume	  (ml)	  
	   55±8	   51±11	   43±5	   NS	   NS	   0.1	  
	  







(obese	  vs	  lean)	  
Weight	  (kg)	  
	   108±7*	   77±4	   76±4	   <0.001	   NS	   <0.001	  
Systolic	  BP	  
(mmHg)	   93±13	   81±9	   79±5	   0.08	   NS	   0.06	  
RV	  systolic	  
pressure	  (mmHg)	   18±4	   13±3	   11±2	   0.02	   NS	   0.002	  
RA	  pressure	  
(mmHg)	   7.3±2.5	   4.6±2.3	   2.9±0.8	   0.06	   NS	   0.003	  
LA	  pressure	  
(mmHg)	   8.5±1.7	   5.8±1.6	   3.7±0.9	   0.008	   0.07	   <0.001	  
LA	  volume	  (ml)	  
	   52±7	   47±5	   39±3	   NS	   0.01	   <0.001	  
	  
*	  p<0.05	  between	  cycle	  1	  and	  cycle	  2.	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Figure	  1.	  Study	  design	  
	  
	   	  
	   60	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Figure	  3.	  Conduction	  velocity	  by	  region	  after	  cycle	  1	  (left)	  and	  cycle	  2	  (right)
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Figure	  5.	  Epicardial	  effective	  refractory	  periods	  at	  endpoint	  study.	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Chapter	  3	  -­‐	  The	  role	  of	  endothelin-­‐receptor	  blockade	  in	  the	  
prevention	  of	  the	  substrate	  for	  atrial	  fibrillation	  –	  an	  
interventional	  study	  in	  an	  obese	  ovine	  model	  
3.1	  Introduction	  
Atrial	  fibrillation	  (AF)	  is	  the	  most	  common	  heart	  rhythm	  disorder	  in	  adults	  with	  its	  
prevalence	  reaching	  epidemic	  proportions.269	  Patients	  are	  often	  highly	  symptomatic	  
and	  notable	  complications	  include	  stroke,	  cardiomyopathy	  and	  dementia.	  This	  has	  
resulted	  in	  a	  significant	  increase	  in	  hospitalization	  and	  cost	  to	  the	  community.8	  
Several	  factors	  have	  been	  implicated	  for	  the	  burgeoning	  frequency	  of	  AF.	  In	  addition	  
to	  the	  classical	  risk	  factors	  such	  as	  aging	  and	  hypertension,	  obesity	  has	  more	  recently	  
emerged	  as	  an	  independent	  association	  with	  both	  the	  development	  and	  progression	  
of	  the	  disease.	  Obesity	  is	  also	  at	  epidemic	  levels	  and	  confers	  a	  49%	  increased	  risk	  of	  
developing	  AF,	  the	  risk	  increasing	  in	  parallel	  with	  increasing	  BMI.16	  	  
Previous	  studies	  have	  provided	  direct	  evidence	  for	  the	  role	  of	  obesity	  in	  establishing	  
the	  substrate	  predisposing	  to	  AF.23,	  24	  In	  an	  ovine	  model,	  progressive	  weight	  gain	  was	  
associated	  with	  conduction	  slowing	  and	  more	  inducible	  AF.	  Importantly	  this	  occurred	  
without	  the	  usual	  confounding	  factors	  seen	  in	  humans,	  namely	  obstructive	  sleep	  
apnoea	  and	  glucose	  intolerance.	  In	  addition,	  increasing	  weight	  was	  associated	  with	  
upregulation	  of	  profibrotic	  proteins	  in	  atrial	  tissue.	  In	  particular,	  endothelin-­‐A	  and	  B	  
receptors	  were	  upregulated	  as	  weight	  increased.	  	  
Endothelin	  causes	  cardiac	  fibrosis	  directly	  and	  upregulation	  is	  associated	  with	  a	  
multitude	  of	  cardiac	  conditions.99	  Endothelin	  exposure	  causes	  conduction	  slowing	  in	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ventricular	  tissue100	  and	  upregulation	  of	  endothelin	  receptors	  occurs	  in	  atrial	  tissue	  in	  
a	  number	  of	  heart	  failure	  animal	  models.101,	  102	  
Bosentan	  is	  an	  orally	  active	  non-­‐peptide	  endothelin	  receptor	  antagonist	  (ERA)	  of	  both	  
receptor	  subtypes,	  with	  an	  affinity	  for	  ET-­‐A.	  It	  is	  used	  clinically	  in	  the	  management	  of	  
patients	  with	  primary	  pulmonary	  hypertension.250	  Later	  trials	  examined	  its	  use	  in	  
congestive	  cardiac	  failure	  but	  failed	  to	  show	  clinical	  benefit.	  270	  With	  the	  progressive	  
upregulation	  of	  ET	  receptors	  associated	  with	  weight	  gain	  and	  its	  established	  role	  in	  
the	  fibrotic	  cascade,	  a	  central	  feature	  of	  the	  substrate	  for	  AF,	  we	  hypothesised	  that	  
intervention	  to	  block	  this	  pathway	  would	  prevent	  the	  development	  of	  the	  substrate	  
for	  AF.	  Therefore,	  the	  present	  study	  investigates	  the	  effect	  of	  ERA	  on	  the	  
electrophysiological	  and	  structural	  atrial	  abnormalities	  associated	  with	  obesity	  in	  an	  
ovine	  model.	  
3.2	  Methods	  
Twenty	  ovine	  (Merino	  Cross)	  subjects	  were	  studied	  in	  accordance	  with	  the	  National	  
Health	  and	  Medical	  Research	  Council	  of	  Australia	  guidelines	  on	  animal	  research.	  
Approval	  for	  the	  study	  was	  granted	  by	  animal	  research	  committees	  of	  the	  University	  
of	  Adelaide	  and	  South	  Australian	  Health	  and	  Medical	  Research	  Institute,	  Adelaide,	  
Australia.	  
3.2.1	  Study	  Protocol	  
The	  study	  design	  is	  shown	  in	  Figure	  1.	  The	  obese	  model	  and	  intervention	  are	  
described	  below.	  Animals	  underwent	  sequential	  percutaneous	  endocardial	  
electrophysiological	  and	  electroanatomical	  evaluation	  at	  baseline,	  30	  and	  60	  weeks.	  
In	  addition,	  at	  each	  time	  point,	  cardiac	  MRI	  and	  DEXA	  scans	  were	  performed.	  To	  allow	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more	  detailed	  electrophysiological	  characterization,	  at	  terminal	  study,	  a	  high-­‐density	  
plaque	  was	  utilized	  to	  perform	  epicardial	  mapping.	  Following	  this,	  tissue	  was	  
harvested	  to	  assess	  the	  degree	  of	  atrial	  fibrosis,	  inflammation	  and	  pro-­‐fibrotic	  protein	  
expression.	  All	  procedures	  are	  described	  below.	  
3.2.2	  Obese	  ovine	  model	  
Animals	  had	  obesity	  induced	  using	  an	  ad	  libitum	  diet	  of	  high	  fat	  pellets,	  
predominantly	  consisting	  of	  wheat,	  barley	  and	  canola	  seed.	  Excess	  voluntary	  intake	  
was	  of	  grass	  alfalfa	  silage	  and	  hay.	  As	  previously	  described,24	  the	  pellets	  were	  
gradually	  introduced	  at	  8%	  excess	  basal	  energy	  requirements	  and	  rationed	  to	  70%	  of	  
the	  total	  dry	  matter	  intake.	  Plasma	  samples	  were	  collected	  at	  intervals	  to	  ensure	  
stability	  of	  haematological	  and	  biochemical	  indices.	  This	  was	  continued	  for	  the	  
duration	  of	  the	  study,	  with	  gradual	  increase	  in	  weights	  in	  all	  animals	  over	  60	  weeks.	  
Weights	  were	  recorded	  weekly	  and	  reported	  weights	  were	  those	  taken	  in	  a	  shorn	  and	  
fasted	  state	  immediately	  prior	  to	  electrophysiological	  procedures.	  	  
Animals	  were	  randomly	  allocated	  to	  being	  either	  in	  the	  control	  group	  or	  to	  undergo	  
treatment	  with	  bosentan.	  In	  both	  groups,	  feeding	  was	  titrated	  identically	  to	  maintain	  
a	  constant	  and	  gradual	  weight	  gain.	  
3.2.3	  Treatment	  (Endothelin	  Receptor	  Antagonist)	  group	  
Ten	  animals	  were	  randomized	  to	  receive	  bosentan	  treatment	  during	  the	  60-­‐week	  
period	  of	  weight	  gain.	  Pharmacokinetic	  studies	  were	  previously	  performed	  to	  ensure	  
twice	  daily	  dosing	  was	  appropriate	  and	  that	  significant	  hypotension	  did	  not	  occur.	  
Therefore,	  treatment	  was	  given	  orally	  at	  the	  standard	  human	  dose	  of	  125mg	  twice	  
daily.	  Bosentan	  powder	  (Synthesis	  med	  chem	  Pty	  Ltd,	  Melbourne,	  Australia)	  was	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suspended	  with	  tragacanth	  mucilage	  (125mg/40ml).	  Animal	  age,	  housing	  conditions	  
and	  feeding	  regimen	  were	  identical	  in	  treatment	  and	  control	  groups.	  	  
3.2.4	  Animal	  anaesthesia	  
All	  procedures	  were	  performed	  under	  general	  anaesthetic.	  A	  pre-­‐med	  of	  diazepam	  
0.4mg/kg	  was	  given	  prior	  to	  induction	  with	  ketamine	  5mg/kg.	  Isoflurane	  2.5%	  with	  4	  
litres/minute	  of	  oxygen	  was	  used	  for	  maintenance.	  Non-­‐invasive	  blood	  pressure,	  
heart	  rate,	  pulse	  oximetry	  and	  end-­‐tidal	  CO2	  were	  continuously	  monitored.	  	  
3.2.5	  Sequential	  endocardial	  electrophysiological	  study	  
Internal	  jugular	  and	  femoral	  venous	  access	  were	  obtained	  using	  a	  conventional	  
percutaneous	  approach.	  A	  10-­‐pole	  coronary	  sinus	  (CS)	  catheter	  (2–5–2	  mm	  inter-­‐
electrode	  spacing)	  was	  positioned	  with	  the	  proximal	  bipole	  at	  the	  CS	  ostium.	  
Transseptal	  puncture	  was	  performed	  using	  an	  SL0	  sheath	  and	  BRK	  needle	  using	  
conventional	  techniques,	  as	  previously	  described.24	  
Surface	  ECG	  and	  bipolar	  endocardial	  electrograms	  were	  monitored	  continuously	  and	  
stored	  on	  a	  computer-­‐based	  digital	  amplifier/recorder	  system	  (LabSystem	  Pro,	  Bard	  
Electrophysiology,	  Lowell,	  MA)	  with	  storage	  for	  offline	  analysis.	  Intracardiac	  
electrograms	  were	  filtered	  from	  30	  to	  500	  Hz	  and	  measured	  with	  computer-­‐assisted	  
calipers	  at	  a	  sweep	  speed	  of	  200mm/s.	  
Electroanatomical	  mapping	  
Electroanatomical	  maps	  were	  created	  in	  sinus	  rhythm	  using	  the	  Carto	  XP	  system	  
(Biosense	  Webster,	  Diamond	  Bar,	  CA)	  as	  previously	  described.63	  Both	  right	  and	  left	  
atria	  were	  mapped	  using	  a	  3.5-­‐mm	  tip	  catheter	  ablation	  catheter	  (Navistar,	  
Biosense	  Webster,	  Diamond	  Bar,	  CA)	  with	  a	  minimum	  of	  80	  equally	  distributed	  points	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collected	  in	  each	  chamber.	  Endocardial	  contact	  was	  confirmed	  with	  a	  combination	  of	  
electrogram	  stability,	  fluoroscopy	  and	  the	  CARTO	  point	  stability	  criteria	  (≤6mm	  
stability	  in	  space,	  ≤5ms	  in	  local	  activation	  time).	  Location,	  voltage	  and	  activation	  
timing	  were	  recorded	  at	  each	  point.	  For	  analysis	  the	  atria	  was	  divided	  as	  follows:	  
Septal	  right	  atrium	  (RA);	  High	  lateral	  RA;	  Low	  lateral	  RA;	  Posterior	  left	  atrium	  (LA);	  
Lateral	  LA;	  and	  Inferior	  LA.	  The	  following	  were	  determined:	  
1. Conduction	  velocity	  in	  each	  region,	  determined	  by	  the	  mean	  velocity	  
between	  3-­‐5	  pairs	  of	  points	  in	  the	  direction	  of	  conduction	  demonstrated	  
by	  isochronal	  maps;	  	  
2. Signal	  fractionation,	  defined	  as	  a	  signal	  greater	  than	  50ms	  duration	  with	  at	  
least	  four	  deflections;	  
3. Atrial	  voltage.	  Low	  voltage	  was	  defined	  as	  an	  area	  with	  three	  contiguous	  
points	  with	  a	  bipolar	  voltage	  of	  <0.5mV.	  Scar	  was	  an	  area	  with	  three	  
contiguous	  points	  <0.05mV.	  
Effective	  refractory	  periods	  
Effective	  refractory	  period	  (ERP)	  was	  measured	  at	  three	  times	  the	  tissue	  capture	  
threshold	  at	  a	  pulse	  width	  of	  2ms.	  This	  was	  performed	  from	  the	  following	  8	  sites:	  
Septal	  RA;	  High	  lateral	  RA;	  Low	  lateral	  RA;	  Posterior	  LA;	  Lateral	  LA;	  Inferior	  LA;	  
Proximal	  coronary	  sinus	  (CS);	  and	  Distal	  CS.	  Eight	  S1	  stimuli	  were	  delivered	  with	  S1	  
cycle	  lengths	  of	  400	  and	  200ms,	  with	  incremental	  S2	  (10ms	  increments)	  commencing	  
at	  a	  coupling	  interval	  of	  100ms,	  using	  a	  Micropace	  EPS	  320	  stimulator	  (Micropace,	  
Canterbury,	  Australia).	  The	  ERP	  was	  the	  longest	  S1-­‐S2	  interval	  without	  atrial	  capture.	  
The	  mean	  of	  two	  attempts	  was	  recorded.	  An	  additional	  attempt	  was	  made	  if	  the	  
difference	  between	  attempts	  was	  greater	  than	  10ms.	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AF	  induction	  
Inducibility	  of	  AF	  was	  determined	  using	  a	  burst	  pacing	  protocol	  from	  the	  left	  atrial	  
appendage,	  performed	  at	  the	  terminal	  study.	  Twenty	  impulses	  were	  delivered	  at	  the	  
lowest	  cycle	  length	  with	  1:1	  atrial	  capture.	  An	  AF	  episode	  was	  defined	  as	  irregular	  
atrial	  activity	  lasting	  ≥2	  seconds.	  This	  protocol	  was	  repeated	  five	  times	  and	  the	  
number	  of	  episodes	  and	  total	  duration	  were	  recorded.	  Sustained	  AF	  was	  defined	  as	  
an	  episode	  lasting	  >10	  minutes.	  In	  the	  event	  of	  sustained	  AF,	  no	  further	  testing	  was	  
performed.	  
Haemodynamic	  recordings	  
Non-­‐invasive	  systolic	  blood	  pressure	  and	  invasive	  mean	  right	  atrial	  and	  systolic	  right	  
ventricular	  pressures	  were	  recorded	  at	  the	  start	  of	  each	  procedure.	  Mean	  left	  atrial	  
pressure	  was	  recorded	  immediately	  following	  transseptal	  puncture.	  
3.2.6	  Terminal	  epicardial	  electrophysiological	  study	  
Left	  lateral	  thoracotomy	  was	  performed	  to	  access	  the	  left	  atrium.	  A	  custom	  made	  90-­‐
pole	  plaque	  was	  placed	  on	  the	  left	  atrial	  appendage.	  Pacing	  was	  performed	  from	  each	  
of	  the	  four	  corners	  of	  the	  plaque	  at	  400ms.	  Epicardial	  electrograms	  were	  recorded	  
and	  the	  following	  determined:	  
1. Effective	  refractory	  periods	  were	  measured	  using	  the	  same	  protocol	  as	  the	  
endocardial	  study.	  	  
2. Conduction	  velocity	  was	  determined	  using	  activation	  maps	  analysed	  by	  
custom	  software,	  as	  previously	  described.59	  The	  peak	  of	  the	  largest	  
amplitude	  deflection	  on	  each	  bipolar	  electrogram	  was	  automatically	  
annotated	  and	  manually	  verified.	  Local	  conduction	  velocity	  was	  calculated	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for	  each	  point	  from	  triangulated	  local	  vectors,	  allowing	  subsequent	  
calculation	  of	  mean	  velocity	  for	  each	  map.	  
3. Conduction	  heterogeneity	  was	  calculated	  using	  established	  phase	  mapping	  
techniques	  integrated	  into	  the	  software,	  as	  previously	  described.59	  
Absolute	  conduction	  phase	  delay	  was	  calculated	  by	  subtracting	  the	  5th	  
from	  the	  95th	  percentile	  of	  the	  phase	  difference	  distribution	  (P5-­‐95).	  
Conduction	  heterogeneity	  index	  was	  derived	  from	  dividing	  P5-­‐95	  by	  the	  
median	  (P50).	  
3.2.7	  Cardiac	  MRI	  
Chamber	  volumes	  were	  measured	  using	  MRI	  (Siemens	  Sonata	  1.5	  Tesla,	  MR	  Imaging	  
Systems,	  Siemens	  Medical	  Solutions,	  Erlangen,	  Germany).	  6-­‐mm	  slices	  were	  taken	  
through	  the	  left	  atrium	  and	  ventricle.	  Images	  were	  taken	  using	  electrocardiogram-­‐
gating	  and	  periodic	  breath	  holding.	  Analyses	  were	  performed	  offline	  using	  CVI42	  
(Circle	  Cardiovascular	  Imaging	  Inc.,	  Calgary,	  Canada).	  
3.2.8	  Dual-­‐Energy	  X-­‐ray	  Absorptiometry	  (DEXA)	  
Scans	  were	  acquired	  using	  a	  GE-­‐Lunar	  Prodigy	  Vision	  DXA	  bone	  densitometer	  using	  
Encore	  13.60.033	  software	  (GE-­‐Lunar,	  Madison,	  WI,	  USA).	  Scans	  were	  performed	  
using	  Total	  Body	  scan	  protocol	  in	  standard	  or	  thick	  mode	  to	  allow	  for	  variation	  in	  
tissue	  depth.	  
3.2.9	  Tissue	  analysis	  
At	  study	  completion,	  the	  heart	  was	  removed	  and	  the	  left	  atrial	  appendage	  was	  
isolated	  and	  fixed	  in	  10%	  buffered	  formalin,	  paraffin	  embedded,	  and	  5μm	  sections	  cut	  
and	  stained	  with	  Masson’s	  trichrome.	  	  For	  the	  immunohistochemical	  study,	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polyclonal	  antibodies	  to	  TGF-­‐β	  (Sigma-­‐Aldrich,	  St	  Louis,	  MO,	  Cat#SAB4502954),	  
Angiotensin	  II	  (Abbiotec,	  San	  Diego,	  CA,	  Cat#251229),	  CTGF	  (Abbiotec,	  San	  Diego,	  CA,	  
Cat#251261),	  IL-­‐6	  (Abbiotec,	  San	  Diego,	  CA,	  Cat#250717)	  and	  PDGF	  (Abcam,	  
Cambridge,	  UK,	  Cat#ab61219)	  were	  used	  at	  dilutions	  of	  1:500,	  1:250,	  1:400,	  1:500	  
and	  1:6400,	  respectively,	  in	  a	  standard	  streptavidin-­‐biotinylated	  immunoperoxidase	  
technique.	  All	  sections	  underwent	  antigen	  retrieval	  using	  citrate	  buffer	  pH6.0	  prior	  to	  
overnight	  antibody	  incubation.	  This	  was	  followed	  by	  a	  biotinylated	  anti-­‐rabbit	  
secondary	  (Vector	  Laboratories,	  Burlingame,	  CA,	  Cat#BA-­‐1000),	  then	  washing	  in	  
phosphate	  buffered	  saline.	  Slides	  were	  then	  incubated	  with	  a	  streptavidin-­‐conjugated	  
peroxidase	  tertiary	  (Pierce,	  Pasadena,	  CA,	  Cat#21127).	  Sections	  were	  visualised	  using	  
diaminobenzidine	  tetrahydrochloride,	  washed,	  counterstained	  with	  haematoxylin,	  
dehydrated,	  cleared,	  and	  mounted	  on	  glass	  slides.	  A	  minus	  primary	  control,	  as	  well	  as	  
a	  control	  showing	  the	  normal	  pattern	  of	  expression	  of	  the	  antigen	  in	  question,	  was	  
run	  with	  each	  batch	  of	  slides.	  	  	  	  	  
Images	  of	  the	  tissue	  were	  digitally	  captured	  from	  5	  random	  fields	  per	  section	  at	  40x	  
magnification	  using	  NanoZoomer	  Digital	  Pathology	  System	  software	  (Hamamatsu	  
Phonetics,	  Japan).	  Quantitative	  assessments	  of	  collagen	  content	  and	  immuno-­‐staining	  
were	  made	  with	  the	  appropriate	  colour	  range	  selection	  using	  Image-­‐Pro	  Premium	  
v9.1	  (Media	  Cybernetics	  Inc.,	  Rockville,	  MD).	  Results	  were	  calculated	  in	  percentage	  
relative	  to	  the	  whole	  tissue	  area.	  
3.2.10	  Statistical	  Analysis	  
Normally	  distributed	  data	  was	  expressed	  as	  mean	  ±	  standard	  deviation	  and	  compared	  
with	  unpaired	  t-­‐test.	  Differences	  between	  groups	  over	  time	  were	  tested	  using	  
analysis	  of	  variance.	  Conduction	  velocity	  and	  ERP	  across	  regions	  were	  analysed	  using	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a	  mixed	  effects	  model	  ANOVA	  with	  sheep	  ID	  used	  as	  a	  random	  effect	  to	  account	  for	  
the	  dependence	  in	  observations	  from	  the	  same	  animal.	  Fixed	  effects	  included	  
combinations	  of	  group,	  time-­‐point	  and	  region	  with	  a	  maximum	  of	  two	  fixed	  effects	  
entered	  into	  the	  statistical	  model	  at	  one	  time.	  	  Main	  effects	  and	  their	  interaction	  
were	  tested.	  If	  a	  significant	  interaction	  was	  present,	  post-­‐hoc	  testing	  was	  performed.	  
AF	  duration	  was	  non-­‐parametric;	  therefore,	  log-­‐transformation	  was	  performed	  prior	  
to	  t-­‐test	  comparison,	  with	  values	  expressed	  as	  median	  and	  interquartile	  range.	  P-­‐
values	  of	  less	  than	  0.05	  were	  considered	  statistically	  significant.	  Analyses	  were	  
performed	  using	  SPSS	  version	  23	  (SPSS	  Inc.	  Chicago,	  IL).	  
3.3	  Results	  
3.3.1	  Weight,	  structural	  and	  haemodynamic	  parameters	  
Table	  1	  presents	  the	  changes	  in	  anthropometry,	  haemodynamic	  and	  cardiac	  structure	  
in	  the	  two	  groups.	  Both	  groups	  increased	  in	  weight	  and	  body	  fat	  equally	  over	  60	  
weeks.	  Left	  and	  right	  atrial	  pressures	  significantly	  increased	  with	  increasing	  weight,	  
accompanied	  by	  a	  non-­‐significant	  increase	  in	  systolic	  blood	  pressure	  and	  RV	  systolic	  
pressure.	  There	  was	  a	  non-­‐significant	  increase	  in	  left	  atrial	  volume	  and	  left	  ventricular	  
mass	  with	  increasing	  weight	  but	  no	  change	  in	  LV	  volume	  or	  function.	  
There	  was	  no	  significant	  difference	  in	  haemodynamics,	  chamber	  volumes,	  LV	  mass	  or	  
function	  between	  treatment	  and	  control	  groups	  at	  any	  time-­‐point.	  
3.3.2	  Electrophysiological	  parameters	  
Conduction	  velocity	  and	  conduction	  heterogeneity	  
Sequential	  endocardial	  electrophysiological	  studies	  demonstrated	  that	  there	  was	  
progressive	  endocardial	  conduction	  slowing	  seen	  with	  increasing	  weight	  in	  the	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control	  group	  (p<0.001).	  The	  ERA	  group	  demonstrated	  significant	  attenuation	  of	  this	  
conduction	  slowing	  when	  compared	  with	  controls	  (p=0.001)	  at	  both	  30	  weeks	  
(1.24±0.05	  vs	  1.00±0.05m/s)	  and	  60	  weeks	  (1.15±0.05	  vs	  0.94±0.05m/s)	  as	  shown	  in	  
Figure	  2.	  This	  improvement	  in	  conduction	  velocity	  was	  homogeneous	  across	  all	  atrial	  
sites	  (Site*Group	  interaction=0.17).	  
At	  the	  end	  of	  the	  study	  period,	  high-­‐density	  epicardial	  mapping	  of	  the	  LA	  confirmed	  
the	  marked	  differences	  in	  the	  conduction	  properties	  of	  the	  atria.	  Conduction	  velocity	  
at	  60	  weeks	  was	  higher	  in	  the	  ERA	  group	  than	  controls	  (0.98±0.03	  vs	  0.92±0.03m/s,	  
p=0.001)	  as	  shown	  in	  figure	  3.	  Epicardial	  conduction	  was	  also	  less	  heterogeneous	  with	  
ERA	  treatment	  (1.28±0.05	  vs	  1.47±0.05,	  p=0.02).	  
Effective	  refractory	  periods	  
There	  was	  no	  significant	  change	  in	  ERP	  with	  increasing	  weight,	  overall	  or	  when	  
analysed	  by	  chamber.	  There	  was	  no	  difference	  in	  ERP	  between	  groups	  at	  mid-­‐	  or	  
endpoint	  at	  either	  cycle	  length	  (Figure	  4).	  Terminal	  epicardial	  ERP	  determination	  
demonstrated	  that	  there	  was	  no	  significant	  difference	  between	  the	  groups.	  
Signal	  fractionation	  
Signal	  fractionation	  increased	  with	  increasing	  weight	  in	  both	  groups	  (p<0.001)	  as	  
shown	  in	  figure	  5.	  ERA	  treated	  animals	  had	  significantly	  less	  signal	  fractionation	  than	  
control	  animals	  at	  60	  weeks	  (15.2±3.6	  vs	  28.6±8.0%,	  p=0.0001).	  
Atrial	  bipolar	  voltage	  
There	  was	  no	  significant	  reduction	  in	  endocardial	  voltage	  with	  increasing	  weight	  or	  
between	  groups	  (5.81±0.99	  vs	  5.77±1.07mV	  at	  endpoint).	  No	  areas	  of	  low	  voltage	  
(<0.5mV)	  or	  scar	  were	  seen	  in	  any	  animal.	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AF	  inducibility	  
Figure	  6	  shows	  the	  AF	  burden	  at	  endpoint	  study.	  The	  ERA	  treated	  group	  had	  
significantly	  fewer	  AF	  episodes	  (46.7±28.2	  vs	  73.3±22.4%,	  p=0.041).	  The	  total	  AF	  
duration	  was	  also	  reduced	  by	  ERA	  treatment	  (17.0	  [IQR	  37.0]	  vs	  47.0s	  [IQR	  139.5],	  
p=0.04).	  One	  control	  animal	  had	  sustained	  AF	  (>10mins)	  during	  testing	  and	  was	  
considered	  to	  have	  100%	  inducibility.	  Two	  animals	  (1	  ERA	  treated,	  1	  control)	  animals	  
had	  sustained	  AF	  prior	  to	  induction	  and	  were	  excluded	  from	  inducibility	  and	  duration	  
analysis.	  
3.3.3	  Histological	  parameters	  
Tissue	  fibrosis	  
There	  was	  a	  reduction	  in	  interstitial	  fibrosis	  in	  animals	  treated	  with	  ERA	  when	  
compared	  with	  controls.	  Masson’s	  trichrome	  staining	  of	  the	  LA	  (figure	  7,	  upper	  panel)	  
demonstrated	  a	  fibrotic	  area	  of	  3.81±1.73%	  vs	  6.02±1.62%	  in	  the	  ERA	  treated	  and	  
control	  groups	  respectively	  (p=0.02).	  
Pro-­‐fibrotic	  proteins	  
Results	  of	  immunohistochemistry	  of	  left	  atrial	  tissue	  for	  pro-­‐fibrotic	  protein	  
expression	  are	  shown	  in	  figure	  8.	  ERA	  treated	  animals	  had	  reduced	  expression	  of	  
angiotensin	  II	  (0.65±0.13	  vs	  0.84±0.18%,	  p=0.05),	  connective	  tissue	  growth	  factor	  
(0.89±0.30	  vs	  1.60±0.36%,	  p=0.003),	  and	  platelet	  derived	  growth	  factor	  (1.01±0.44	  vs	  
1.47±0.22%,	  p=0.04)	  compared	  to	  obese	  controls.	  There	  was	  no	  difference	  in	  TGF-­‐β	  
expression	  between	  groups	  (2.17±0.64	  vs	  2.21±0.94%,	  p=NS).	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Inflammation	  
There	  was	  reduced	  inflammatory	  protein	  expression	  with	  ERA	  treatment	  (figure	  9),	  
with	  reduction	  in	  CD68	  (0.35±0.09	  vs	  0.53±0.18,	  p=0.03)	  and	  IL6	  expression	  
(1.89±1.12	  vs	  3.42±1.28,	  p=0.02).	  	  
Gap	  junctions	  
There	  was	  greater	  expression	  of	  the	  gap	  junction	  protein	  connexin	  43	  with	  ERA	  
treatment	  than	  in	  controls	  (2.79±0.67	  vs	  1.94±0.54%,	  p=0.01).	  (figure	  7,	  lower	  panel).	  
3.4	  Discussion	  
Obesity	  is	  increasingly	  recognized	  as	  an	  important	  determinant	  of	  the	  “rising	  tide”	  in	  
epidemic	  of	  AF.	  Previous	  studies	  have	  demonstrated	  the	  evolution	  of	  the	  substrate	  
recognized	  to	  predispose	  to	  AF	  with	  progressive	  weight	  gain;	  however,	  the	  
mechanisms	  for	  these	  changes	  have	  been	  elusive.	  The	  current	  study	  undertakes	  an	  
interventional	  study	  to	  evaluate	  the	  role	  of	  endothelin	  receptor	  pathways	  in	  the	  
development	  of	  the	  substrate	  for	  AF	  in	  obesity	  to	  provide	  new	  information	  on	  the	  
pathophysiological	  links	  between	  these	  conditions.	  	  
Endothelin	  receptor	  blockade	  prevented	  the	  development	  of	  atrial	  substrate	  in	  an	  
obese	  ovine	  model.	  Treatment	  with	  bosentan	  during	  weight	  gain	  was	  associated	  with:	  
1. Attenuation	  of	  the	  marked	  conduction	  abnormalities	  that	  result	  from	  weight	  
gain,	  characterised	  by	  prevention	  of	  conduction	  slowing,	  conduction	  
heterogeneity	  and	  signal	  fractionation;	  
2. Prevention	  of	  the	  structural	  changes	  associated	  with	  obesity.	  In	  particular,	  
there	  was	  marked	  attenuation	  of	  the	  interstitial	  fibrosis	  and	  preservation	  of	  
gap-­‐junctional	  content;	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3. As	  a	  result	  of	  these	  changes	  there	  was	  a	  reduced	  vulnerability	  to	  AF.	  
Importantly,	  these	  effects	  observed	  with	  ERA	  treatment,	  seem	  to	  be	  mediated	  
through	  a	  reduction	  in	  inflammatory	  (IL-­‐6)	  and	  profibrotic	  markers	  (Connective	  tissue	  
growth	  factor,	  Platelet	  derived	  growth	  factor,	  and	  Angiotensin	  II)	  but	  not	  TGF-­‐β.	  
These	  beneficial	  effects	  were	  observed	  despite	  the	  evolution	  of	  progressive	  obesity	  
and	  without	  a	  significant	  impact	  on	  haemodynamic	  parameters.	  
Substrate	  for	  AF	  
Several	  studies	  have	  evaluated	  the	  substrate	  predisposing	  to	  the	  development	  of	  AF.	  
These	  have	  consistently	  identified	  the	  presence	  of	  diffuse	  atrial	  fibrosis	  with	  the	  
associated	  conduction	  abnormalities	  as	  being	  central	  to	  the	  remodelling	  associated	  
with	  conditions	  predisposing	  to	  AF.	  In	  particular,	  this	  has	  been	  demonstrated	  in	  the	  
preclinical	  setting	  in	  models	  of	  heart	  failure58,	  hypertension59,	  60,	  sleep	  apnea192,	  and	  
coronary	  ischaemia271.	  Importantly	  similar	  observations	  have	  also	  been	  confirmed	  in	  
the	  clinic	  with	  areas	  of	  low	  voltage	  and	  electrical	  silence,	  conduction	  slowing,	  and	  
fractionated	  electrograms.63,	  67,	  272	  Interestingly	  similar	  changes	  were	  observed	  in	  
patients	  with	  “lone	  AF”.68	  
Previous	  animal	  studies	  investigating	  the	  effect	  of	  obesity	  have	  demonstrated	  
progressive	  atrial	  conduction	  slowing,	  increased	  heterogeneity,	  signal	  fractionation	  
and	  increased	  propensity	  to	  AF.	  The	  findings	  were	  associated	  with	  diffuse,	  interstitial	  
atrial	  fibrosis	  and	  upregulation	  of	  pro-­‐fibrotic	  proteins.23,	  24	  In	  the	  clinical	  setting,	  
atrial	  electrophysiology	  has	  been	  shown	  to	  differ	  in	  obese	  patients	  with	  AF,	  with	  
shorter	  ERPs	  and	  slower	  conduction	  into	  pulmonary	  veins	  than	  in	  lean	  patients	  with	  
AF.202	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The	  present	  study	  confirms	  the	  findings	  of	  these	  prior	  studies	  demonstrating	  the	  
presence	  of	  interstitial	  atrial	  fibrosis,	  heterogeneous	  and	  slowed	  conduction,	  with	  up	  
regulation	  of	  fibrotic	  and	  inflammatory	  markers	  associated	  with	  obesity.	  Intervention	  
using	  an	  endothelin	  receptor	  blocker,	  a	  recognised	  cascade	  that	  leads	  to	  fibrosis,	  
partially	  prevented	  the	  development	  of	  these	  abnormalities	  with	  reduced	  collagen	  
staining	  on	  Masson’s	  trichrome,	  reduced	  inflammation	  and	  increased	  connexin	  43	  
expression	  associated	  with	  resolution	  of	  the	  conduction	  abnormalities	  associated	  
with	  obesity.	  Importantly,	  it	  reduced	  vulnerability	  to	  AF.	  Notably,	  there	  was	  no	  
significant	  difference	  in	  haemodynamic	  parameters	  between	  the	  groups,	  suggesting	  
that	  endothelin	  receptor	  blockade	  in	  obesity	  may	  prevent	  atrial	  fibrosis	  directly,	  
without	  an	  effect	  on	  either	  systemic	  or	  intracardiac	  pressures.	  	  
Mechanisms	  for	  the	  formation	  of	  the	  atrial	  substrate	  for	  AF	  
Guarda	  et	  al.	  first	  demonstrated	  endothelin-­‐1	  to	  be	  directly	  responsible	  for	  cardiac	  
fibrosis.	  Cardiac	  fibroblasts	  maintained	  in	  ET-­‐1	  had	  a	  dose	  dependent	  increase	  in	  
collagen	  deposition	  compared	  with	  controls.99	  Endothelin	  exposure	  is	  associated	  with	  
fibrosis,	  decreased	  gap	  junction	  expression	  and	  conduction	  slowing	  in	  ventricular	  
myocytes.100	  Human	  atrial	  tissue	  demonstrates	  positive	  inotropy	  in	  response	  to	  
endothelin	  incubation91	  and	  AF	  is	  associated	  with	  endothelin	  receptor	  upregulation95.	  
Surgical	  patients	  with	  increased	  endothelin-­‐1	  expression	  in	  left	  atrial	  tissue	  more	  
commonly	  had	  AF,	  hypertension	  and	  atrial	  dilatation.96	  Gelzer	  et	  al.	  found	  acute	  ET-­‐A	  
blockade	  shortened	  sinus	  node	  recovery	  time	  in	  normal	  pigs,	  without	  an	  effect	  on	  
atrial	  or	  ventricular	  refractory	  periods.273	  No	  studies	  have	  previously	  investigated	  the	  
effect	  of	  endothelin	  receptor	  blockade	  on	  atrial	  conduction	  velocity.	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We	  have	  previously	  demonstrated	  upregulation	  of	  endothelin-­‐A	  and	  B	  in	  atrial	  tissue	  
of	  obese	  ovine	  subjects.23	  In	  addition,	  there	  was	  upregulation	  of	  other	  profibrotic	  
molecules,	  namely	  transforming	  growth	  factor	  beta	  (TGF-­‐	  β),	  connective	  tissue	  
growth	  factor	  (CTGF),	  platelet	  derived	  growth	  factor	  (PDGF),	  all	  of	  which	  have	  been	  
directly	  implicated	  in	  atrial	  fibrosis.	  Our	  study	  investigated	  these	  proteins	  and	  grants	  
some	  insight	  into	  the	  mechanisms	  by	  which	  obesity	  causes	  fibrosis.	  	  
TGF-­‐β	  is	  directly	  involved	  cardiac	  fibrosis.	  Fibroblasts	  exposed	  to	  TGF-­‐β	  have	  a	  dose	  
and	  time	  dependent	  increase	  in	  collagen	  production.274	  In	  a	  canine	  heart	  failure	  
model,	  atrial	  TGF-­‐β	  was	  significantly	  upregulated	  in	  association	  with	  atrial	  fibrosis275	  
and	  blockade	  of	  TGF-­‐β	  receptors	  resulted	  in	  reduced	  fibrosis	  and	  propensity	  to	  AF.260	  
In	  our	  study,	  endothelin	  receptor	  blockade	  reduced	  fibrosis	  without	  an	  effect	  on	  TGF-­‐
β	  expression.	  This	  suggests	  that	  TGF-­‐β	  acts	  independently	  upstream	  to	  endothelin	  
and	  is	  in	  keeping	  with	  studies	  examining	  lung	  fibroblasts	  276	  and	  vascular	  endothelial	  
cells.103	  It	  is	  likely	  that	  TGF-­‐β	  continues	  to	  have	  a	  profibrotic	  effect	  despite	  endothelin	  
receptor	  blockade	  and	  could	  explain	  why	  fibrosis	  is	  not	  completely	  prevented.	  TGF-­‐β	  
antagonism	  may	  represent	  an	  alternative	  therapeutic	  option	  for	  obesity	  related	  atrial	  
fibrosis,	  potentially	  in	  combination	  with	  ERA	  treatment.	  
Mice	  with	  overexpression	  of	  AngII	  have	  increased	  atrial	  fibrosis	  with	  more	  inducible	  
AF.127	  Atrial	  AngII	  expression	  is	  increased	  in	  dogs	  with	  atrial	  fibrosis	  associated	  with	  
heart	  failure.129	  In	  our	  study,	  animals	  treated	  with	  ERA	  showed	  downregulation	  of	  
AngII	  receptors.	  The	  angiotensin	  and	  endothelin	  systems	  have	  complex	  bidirectional	  
interactions;	  our	  findings	  may	  be	  explained	  by	  a	  negative	  feedback	  loop,	  or	  may	  be	  
related	  to	  the	  downregulation	  of	  CTGF,	  which	  is	  a	  mediator	  of	  AngII	  induced	  vascular	  
fibrosis.134	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CTGF	  has	  previously	  been	  found	  to	  be	  a	  regulator	  of	  the	  effects	  of	  endothelin-­‐1	  in	  
cardiac	  tissue.	  Recchia	  et	  al.	  examined	  the	  atrial	  tissue	  of	  mice	  following	  ET-­‐1	  infusion	  
and	  found	  increased	  CTGF	  expression	  with	  increasing	  concentration	  of	  ET-­‐1.	  
Additionally,	  ET-­‐A	  and	  ET-­‐B	  blockade	  prevented	  upregulation.138	  Our	  results	  were	  in	  
keeping	  with	  these	  findings,	  with	  significant	  downregulation	  of	  CTGF	  with	  ERA	  
treatment.	  This	  is	  strongly	  suggestive	  that	  CTGF	  acts	  downstream	  to	  endothelin	  in	  the	  
fibrotic	  cascade	  and	  that	  CTGF	  blockade	  in	  addition	  to	  endothelin	  antagonism	  may	  
not	  be	  an	  effective	  therapeutic	  strategy.	  
PDGF	  is	  associated	  with	  atrial	  fibrosis	  and	  AF,	  as	  demonstrated	  by	  a	  pressure	  
overloaded	  mouse	  model.143	  Administration	  of	  endothelin	  had	  no	  significant	  effect	  on	  
PDGF	  in	  rat	  aortic	  tissue,277	  but	  blockade	  of	  endothelin	  receptors	  reduced	  PDGF	  
expression	  in	  the	  coronary	  arteries	  of	  rats	  undergoing	  cardiac	  transplantation.278	  Our	  
study	  was	  in	  keeping	  with	  the	  latter	  study;	  we	  demonstrated	  reduced	  expression	  in	  
the	  atrial	  tissue	  of	  animals	  treated	  with	  ERA	  than	  in	  controls.	  This	  offers	  new	  insight	  
into	  the	  mechanisms	  of	  fibrosis	  in	  obesity	  and	  is	  suggestive	  that	  PDGF	  acts	  
downstream	  to	  endothelin.	  
IL-­‐6	  exposure	  is	  associated	  with	  cardiac	  fibrosis	  and	  hypertrophy	  in	  a	  mouse	  model279	  
and	  serum	  IL-­‐6	  has	  been	  shown	  to	  correlate	  with	  human	  AF	  more	  than	  several	  other	  
inflammatory	  markers,	  including	  C-­‐reactive	  protein.280	  ET-­‐1	  induces	  IL-­‐6	  release	  from	  
human	  vascular	  smooth	  muscle	  cells.281	  Our	  study	  is	  in	  keeping	  with	  this;	  ERA	  
treatment	  was	  associated	  with	  reduction	  in	  IL-­‐6	  expression,	  suggestive	  of	  an	  anti-­‐
inflammatory	  action.	  
Connexin	  43	  is	  the	  most	  prominent	  gap	  junction	  protein	  in	  atrial	  tissue	  and	  reduced	  
expression	  is	  associated	  with	  conduction	  slowing	  and	  fibrosis.282	  ERA	  treatment	  was	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associated	  with	  a	  higher	  expression	  of	  Cx43,	  a	  histological	  finding	  supportive	  of	  the	  
reduced	  conduction	  slowing	  with	  demonstrated	  on	  both	  endocardial	  and	  epicardial	  
mapping.	  
Clinical	  Implications	  
Using	  an	  interventional	  design,	  this	  study	  demonstrates	  that	  ERA	  can	  attenuate	  the	  
formation	  of	  the	  AF	  substrate	  due	  to	  weight	  gain	  and	  obesity.	  It	  demonstrates	  the	  
central	  role	  of	  the	  endothelin	  pathways	  in	  the	  formation	  of	  the	  substrate	  for	  AF.	  
Recent	  studies	  have	  highlighted	  the	  importance	  of	  weight	  and	  risk	  factor	  
management	  in	  the	  management	  of	  AF.224,	  229	  However,	  in	  the	  clinic,	  weight	  loss	  is	  not	  
always	  possible.	  Additionally,	  fluctuation	  in	  weight	  is	  often	  observed	  and	  has	  a	  proven	  
negative	  impact	  on	  AF	  burden.229	  Treatment	  with	  an	  endothelin	  receptor	  antagonist	  
may	  play	  an	  important	  role	  in	  the	  clinical	  management	  of	  patients	  with	  obesity	  
related	  AF	  and	  possibly	  during	  periods	  of	  weight	  loss	  if	  weight	  fluctuation	  occurs.	  ERA	  
use	  in	  these	  clinical	  scenarios	  warrants	  clinical	  evaluation,	  along	  with	  its	  potential	  role	  
in	  the	  management	  of	  AF	  associated	  with	  other	  conditions.	  
Study	  limitations	  
This	  study	  investigated	  the	  effect	  of	  endothelin	  receptor	  blockade	  in	  an	  obese	  ovine	  
model.	  As	  with	  all	  animal	  models,	  this	  may	  vary	  from	  human	  pathophysiology	  and	  the	  
involvement	  or	  effect	  of	  specific	  pro-­‐fibrotic	  pathways	  may	  differ.	  Treatment	  was	  
given	  during	  the	  development	  of	  obesity,	  which	  may	  not	  allow	  extrapolation	  to	  the	  
clinical	  scenario	  of	  treatment	  being	  required	  once	  obesity,	  and	  hence	  atrial	  substrate,	  
has	  already	  developed.	  However,	  it	  may	  prevent	  the	  progression	  of	  substrate,	  in	  
particular	  in	  patients	  with	  weight	  fluctuation.	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3.5	  Conclusion	  
Endothelin	  receptor	  pathways	  are	  important	  determinants	  of	  the	  substrate	  for	  AF	  in	  
obesity.	  Blockade	  of	  endothelin	  receptors	  partially	  prevents	  the	  development	  of	  atrial	  
substrate	  due	  to	  weight	  gain.	  This	  may	  represent	  a	  unique	  therapeutic	  target	  in	  AF	  
associated	  with	  obesity.	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Table	  1.	  Structural	  and	  haemodynamic	  characteristics	  of	  ERA	  treated	  and	  control	  groups.	  




Baseline	   30	  wks	   60	  wks	   Baseline	   30	  wks	   60	  wks	  
Weight	  (kg)	   68±7	   87±9	   95±9	   68±5	   87±7	   92±7	   <0.001	   NS	  
Body	  fat	  (%)	   19±6	   37±5	   43±4	   18±6	   37±6	   41±5	   <0.001	   NS	  
Systolic	  BP	  
(mmHg)	  
83±18	   85±8	   89±10	   85±15	   86±8	   90±11	   NS	   NS	  
RV	  systolic	  
pressure	  (mmHg)	  
16±3	   18±2	   19±3	   17±2	   18±2	   19±3	   NS	   NS	  
RA	  pressure	  
(mmHg)	  
3.0±2.4	   5.3±1.8	   5.6±2.6	   2.8±1.6	   5.4±1.8	   4.8±2.6	   0.006	   NS	  
LA	  pressure	  
(mmHg)	  
4.6±2.3	   6.9±1.6	   6.7±1.5	   4.5±2.1	   6.9±1.5	   6.8±1.9	   0.003	   NS	  
LA	  volume	  (ml)	   49±10	   57±9	   58±13	   52±11	   59±8	   57±10	   NS	   NS	  
LVESV	  (ml)	   69±19	   60±11	   72±22	   69±20	   67±9	   67±12	   NS	   NS	  
LVEF	  (%)	   49±7	   50±11	   48±8	   47±12	   48±4	   46±6	   NS	   NS	  
LV	  mass	  (g)	   112±10	   135±25	   139±35	   116±10	   133±20	   133±12	   0.17	   NS	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Figure	  1.	  Study	  design.	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Figure	  2.	  Conduction	  velocity	  (CV)	  at	  the	  study	  baseline,	  midpoint	  and	  endpoint	  (left)	  
and	  by	  region	  at	  endpoint	  study	  (right).	  	  
	  
	  
	   	  
	   86	  
Figure	  3.	  Epicardial	  conduction	  velocity	  (CV)	  at	  each	  corner	  of	  the	  LA	  plaque	  (top)	  and	  
conduction	  heterogeneity	  (bottom),	  with	  representative	  examples.	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Figure	  4.	  Effective	  refractory	  periods	  (ERP).	  The	  upper	  panel	  shows	  endocardial	  
results	  at	  study	  baseline,	  midpoint	  and	  end	  point,	  the	  lower	  panel	  shows	  epicardial	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Figure	  5.	  Proportion	  of	  fractionated	  signal	  at	  baseline,	  midpoint	  and	  endpoint	  (top).	  
Representative	  examples	  of	  LA	  voltage	  and	  fractionation	  maps	  in	  both	  groups	  at	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Figure	  6.	  AF	  inducibility	  at	  end	  point	  study.	  The	  proportion	  of	  episodes	  >2s	  is	  shown	  
on	  the	  left,	  the	  total	  AF	  duration	  (log	  transformed	  for	  statistical	  analysis)	  on	  the	  right.	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Figure	  7.	  Masson’s	  trichrome	  staining	  of	  LAA	  tissue	  at	  40x	  magnification	  (upper	  
panels).	  Immunohistochemistry	  of	  gap	  junction	  protein	  connexin43	  at	  40x	  
magnification	  (lower	  panels).	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Figure	  8.	  LAA	  immunohistochemistry	  of	  pro-­‐fibrotic	  molecules	  (40x	  magnification).	  
Representative	  examples	  are	  shown	  on	  the	  left	  and	  graphs	  comparing	  treatment	  and	  
control	  groups	  on	  the	  right.	  TGF-­‐β	  =	  Transforming	  growth	  factor;	  AngII	  =	  Angiotensin	  
II;	  CTGF	  =	  Connective	  tissue	  growth	  factor;	  PDGF	  =	  Platelet	  derived	  growth	  factor	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Figure	  9.	  LAA	  immunohistochemistry	  of	  inflammatory	  molecules	  (40x	  magnification).	  
Representative	  examples	  are	  shown	  on	  the	  left	  and	  graphs	  comparing	  treatment	  and	  
control	  groups	  on	  the	  right.	  IL-­‐6	  =	  Interleukin-­‐6	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Chapter	  4	  –	  Treatment	  with	  tranilast	  prevents	  atrial	  
remodelling	  and	  AF	  in	  an	  obese	  ovine	  model	  
4.1	  Introduction	  
Atrial	  fibrillation	  is	  the	  commonest	  sustained	  arrhythmia	  and	  is	  responsible	  for	  a	  large	  
socioeconomic	  burden.283	  The	  development	  of	  AF	  is	  increasingly	  recognised	  to	  be	  due	  
to	  both	  electrical	  and	  structural	  remodelling	  of	  atrial	  tissue.	  Electrical	  remodelling	  is	  
generally	  due	  to	  increased	  heart	  rates	  and	  predominantly	  leads	  to	  reductions	  in	  
refractory	  periods.	  On	  the	  other	  hand,	  structural	  remodelling	  is	  associated	  with	  
conduction	  abnormalities	  in	  atrial	  tissue,	  promoting	  electrical	  reentry	  and	  
contributing	  to	  the	  maintenance	  of	  the	  arrhythmia.	  A	  multitude	  of	  conditions	  are	  
responsible	  for	  the	  development	  of	  this	  remodelling,	  most	  commonly	  advancing	  age,	  
hypertension,	  coronary	  artery	  disease,	  heart	  failure,	  obstructive	  sleep	  apnoea	  and	  
obesity.	  
Several	  pro-­‐fibrotic	  molecules	  play	  a	  role	  in	  the	  development	  of	  atrial	  fibrosis;	  
transforming	  growth	  factor	  beta	  (TGF-­‐β)	  play	  a	  central	  role	  in	  the	  pathophysiology	  of	  
this	  process.	  It	  induces	  myofibroblast	  differentiation	  in	  response	  to	  several	  cardiac	  
conditions	  and	  overexpression	  is	  directly	  associated	  with	  interstitial	  atrial	  fibrosis	  and	  
susceptibility	  to	  AF.112	  We	  have	  previous	  demonstrated	  that	  TGF-­‐β	  receptors	  are	  
upregulated	  in	  the	  atrial	  tissue	  of	  obese	  animals,	  along	  with	  the	  development	  of	  atrial	  
fibrosis	  and	  propensity	  to	  AF.24	  
Tranilast	  (N-­‐(3,4-­‐dimethoxycinnamoyl)	  anthranilic	  acid)	  is	  an	  anti-­‐inflammatory/anti-­‐
fibrotic	  compound,	  predominantly	  affecting	  TGF-­‐β.	  It	  is	  used	  in	  Japan	  and	  South	  
Korea	  as	  a	  treatment	  for	  asthma	  and	  other	  allergic	  conditions,	  as	  well	  as	  hypertrophic	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and	  keloid	  scarring.	  Animal	  studies	  have	  demonstrated	  benefit	  in	  atrial	  remodelling	  
secondary	  to	  heart	  failure.260	  We	  sought	  to	  examine	  the	  effect	  of	  tranilast	  treatment	  
on	  atrial	  electrophysiology	  in	  an	  obese	  animal	  model.	  
4.2	  Methods	  
Sixteen	  ovine	  (Merino-­‐cross)	  subjects	  were	  studied	  according	  to	  National	  Health	  and	  
Medical	  Research	  Council	  of	  Australia	  guidelines	  on	  animal	  research.	  Animal	  research	  
committees	  of	  the	  University	  of	  Adelaide	  and	  South	  Australian	  Health	  and	  Medical	  
Research	  Institute	  granted	  approval	  for	  the	  study.	  
4.2.1	  Study	  Protocol	  
Animals	  underwent	  sequential	  investigations	  at	  baseline,	  32	  and	  64	  weeks,	  as	  shown	  
in	  figure	  1.	  Percutaneous	  endocardial	  electrophysiological	  and	  electroanatomical	  
evaluation	  was	  performed	  on	  all	  animals,	  along	  with	  cardiac	  MRI	  to	  assess	  cardiac	  
structure	  and	  function.	  Additionally	  at	  terminal	  study,	  high-­‐density	  mapping	  of	  the	  
epicardial	  surface	  was	  performed	  using	  a	  90-­‐pole	  plaque,	  to	  allow	  more	  detailed	  
electrophysiological	  study.	  Following	  this,	  cardiac	  tissue	  samples	  were	  taken	  to	  assess	  
atrial	  fibrosis,	  inflammation	  and	  pro-­‐fibrotic	  protein	  expression.	  All	  procedures	  are	  
described	  below.	  
4.2.2	  Obesity	  induction	  
Obesity	  was	  using	  a	  diet	  of	  high	  fat	  pellets	  consisting	  of	  wheat,	  barley	  and	  canola	  
seed.	  Excess	  voluntary	  intake	  was	  of	  grass	  alfalfa	  silage	  and	  hay.	  As	  previously	  
described,24	  the	  pellets	  were	  gradually	  introduced	  at	  8%	  excess	  basal	  energy	  
requirements	  and	  rationed	  to	  70%	  of	  the	  total	  dry	  matter	  intake.	  This	  was	  continued	  
for	  the	  duration	  of	  the	  study,	  to	  allow	  gradual	  increase	  in	  weights	  in	  all	  animals	  over	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64	  weeks.	  Weights	  were	  recorded	  weekly	  and	  reported	  weights	  were	  those	  taken	  in	  a	  
shorn	  and	  fasted	  state	  immediately	  prior	  to	  electrophysiological	  procedures.	  Plasma	  
samples	  were	  collected	  at	  intervals	  to	  ensure	  stability	  of	  haematological	  and	  
biochemical	  indices.	  
At	  study	  commencement,	  animals	  were	  randomly	  allocated	  to	  being	  either	  in	  the	  
control	  group	  or	  to	  undergo	  treatment	  with	  tranilast.	  Feeding	  was	  titrated	  identically	  
in	  all	  animals	  to	  maintain	  a	  constant	  and	  gradual	  weight	  gain.	  
4.2.3	  Treatment	  (tranilast)	  group	  
Eight	  animals	  were	  randomised	  to	  receive	  tranilast	  treatment	  during	  the	  64-­‐week	  
period	  of	  weight	  gain.	  Treatment	  was	  given	  orally	  at	  a	  dose	  of	  1g	  twice	  daily.	  
Pharmacokinetic	  studies	  were	  previously	  performed	  to	  ensure	  twice	  daily	  dosing	  was	  
appropriate.	  Tranilast	  powder	  (Synthesis	  med	  chem	  Pty	  Ltd,	  Melbourne,	  Australia)	  
was	  suspended	  with	  tragacanth	  mucilage	  (1g/40ml).	  	  
4.2.4	  Animal	  anaesthesia	  
All	  procedures	  were	  performed	  under	  general	  anaesthetic.	  A	  pre-­‐med	  of	  diazepam	  
0.4mg/kg	  was	  given	  prior	  to	  induction	  with	  ketamine	  5mg/kg.	  Isoflurane	  2.5%	  with	  4	  
litres/minute	  of	  oxygen	  was	  used	  for	  maintenance.	  Non-­‐invasive	  blood	  pressure,	  
heart	  rate,	  pulse	  oximetry	  and	  end-­‐tidal	  CO2	  were	  continuously	  monitored.	  
4.2.5	  Endocardial	  electrophysiological	  study	  
Internal	  jugular	  and	  femoral	  venous	  access	  were	  obtained	  using	  a	  conventional	  
percutaneous	  approach.	  A	  10-­‐pole	  coronary	  sinus	  (CS)	  catheter	  (2–5–2	  mm	  inter-­‐
electrode	  spacing)	  was	  positioned	  via	  the	  internal	  jugular	  vein,	  with	  the	  proximal	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bipole	  at	  the	  CS	  ostium.	  Left	  atrial	  mapping	  was	  performed	  after	  transseptal	  puncture	  
using	  an	  SL0	  sheath	  and	  BRK	  needle,	  as	  previously	  described.24	  
Surface	  ECG	  and	  bipolar	  endocardial	  electrograms	  were	  monitored	  continuously	  and	  
stored	  on	  a	  computer-­‐based	  digital	  amplifier/recorder	  system	  (LabSystem	  Pro,	  Bard	  
Electrophysiology,	  Lowell,	  MA)	  with	  storage	  for	  offline	  analysis.	  Intracardiac	  
electrograms	  were	  filtered	  from	  30	  to	  500	  Hz	  and	  measured	  with	  computer-­‐assisted	  
calipers	  at	  a	  sweep	  speed	  of	  200mm/s.	  
Electroanatomical	  mapping	  
Electroanatomical	  maps	  were	  created	  in	  sinus	  rhythm	  using	  the	  Carto	  XP	  system	  
(Biosense	  Webster,	  Diamond	  Bar,	  CA)	  as	  previously	  described.63	  Right	  and	  left	  atrial	  
maps	  were	  recorded	  using	  a	  3.5-­‐mm	  tip	  catheter	  ablation	  catheter	  (Navistar,	  
Biosense	  Webster,	  Diamond	  Bar,	  CA)	  with	  a	  minimum	  of	  80	  equally	  distributed	  points	  
collected	  in	  each	  chamber.	  Endocardial	  contact	  was	  confirmed	  with	  a	  combination	  of	  
electrogram	  stability,	  fluoroscopy	  and	  the	  Carto	  point	  stability	  criteria	  (≤6mm	  stability	  
in	  space,	  ≤5ms	  in	  local	  activation	  time).	  Location,	  voltage	  and	  activation	  timing	  were	  
recorded	  at	  each	  point.	  For	  analysis	  the	  atria	  was	  divided	  as	  follows:	  Septal	  right	  
atrium	  (RA);	  High	  lateral	  RA;	  Low	  lateral	  RA;	  Posterior	  left	  atrium	  (LA);	  Lateral	  LA;	  and	  
Inferior	  LA.	  The	  following	  parameters	  were	  determined:	  
1. Regional	  Conduction	  velocity	  
• The	  direction	  of	  conduction	  was	  determined	  from	  examination	  of	  
isochronal	  maps.	  3-­‐5	  pairs	  of	  points	  were	  taken	  in	  the	  direction	  of	  
conduction,	  with	  velocity	  being	  calculated	  using	  the	  distance	  and	  
timing	  as	  reported	  by	  the	  mapping	  system.	  
2. Signal	  fractionation	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• This	  was	  defined	  as	  a	  signal	  greater	  than	  50ms	  duration	  with	  at	  least	  
four	  deflections.	  
3. Bipolar	  voltage.	  	  
• Low	  voltage	  was	  defined	  as	  an	  area	  with	  three	  contiguous	  points	  with	  
a	  bipolar	  voltage	  of	  <0.5mV.	  
• Scar	  was	  an	  area	  with	  three	  contiguous	  points	  <0.05mV.	  
Effective	  refractory	  periods	  
Effective	  refractory	  period	  (ERP)	  was	  measured	  at	  three	  times	  the	  tissue	  capture	  
threshold	  at	  a	  pulse	  width	  of	  2ms,	  using	  a	  Micropace	  EPS	  320	  stimulator	  (Micropace,	  
Canterbury,	  Australia).	  This	  was	  performed	  from	  the	  following	  8	  sites:	  Septal	  RA;	  High	  
lateral	  RA;	  Low	  lateral	  RA;	  Posterior	  LA;	  Lateral	  LA;	  Inferior	  LA;	  Proximal	  coronary	  
sinus	  (CS);	  and	  Distal	  CS.	  Eight	  S1	  stimuli	  were	  delivered	  with	  S1	  cycle	  lengths	  of	  400	  
and	  200ms,	  with	  incremental	  S2	  impulses	  (10ms	  increments),	  commencing	  at	  a	  
coupling	  interval	  of	  100ms.	  The	  ERP	  was	  the	  longest	  S1-­‐S2	  interval	  without	  atrial	  
capture.	  The	  mean	  of	  two	  attempts	  was	  recorded.	  An	  additional	  attempt	  was	  made	  if	  
the	  difference	  between	  attempts	  was	  greater	  than	  10ms.	  	  	  
AF	  induction	  
Inducibility	  of	  AF	  was	  determined	  using	  a	  burst	  pacing	  protocol	  from	  the	  left	  atrial	  
appendage,	  performed	  at	  the	  terminal	  study.	  Twenty	  impulses	  were	  delivered	  at	  the	  
lowest	  cycle	  length	  with	  1:1	  atrial	  capture.	  An	  episode	  was	  defined	  as	  irregular	  atrial	  
activity	  lasting	  greater	  than	  or	  equal	  to	  3	  seconds.	  This	  protocol	  was	  repeated	  five	  
times	  and	  the	  total	  duration	  was	  recorded.	  Sustained	  AF	  was	  defined	  as	  an	  episode	  
lasting	  >10	  minutes.	  In	  the	  event	  of	  sustained	  AF,	  no	  further	  testing	  was	  performed.	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Haemodynamic	  recordings	  
Non-­‐invasive	  systolic	  blood	  pressure	  and	  invasive	  mean	  right	  atrial	  and	  systolic	  right	  
ventricular	  pressures	  via	  the	  SR0	  sheath	  were	  recorded	  at	  the	  start	  of	  each	  
procedure.	  Mean	  left	  atrial	  pressure	  was	  recorded	  immediately	  following	  transseptal	  
puncture.	  
4.2.6	  Terminal	  epicardial	  electrophysiological	  study	  
Left	  lateral	  thoracotomy	  was	  performed	  to	  access	  the	  left	  atrium.	  A	  custom	  made	  90-­‐
pole	  plaque	  was	  placed	  on	  the	  left	  atrial	  appendage	  and	  connected	  to	  the	  computer-­‐
based	  digital	  amplifier/recorder	  system	  (LabSystem	  Pro,	  Bard	  Electrophysiology,	  
Lowell,	  MA).	  Pacing	  was	  performed	  from	  each	  of	  the	  four	  corners	  of	  the	  plaque	  at	  
400ms.	  Epicardial	  electrograms	  were	  recorded	  and	  the	  following	  determined:	  
1. Effective	  refractory	  periods	  were	  measured	  using	  the	  same	  protocol	  as	  the	  
endocardial	  study.	  	  
2. Conduction	  velocity	  was	  determined	  using	  activation	  maps	  analysed	  by	  
custom	  software,	  as	  previously	  described.59	  The	  peak	  of	  the	  largest	  
amplitude	  deflection	  on	  each	  bipolar	  electrogram	  was	  automatically	  
annotated	  and	  manually	  verified.	  Local	  conduction	  velocity	  was	  calculated	  
for	  each	  point	  from	  triangulated	  local	  vectors,	  allowing	  subsequent	  
calculation	  of	  mean	  velocity	  for	  each	  map.	  
3. Conduction	  heterogeneity	  was	  calculated	  using	  established	  phase	  mapping	  
techniques	  integrated	  into	  the	  software,	  as	  previously	  described.59	  Absolute	  
conduction	  phase	  delay	  was	  calculated	  by	  subtracting	  the	  5th	  from	  the	  95th	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percentile	  of	  the	  phase	  difference	  distribution	  (P5-­‐95).	  Conduction	  
heterogeneity	  index	  was	  derived	  from	  dividing	  P5-­‐95	  by	  the	  median	  (P50).	  
4.2.7	  Cardiac	  MRI	  
Chamber	  volumes	  were	  measured	  using	  MRI	  (Siemens	  Sonata	  1.5	  Tesla,	  MR	  Imaging	  
Systems,	  Siemens	  Medical	  Solutions,	  Erlangen,	  Germany).	  6-­‐mm	  slices	  were	  taken	  
through	  the	  left	  atrium	  and	  ventricle.	  Images	  were	  taken	  using	  electrocardiogram-­‐
gating	  and	  periodic	  breath	  holding.	  Analyses	  were	  performed	  offline	  using	  CVI42	  
(Circle	  Cardiovascular	  Imaging	  Inc.,	  Calgary,	  Canada).	  
4.2.8	  Statistical	  Analysis	  
Normally	  distributed	  data	  was	  expressed	  as	  mean	  ±	  standard	  deviation	  and	  compared	  
using	  unpaired	  t-­‐test.	  Analysis	  of	  variance	  was	  used	  to	  detect	  differences	  between	  
groups	  over	  time.	  Due	  to	  the	  dependence	  in	  observations	  from	  the	  same	  animal,	  
conduction	  velocity	  and	  ERP	  across	  regions	  were	  analysed	  using	  a	  mixed	  effects	  
model	  ANOVA.	  Sheep	  ID	  was	  used	  as	  a	  random	  effect	  and	  combinations	  of	  group,	  
timepoint	  and	  region	  were	  used	  as	  fixed	  effects.	  A	  maximum	  of	  two	  fixed	  effects	  
were	  entered	  into	  the	  statistical	  model	  at	  one	  time,	  with	  testing	  of	  both	  main	  effects	  
and	  their	  interaction.	  If	  a	  significant	  interaction	  was	  present,	  post-­‐hoc	  testing	  was	  
performed.	  AF	  duration	  was	  non-­‐parametric;	  therefore,	  log-­‐transformation	  was	  
performed	  prior	  to	  t-­‐test	  comparison,	  with	  values	  expressed	  as	  median	  and	  
interquartile	  range.	  P-­‐values	  of	  less	  than	  0.05	  were	  considered	  statistically	  significant.	  
Analyses	  were	  performed	  using	  SPSS	  version	  23	  (SPSS	  Inc.	  Chicago,	  IL).	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4.3	  Results	  
4.3.1	  Weight,	  structural	  and	  haemodynamic	  parameters	  
Table	  1	  presents	  the	  changes	  in	  anthropometry,	  haemodynamic	  and	  cardiac	  structure	  
in	  the	  two	  groups.	  Both	  groups	  increased	  in	  weight	  equally	  over	  64	  weeks.	  Left	  and	  
right	  atrial	  pressures	  significantly	  increased	  with	  increasing	  weight,	  accompanied	  by	  a	  
non-­‐significant	  increase	  in	  systolic	  blood	  pressure	  and	  right	  ventricular	  systolic	  
pressure.	  There	  was	  a	  non-­‐significant	  increase	  in	  left	  atrial	  volume	  and	  left	  ventricular	  
mass	  with	  increasing	  weight	  but	  no	  change	  in	  LV	  volume	  or	  function.	  
There	  was	  no	  significant	  difference	  in	  haemodynamics,	  chamber	  volumes,	  LV	  mass	  or	  
function	  between	  treatment	  and	  control	  groups	  at	  any	  timepoint.	  
4.3.2	  Electrophysiological	  parameters	  
Atrial	  conduction	  
With	  increasing	  weight,	  progressive	  slowing	  of	  atrial	  conduction	  occurred	  in	  both	  
groups	  (p<0.001).	  Animals	  treated	  with	  tranilast	  had	  significantly	  less	  endocardial	  
conduction	  slowing	  than	  controls	  (p<0.001)	  at	  both	  midpoint	  and	  endpoint,	  as	  shown	  
in	  figure	  2.	  On	  analysis	  by	  region	  at	  end	  point	  study,	  this	  change	  was	  found	  to	  be	  
heterogeneous,	  with	  significant	  differences	  in	  conduction	  across	  atrial	  regions.	  In	  the	  
left	  atrium,	  tranilast	  treatment	  was	  associated	  with	  relative	  preservation	  of	  
conduction	  on	  the	  posterior	  (1.18±0.10	  vs	  0.96±0.06m/s,	  p<0.001)	  and	  lateral	  
(1.19±0.06	  vs	  0.95±0.05m/s,	  p<0.001)	  walls.	  In	  the	  right	  atrium,	  the	  upper	  lateral	  
(1.15±0.05	  vs	  0.89±0.12m/s,	  p<0.001)	  wall	  showed	  significantly	  higher	  conduction	  
velocities	  in	  tranilast	  treated	  animals.	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Similarly,	  epicardial	  conduction	  at	  the	  64-­‐week	  end	  point	  study	  was	  higher	  in	  the	  
tranilast	  treated	  group	  (1.19±0.06	  vs	  0.95±0.05m/s,	  p<0.001),	  as	  shown	  in	  figure	  3.	  
This	  improvement	  in	  conduction	  velocity	  was	  homogeneous	  across	  all	  four	  plaque	  
sites	  (site*group	  interaction	  p=0.21).	  Notably,	  there	  was	  no	  difference	  in	  conduction	  
heterogeneity	  between	  treatment	  and	  control	  groups	  at	  any	  epicardial	  site.	  
Effective	  refractory	  periods	  
There	  was	  no	  significant	  change	  in	  ERP	  with	  increasing	  weight.	  At	  midpoint	  study,	  
there	  was	  a	  significant	  reduction	  in	  atrial	  ERP	  following	  200ms	  drivetrain	  in	  the	  
tranilast	  treated	  animals,	  when	  compared	  with	  controls	  (136±10	  vs	  146±10ms).	  This	  
was	  not	  seen	  with	  a	  400ms	  drive	  train	  and	  was	  also	  not	  apparent	  at	  end	  point	  study.	  	  
Signal	  fractionation	  
Signal	  fractionation	  increased	  with	  increasing	  weight	  in	  both	  groups	  (p<0.001)	  as	  
shown	  in	  figure	  5.	  Tranilast	  treated	  animals	  had	  significantly	  less	  signal	  fractionation	  
than	  control	  animals	  at	  60	  weeks	  (16.7±6.2	  vs	  29.3±8.8%,	  p=0.01).	  
Atrial	  bipolar	  voltage	  
There	  was	  no	  significant	  reduction	  in	  endocardial	  voltage	  with	  increasing	  weight	  or	  
between	  groups.	  No	  areas	  of	  low	  voltage	  (<0.5mV)	  were	  seen	  in	  any	  animal.	  
AF	  inducibility	  	  
The	  tranilast	  treated	  group	  had	  significantly	  less	  AF	  during	  the	  induction	  protocol	  (12s	  
[IQR	  36]	  vs	  43s	  [IQR	  110],	  p=0.05),	  as	  shown	  in	  figure	  6.	  Two	  animals	  (1	  tranilast	  
treated,	  1	  control)	  had	  sustained	  AF	  (>10mins)	  during	  testing	  and	  were	  excluded	  from	  
inducibility	  analysis.	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4.4	  Discussion	  
This	  study	  gives	  us	  new	  information	  on	  the	  mechanism	  of	  the	  abnormalities	  in	  atrial	  
electrophysiology	  seen	  in	  obesity.	  The	  following	  effects	  were	  seen	  with	  tranilast	  
treatment:	  
1. Attenuation	  of	  the	  marked	  reduction	  in	  endocardial	  conduction	  velocity	  
associated	  with	  increasing	  obesity,	  with	  associated	  reduction	  in	  signal	  
fractionation.	  Interestingly,	  the	  reduction	  in	  conduction	  velocities	  with	  
increased	  weight	  was	  seen	  across	  all	  atrial	  regions,	  whereas	  the	  animals	  
treated	  with	  tranilast	  demonstrated	  a	  more	  heterogeneous	  pattern,	  with	  
sparing	  of	  certain	  regions	  in	  both	  atria.	  
2. Higher	  epicardial	  conduction	  velocity	  at	  end	  point	  study.	  This	  was	  consistent	  
across	  all	  4	  sites	  on	  the	  plaque.	  There	  was,	  however,	  no	  difference	  in	  local	  
conduction	  heterogeneity	  at	  any	  site.	  
3. As	  a	  result	  of	  this,	  there	  was	  a	  significant	  reduction	  in	  AF	  inducibility	  in	  the	  
treatment	  group.	  
Importantly,	  these	  results	  occurred	  without	  effect	  on	  haemodynamics	  or	  chamber	  
volumes.	  There	  was	  also	  a	  minor,	  but	  significant,	  reduction	  in	  atrial	  ERP	  at	  midpoint	  
study.	  However,	  this	  was	  only	  at	  one	  cycle	  length	  and	  similar	  differences	  were	  not	  
seen	  at	  endpoint	  study.	  Contrary	  to	  this,	  when	  used	  in	  a	  canine	  heart	  failure	  model,	  
this	  effect	  was	  not	  seen;	  rather	  tranilast	  appeared	  to	  protect	  against	  the	  reduction	  in	  
ERP	  associated	  with	  the	  development	  of	  heart	  failure.260	  This	  may	  be	  a	  treatment	  
effect,	  however,	  given	  the	  inconsistent	  changes	  across	  time	  and	  cycle	  length,	  
conclusions	  must	  be	  drawn	  with	  caution.	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Atrial	  substrate	  
Changes	  in	  atrial	  electrophysiology	  have	  been	  demonstrated	  with	  a	  wide	  variety	  of	  
conditions.	  These	  were	  first	  noted	  secondary	  to	  prolonged	  rapid	  atrial	  pacing,	  
resulting	  in	  reductions	  in	  atrial	  refractory	  periods	  and	  increased	  susceptibility	  to	  AF.55	  
Subsequent	  studies	  used	  a	  heart	  failure	  model	  to	  induce	  structural	  remodelling,	  with	  
increases	  in	  localised	  conduction	  slowing	  and	  fibrosis	  of	  atrial	  tissue,	  neither	  of	  which	  
were	  seen	  in	  animals	  subjected	  to	  rapid	  atrial	  pacing	  alone.58	  We	  have	  previously	  
demonstrated	  the	  development	  of	  conduction	  slowing,	  without	  ERP	  change	  in	  an	  
obese	  ovine	  model.	  Our	  study	  again	  demonstrated	  this	  progressive	  conduction	  
slowing	  with	  increasing	  weight,	  without	  changes	  in	  ERP.	  
TGF-­‐β	  and	  cardiac	  fibrosis	  
TGF-­‐β	  has	  long	  been	  recognised	  to	  be	  a	  central	  mediator	  of	  the	  fibrotic	  pathway.	  Its	  
effect	  on	  infarcted,	  hypertrophic	  and	  cardiomyopathic	  ventricular	  tissue	  has	  been	  
well	  characterised.284	  More	  recent	  work	  has	  investigated	  its	  relationship	  with	  atrial	  
fibrosis.	  Overexpression	  of	  TGF-­‐β	  in	  a	  transgenic	  mouse	  model	  induced	  
heterogeneous	  conduction	  in	  the	  left	  atrium,	  slowed	  conduction	  in	  the	  right	  atrium	  
and	  increased	  susceptibility	  to	  AF.112	  The	  cardiac	  profibrotic	  effects	  of	  TGF-­‐β	  may	  be	  
enhanced	  in	  atrial	  tissue.113	  Previous	  studies	  have	  demonstrated	  TGF-­‐β	  inhibition	  to	  
have	  a	  disease-­‐modifying	  role.	  Pressure	  overloaded	  rats	  treated	  with	  anti	  TGF-­‐β	  
antibodies	  demonstrated	  dramatically	  reduced	  myocardial	  fibrosis.259	  Tranilast	  was	  
found,	  in	  conjunction	  with	  TGF-­‐β	  mRNA	  downregulation,	  to	  reduce	  ventricular	  
fibrosis	  in	  one	  study	  of	  hypertensive	  rats,285	  along	  with	  reduced	  mortality.286	  It	  also	  
prevented	  cardiac	  fibrosis	  in	  rats	  with	  diabetic	  cardiomyopathy,	  despite	  persistent	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hypertension	  and	  hyperglycaemia.287	  Although	  initial	  human	  studies	  of	  its	  effect	  on	  
coronary	  restenosis	  were	  encouraging262,	  a	  subsequent	  multicentre,	  randomised	  trial	  
reported	  no	  significant	  effect.263	  Recent	  investigation	  has	  found	  that	  it	  reduces	  both	  
atrial	  fibrosis	  and	  AF	  inducibility	  when	  used	  in	  a	  canine	  heart	  failure	  model.260	  Our	  
study	  is	  in	  keeping	  with	  these	  findings.	  Atrial	  remodelling	  was	  prevented	  by	  tranilast,	  
as	  demonstrated	  by	  significantly	  improved	  endocardial	  and	  epicardial	  atrial	  
conduction	  velocities	  in	  the	  treatment	  group.	  This	  corresponded	  with	  a	  reduced	  
susceptibility	  to	  AF	  with	  tranilast	  treatment.	  	  
TGF-­‐β	  and	  obesity	  
We	  have	  previously	  demonstrated	  the	  progressive	  up-­‐regulation	  of	  TGF-­‐β	  receptors	  
in	  atrial	  tissue	  during	  weight	  gain,	  in	  both	  the	  intermediate	  and	  long	  term.23,	  24	  This	  
was	  associated	  with	  both	  increased	  atrial	  fibrosis	  and	  an	  increased	  susceptibility	  to	  
AF.	  TGF-­‐β	  is	  expressed	  in	  adipose	  tissue	  and	  the	  degree	  of	  expression	  correlates	  with	  
BMI	  in	  human	  subjects.209	  210	  A	  recent	  study	  used	  an	  original	  atrial	  organo-­‐culture	  
model	  to	  demonstrated	  that	  TGF-­‐β	  was	  secreted	  by	  human	  epicardial	  fat	  in	  small	  
amounts	  and	  this	  was	  less	  than	  by	  subcutaneous	  fat.	  However,	  Activin	  A,	  a	  member	  
of	  the	  TGF	  superfamily,	  was	  secreted	  by	  epicardial	  fat	  significantly	  more	  than	  in	  non-­‐
cardiac	  fat,	  and	  its	  presence	  induced	  TGF-­‐β	  expression.200	  	  
The	  distribution	  of	  epicardial	  fat	  is	  not	  uniform.	  One	  study	  showed	  the	  SVC,	  left	  atrial	  
appendage	  and	  left	  AV	  groove	  are	  adjacent	  to	  the	  largest	  fat	  depots.288	  Another	  
found	  most	  left	  atrial	  epicardial	  fat	  was	  located	  in	  the	  inferior	  and	  posterior	  region,	  
with	  minimal	  appendage	  and	  lateral	  fat.	  This	  study	  also	  demonstrated	  infiltration	  of	  
fat	  into	  cardiac	  tissue,	  in	  particularly	  in	  the	  posterior	  wall	  of	  the	  left	  atrium,	  which	  
showed	  marked	  differences	  in	  our	  study,	  when	  compared	  with	  the	  inferior	  LA.24	  This	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may	  account	  for	  the	  heterogeneous	  nature	  of	  the	  conduction	  velocities	  in	  tranilast	  
treated	  animals.	  Further	  investigation	  into	  the	  exact	  mechanism	  warrants	  further	  
investigation.	  
Tranilast	  effects	  
Although	  the	  effect	  of	  Tranilast	  is	  predominantly	  on	  the	  TGF-­‐β	  pathway,	  it	  has	  several	  
other	  potentially	  anti-­‐fibrotic	  and	  anti-­‐inflammatory	  effects	  that	  may	  account	  for	  
some	  of	  the	  observed	  effects.	  Macrophages	  exposed	  to	  tranilast	  demonstrated	  
upregulation	  of	  the	  anti-­‐inflammatory	  molecule	  heme	  oxygenase-­‐1,	  downregulation	  
of	  the	  pro-­‐inflammatory	  substance	  cyclooxygenase-­‐2.	  289	  This	  resulted	  in	  inhibition	  of	  
prostaglandins,	  tumour	  necrosis	  factor	  and	  interleukin-­‐1b	  and	  demonstrates	  the	  
potential	  confounding	  effects	  of	  tranilast	  treatment.	  It	  also	  acts	  antagonistically	  on	  
angiotensin	  II,	  inhibiting	  the	  its	  effects	  in	  vascular	  smooth	  muscle.290	  In	  a	  hypertensive	  
rat	  model,	  it	  inhibited	  PDGF	  as	  well	  as	  TGF-­‐β	  induced	  collagen	  synthesis.291,	  292	  It	  may	  
also	  attenuate	  the	  effect	  of	  connective	  tissue	  growth	  factor,	  as	  shown	  in	  renal	  
tissue.292	  It	  is	  unclear	  whether	  these	  effects	  are	  directly	  due	  to	  tranilast,	  or	  whether	  
they	  are	  secondary	  to	  TGF-­‐β	  blockade,	  but	  further	  study	  may	  be	  warranted	  to	  
isolated	  the	  exact	  mechanisms	  of	  pure	  TGF-­‐β	  blockade.	  
Study	  limitations	  
We	  used	  a	  model	  of	  progressive	  obesity	  to	  determine	  the	  effect	  of	  tranilast	  
treatment.	  In	  clinical	  practice,	  it	  is	  unlikely	  that	  treatment	  will	  be	  instated	  during	  
weight	  gain	  rather	  than	  once	  an	  individual	  is	  obese	  and	  develops	  conditions	  related	  to	  
this	  and	  extrapolation	  from	  our	  study	  to	  this	  likely	  clinical	  scenario	  should	  be	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cautious.	  However,	  weight	  fluctuation	  is	  a	  common	  in	  obese	  individuals	  and	  it	  may	  be	  
that	  anti-­‐fibrotic	  treatments	  are	  of	  benefit	  in	  periods	  of	  significant	  weight	  change.	  
4.5	  Conclusion	  
Treatment	  with	  tranilast	  attenuates	  the	  conduction	  slowing	  associated	  with	  obesity	  
with	  minor	  effects	  on	  refractory	  periods.	  These	  conduction	  changes	  are	  
heterogeneous	  across	  both	  atria.	  This	  reduction	  in	  atrial	  substrate	  results	  in	  reduced	  
inducibility	  of	  AF.	  Tranilast	  treatment	  may	  be	  of	  benefit	  in	  obese	  patients	  with	  AF.	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Table	  1.	  Weight,	  structural	  and	  haemodynamic	  parameters.	  
	  




Baseline	   36	  wks	   72	  wks	   Baseline	   36	  wks	   72	  wks	  
Weight	  	  
(kg)	   64±7	   90±10	   99±12	   63±7	   86±7	   94±7	   NS	   <0.001	  
sBP	  
(mmHg)	   85±14	   89±10	   94±12	   83±18	   87±9	   92±11	   NS	   NS	  
RVSP	  
(mmHg)	   14±4	   18±3	   19±4	   16±2	   17±3	   18±3	   NS	   NS	  
LA	  pressure	  
(mmHg)	   4.6±1.8	   6.8±2.1	   6.8±1.5	   4.5±2.4	   6.9±1.7	   6.8±2.1	   NS	   0.05	  
RA	  pressure	  
(mmHg)	   2.7±1.9	   4.5±1.5	   6.6±2.3	   2.7±1.6	   5.0±1.2	   5.0±2.9	   NS	   0.01	  
LA	  volume	  
(ml)	   50±7	   57±7	   61±5	   51±11	   57±7	   57±11	   NS	   NS	  
LVEDV	  
(ml)	   105±15	   131±15	   131±19	   112±22	   129±23	   125±17	   NS	   NS	  
LV	  mass	  
(ml)	   123±25	   133±16	   132±12	   124±19	   134±22	   135±12	   NS	   NS	  
LVEF	  
(%)	   50±5	   43±8	   52±6	   45±14	   45±4	   46±5	   NS	   NS	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Figure	  1.	  Study	  design.	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Figure	  2.	  Conduction	  velocity	  (CV)	  at	  the	  study	  baseline,	  32	  weeks	  and	  64	  weeks	  (left)	  
and	  by	  region	  at	  endpoint	  study	  (right).	  	  
	  
	  
	   	  
	   110	  
Figure	  3.	  Epicardial	  conduction	  velocity	  (CV)	  at	  each	  site	  (left)	  and	  conduction	  
heterogeneity	  (right).	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Figure	  4.	  Effective	  refractory	  periods	  (ERP).	  Endocardial	  results	  at	  each	  timepoint	  
(upper)	  and	  epicardial	  results	  at	  study	  endpoint	  (lower).	  Left	  panels	  are	  at	  a	  400ms	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Figure	  5.	  Proportion	  of	  fractionated	  signal	  at	  baseline,	  midpoint	  and	  endpoint.	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Chapter	  5	  –	  Conclusions	  and	  future	  directions	  
This	  thesis	  explores	  the	  basis	  of	  atrial	  remodelling	  in	  obesity.	  It	  examines	  the	  effect	  of	  
weight	  fluctuation	  in	  the	  process	  of	  weight	  loss	  and	  evaluates	  the	  role	  of	  anti-­‐fibrotics	  
in	  the	  prevention	  of	  atrial	  remodelling	  in	  an	  obese	  ovine	  model.	  	  
The	  first	  study	  compared	  animals	  undergoing	  weight	  fluctuation	  with	  both	  lean	  and	  
obese	  groups.	  Sustained	  obesity	  was	  associated	  with	  a	  homogeneous	  reduction	  in	  
conduction	  velocities	  across	  all	  atrial	  sites,	  as	  seen	  in	  previous	  studies	  using	  this	  
model.23,24	  Animals	  subjected	  to	  weight	  fluctuation	  also	  developed	  slowing	  of	  atrial	  
conduction,	  but	  this	  was	  less	  severe	  and	  in	  a	  more	  heterogeneous	  fashion.	  This	  was	  
most	  pronounced	  at	  the	  inferior	  wall	  of	  the	  left	  atrium,	  occurring	  after	  the	  first	  cycle	  
of	  weight	  gain	  and	  loss.	  Following	  the	  second	  cycle,	  the	  posterior	  wall	  of	  the	  LA	  and	  
lower	  lateral	  aspect	  of	  the	  RA	  were	  also	  affected.	  Epicardial	  conduction	  was	  similarly	  
slowed	  and	  was	  markedly	  heterogeneous	  with	  weight	  fluctuation	  but	  again,	  the	  
degree	  of	  conduction	  slowing	  was	  less	  than	  in	  persistently	  obese	  animals.	  
Additionally,	  the	  obese	  group	  were	  found	  to	  have	  reduced	  endocardial	  atrial	  
refractoriness,	  but	  only	  after	  a	  very	  prolonged	  period	  of	  obesity.	  This	  has	  not	  been	  
demonstrated	  in	  this	  obese	  model	  previously.	  Interestingly,	  previous	  studies	  have	  
shown	  reduction	  in	  epicardial	  ERP	  alone	  with	  sustained	  obesity,	  a	  finding	  that	  was	  not	  
seen	  in	  our	  study.	  We	  did,	  however	  find	  that	  weight	  fluctuation	  caused	  significant	  
elevation	  of	  epicardial,	  but	  not	  endocardial,	  ERP.	  This	  highlights	  the	  complex	  and	  
poorly	  understood	  discordance	  between	  endo-­‐	  and	  epicardial	  electrophysiology.	  It	  
has	  long	  been	  recognised	  that	  there	  are	  significant	  differences	  between	  the	  two	  
surfaces,	  particularly	  in	  areas	  where	  the	  atrial	  tissue	  is	  thickened.293	  However,	  recent	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data	  has	  been	  scarce	  and	  one	  current	  limitation	  of	  epicardial	  mapping	  is	  the	  limited	  
area	  available	  for	  plaque	  placement	  and	  the	  difficulty	  in	  mapping	  both	  surfaces	  
simultaneously.	  Studies	  to	  further	  characterise	  these	  differences	  could	  also	  help	  to	  
determine	  the	  differences	  in	  local	  and	  systemic	  factors.	  	  
The	  next	  part	  of	  this	  thesis	  examined	  the	  effect	  of	  pharmacological	  intervention	  in	  the	  
prevention	  of	  atrial	  remodelling,	  through	  blockade	  of	  both	  endothelin	  and	  TGF-­‐β	  
receptors,	  molecules	  that	  previous	  studies	  have	  shown	  to	  be	  upregulated	  in	  
obesity.23,24	  
Endothelin	  receptor	  antagonism	  resulted	  in	  a	  marked,	  homogeneous	  improvement	  in	  
conduction	  velocity	  across	  both	  atria,	  on	  both	  the	  endocardial	  and	  epicardial	  surface.	  
Importantly,	  this	  effect	  was	  seen	  without	  any	  effect	  on	  haemodynamics	  or	  refractory	  
periods	  and	  resulted	  in	  reduced	  AF	  inducibility.	  Histological	  analysis	  of	  atrial	  tissue	  
demonstrated	  a	  significant	  reduction	  in	  interstitial	  fibrosis	  and	  inflammation	  with	  
endothelin	  receptor	  blockade.	  Additionally,	  some	  insight	  was	  granted	  into	  the	  
molecular	  pathways	  involved;	  importantly	  these	  effects	  occurred	  independently	  of	  
the	  TGF-­‐β	  pathway.	  
Blockade	  of	  TGF-­‐β	  receptors	  was	  the	  focus	  of	  the	  final	  study.	  Again,	  this	  intervention	  
was	  effective	  in	  reducing	  the	  development	  of	  obesity-­‐related	  atrial	  substrate.	  In	  
contrast	  to	  endothelin	  receptor	  blockade,	  however,	  this	  was	  in	  a	  more	  
heterogeneous	  fashion,	  with	  individual	  areas	  of	  the	  atria	  demonstrating	  significant	  
conduction	  changes,	  whilst	  others	  remained	  unaffected.	  There	  was	  no	  effect	  on	  
haemodynamics	  with	  tranilast	  treatment,	  however	  a	  transient	  reduction	  in	  ERP	  at	  
midpoint	  study	  was	  noted.	  A	  potential	  explanation	  for	  the	  variation	  in	  conduction	  is	  
the	  paracrine	  action	  of	  adipose	  tissue.	  It	  is	  possible	  that	  areas	  in	  proximity	  to	  large	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epicardial	  fat	  depots	  are	  affected	  differently	  to	  those	  that	  are	  not,	  resulting	  in	  more	  
variation	  in	  conduction	  between	  regions.	  The	  direct	  action	  of	  fat	  on	  atrial	  tissue	  is	  an	  
important	  area	  of	  study;	  recent	  data	  has	  used	  novel	  techniques	  to	  demonstrate	  that	  
adipocytokines,	  including	  members	  of	  the	  TGF-­‐β	  superfamily,	  are	  secreted	  by	  
epicardial	  fat,	  with	  significant	  differences	  to	  those	  produced	  by	  subcutaneous	  fat.200	  
Further	  investigation	  into	  the	  distribution	  and	  secretory	  actions	  of	  epicardial	  fat	  
following	  pharmacological	  intervention	  is	  required	  to	  determine	  the	  relative	  local	  and	  
systemic	  effect	  of	  each	  pro-­‐fibrotic	  factor.	  
The	  findings	  of	  this	  thesis	  have	  important	  clinical	  implications.	  Treatment	  of	  obesity	  
related	  AF	  is	  challenging;	  options	  are	  limited	  and	  mainly	  focussed	  on	  antiarrhythmic	  
therapy	  and	  invasive	  ablation	  procedures.	  The	  first	  study	  could	  help	  counsel	  patients	  
about	  to	  commence	  weight	  loss.	  It	  demonstrates	  that	  weight	  cycling	  is	  not	  an	  optimal	  
pattern,	  however	  it	  is	  preferable	  to	  persistent	  obesity.	  The	  findings	  of	  the	  following	  
two	  studies	  support	  the	  use	  of	  treatments	  to	  target	  the	  underlying	  atrial	  substrate	  in	  
obesity	  and	  are	  suggestive	  that	  this	  strategy	  may	  reduce	  the	  burden	  of	  AF	  in	  this	  
population.	  	  
Future	  directions	  
Future	  mechanistic	  studies	  should	  be	  directed	  at	  more	  focussed	  characterisation	  of	  
the	  location	  and	  volume	  of	  fat	  depots	  to	  determine	  how	  some	  disease	  states	  and	  
treatments	  result	  in	  a	  heterogeneous	  conduction	  pattern	  whereas	  others	  cause	  more	  
homogeneous	  changes.	  Furthermore,	  detailed	  histological	  analysis	  and	  more	  complex	  
tests	  of	  secretory	  function	  would	  grant	  additional	  insights	  into	  these	  effects.	  In	  
addition,	  the	  reversibility	  of	  an	  established	  substrate	  with	  treatment	  using	  anti-­‐
fibrotic	  agents	  needs	  to	  be	  confirmed.	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From	  a	  clinical	  perspective,	  both	  bosentan	  and	  tranilast	  are	  in	  routine	  clinical	  use	  for	  
other	  conditions	  and	  have	  an	  acceptable	  side	  effect	  profile.	  Therefore,	  follow-­‐on	  
human	  clinical	  trials	  examining	  the	  effect	  of	  these	  treatments	  on	  obese	  individuals	  
with	  AF	  are	  warranted	  to	  determine	  their	  efficacy	  in	  reducing	  AF	  burden.	  Although	  
the	  results	  presented	  are	  in	  a	  model	  with	  progressive	  weight	  gain,	  it	  could	  be	  
hypothesised	  that	  these	  interventions	  are	  able	  to	  reduce	  adverse	  atrial	  remodelling	  in	  
individuals	  with	  stable	  obesity	  and	  this	  may	  be	  especially	  true	  in	  those	  who	  have	  
increased	  adipocyte	  activity	  due	  to	  significant	  weight	  fluctuation.	  Another	  important	  
finding	  of	  this	  thesis	  was	  that	  endothelin	  receptor	  blockade	  appears	  to	  act	  
independently	  of	  the	  TGF-­‐β	  pathway.	  This	  suggests	  that	  there	  could	  also	  be	  a	  role	  for	  
combined	  treatment,	  targeting	  both	  pathways	  simultaneously.	  
In	  summary,	  this	  thesis	  highlights	  the	  detrimental	  effect	  of	  weight	  cycling	  on	  atrial	  
electrophysiology,	  despite	  return	  to	  normal	  weight.	  It	  also	  demonstrates	  the	  
beneficial	  effects	  of	  anti-­‐fibrotic	  treatment	  in	  preventing	  atrial	  substrate	  and	  reducing	  
AF	  burden	  in	  obesity.	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